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Abstract 
 
Hereditary retinal diseases are now the leading cause of blindness certification in the working age 
population (age 16-64 years) in England and Wales, of which Retinitis Pigmentosa (RP) is the most 
common disorder. One complication of RP includes cystoid macular oedema (CMO), causing a reduction 
of central vision.  
 
This thesis begins by reviewing retinal anatomy, retinal function and the visual cycle. It provides a 
description of the most common inherited retinal disorders (IRD) together with an update on structural, 
functional and molecular assessment of IRD. The possible underlying causes of RP-associated CMO (RP-
CMO) are explored, including:  1) Breakdown of the blood-retinal barrier, 2) Failure (or dysfunction) of 
the pumping mechanism of the retinal pigment epithelium (RPE), 3) Muller cell oedema and 
dysfunction, 4) Anti-retinal antibodies, and 5) Vitreous traction. Current methods for the diagnosis and 
monitoring of RP-CMO are discussed. A literature review of all treatments attempted to date will be 
provided, including: oral and topical carbonic anhydrase inhibitors, oral, topical, intravitreal and 
periocular steroids, topical non-steroidal anti-inflammatory medications, photocoagulation, vitrectomy 
with internal limiting membrane peel, oral lutein, and intravitreal anti-vascular endothelial growth factor 
injections. 
 
Extensive explanation is provided regarding the clinical trial undertaken entitled ‘The AMOUR Study’, 
which stands for ‘Aflibercept for Macular Oedema in Underlying Retinitis Pigmentosa’. The purpose, 
methods, results and conclusion are provided. 
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Extensive explanation is provided regarding a second retrospective study undertaken entitled ‘The 
CARAMEL Study’, which stands for ‘Carbonic Anhydrase inhibitors for Retinitis Pigmentosa And Macular 
oEdema in various Layers’. The purpose, methods, results and conclusion are provided. 
 
Everything is drawn together in the discussion and concluding remarks section, including a final chapter 
on future directions for the treatment of RP-CMO. 
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Impact statement 
 
The work published herein has provided scientific impact by successfully contributing to the literature of 
cystoid macular oedema associated with retinitis pigmentosa (RP-CMO). This includes: 1 original 
research article in a peer reviewed journal, 1 review article in a peer reviewed journal, 1 case report in a 
peer reviewed journal and 1 article (in 2 parts) in a non-peer reviewed journal, 1 international poster 
presentation and 1 national oral presentation. A further manuscript has been submitted for publication 
and it is my hope to present the results of this research at the international meeting ‘European Society 
of Retinal Specialists’ (EURETINA), which is taking place in September 2019.  
 
This thesis encompasses a continued focus on rare inherited retinal diseases, provides extensive review 
of the avenues of intervention used for RP-CMO to-date (1), poses a potential method to distinguish 
between patients with RP-CMO that are more, or less likely to respond to treatment with carbonic 
anhydrase inhibitors (CAIs) (2) and offers hope that, in selected cases of RP-CMO, intravitreal aflibercept 
can reduce macular thickness +/- improve vision (3, 4).  
 
Inside of academia, this research offers a robust methodology that could be easily reproduced in order 
to carry out further studies using aflibercept for RP-CMO. With this in mind, a drug company in Japan 
has been approached to discuss the funding of a similar study using aflibercept for RP-CMO to allow 
comparisons to be drawn between patient populations. My hope for the future is that a larger, multi-
site, randomised and controlled study will take place over a longer period of time to provide more 
statistically significant, longer-term data to improve our understanding of aflibercept in the treatment of 
RP-CMO.  
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The impact of this research outside of academia has been immediate, whereby, surplus vials of 
aflibercept have been approved for compassionate use in patients with RP-CMO at the hospital where 
this research was carried out. Indeed, the repurposing of this existing medication for a new indication 
will avoid the prolonged preclinical testing required of new compounds. Whilst aflibercept is currently 
licenced for use in neovascular age-related macular degeneration (AMD), macular oedema following 
retinal vein occlusion (RVO), diabetic macular oedema (DMO), and diabetic retinopathy (DR) in patients 
with DMO, it is my longer-term hope that this will extend to include RP-CMO.  
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1.0 Introduction 
 
1.1 Retinal anatomy and function 
 
The retina is a layer of nerve tissue that lines the inside of the eye. It is made up of various layers, 
including (See Figure 1) (5):  
 Retinal Pigment Epithelium (RPE) 
 Photoreceptor outer segments (OS) 
 Photoreceptor inner segments (IS) 
 Outer nuclear layer (ONL) 
 Outer plexiform layer (OPL) 
 Inner nuclear layer (INL) 
 Inner plexiform layer (IPL) 
 Ganglion cell layer (GCL) 
 
The INL contains the cell bodies of bipolar cells that synapse with and transfer information between 
photoreceptors and ganglion cells. Horizonal cells and amacrine cells act to integrate and regulate signal 
transduction throughout the retina (5). There are approximately 120 million rod photoreceptors and 6 
million cone photoreceptors located within the outer retina of the human eye (6). Rod photoreceptor 
cells are located primarily in the periphery and peri-macular region of the retina and function to detect 
low-light and provide some element of night vision, also known as scotopic vision.  Cone photoreceptors 
account for almost all photoreceptors in the central macula and are required for central, fine-resolution 
and colour vision under bright light conditions, also known as photopic vision (6). The RPE has several 
functions, including: maintaining the health of photoreceptors by recycling photopigments, metabolising 
and storing vitamin A, phagocytosing shed photoreceptor OS, as well as other functions (7). By sensing 
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light, photoreceptor cells are able to create nerve impulses that are sent to the brain, via the optic 
nerve, for processing.  
 
 
 
Figure 1: Schematic illustration of retinal cell layers. Brown = RPE cells; Purple = Rod photoreceptors; 
Light blue = Cone photoreceptors; Yellow = Bipolar cells; Green = Ganglion Cells; Red = Horizontal cells; 
Dark blue = Amacrine cells. Taken from Sengillo et al. (2016) (5).  
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1.2 The visual cycle 
 
The visual cycle (see figure 2) is a process designed to detect light and convert it into electrical signal 
(phototransduction) followed by de-activation of the phototransduction cascade and 
recycling/preparation of necessary molecules to enable phototransduction to re-occur (photoresponse 
recovery).  
 
Figure 2: The Visual Cycle. Taken from Bavik et al. (2015) (8). 1 = All-trans-retinol retrieved from the 
blood circulation is converted into a retinyl ester within the RPE through the activity of lecithin retinol 
acyltransferase (LRAT). 2 = RPE65 catalyses the retinyl esters to generate 11-cis-retinol. 3 = 11-cis-retinol 
is then oxidized by retinol dehydrogenase to form 11-cis-retinal. 4 = 11-cis-retinal is delivered to rod and 
cone outer segments where it combines with opsins to form rhodopsin. Light activation of rhodopsin 
initiates visual transduction and liberates all-trans-retinal as a photoproduct. 5 = Reduction of all-trans-
retinal, via all-trans-retinal dehydrogenase, produces all-trans-retinol, which is transferred back to the 
RPE for recycling. The continued activity of RPE65 in the light state ensures sustained levels of 
rhodopsin, closure of ion channels through transducin activation, and reduced oxygen demand (8). 
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1.2.1 Activation of the phototransduction cascade 
 
Phototransduction is the process by which a photon of light detected by the retina creates a chain of 
events leading to the production of a neural signal. In order to appreciate the steps that take place 
following the arrival of a photon, it is first important to understand the baseline state of the 
photoreceptor in its absence. For simplicity, we will concentrate on the rod photoreceptors.  
 
The outer segment of the rod photoreceptor is integral to the process of phototransduction, 
encompassing vast quantities of lipid bilayer membrane that have been arranged into flattened ‘discs’ 
(9). Within this membrane, a light sensitive molecule known as ‘rhodopsin’ can be found.  
 
Rhodopsin is a G-protein-coupled receptor made up of 348 amino acids that has folded into a higher 
level structure to form 7 helical segments (9). Its concave shape extends across the cell membrane and 
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populates the disc membrane at a density of approximately 25,000 molecules per micrometre (9). This is 
equivalent to about 80% of the protein found in the disc membrane of rod OS (10). The chromophore 
termed ‘11-cis-retinal’ is permanently and covalently attached to rhodopsin, which acts as an inverse 
agonist to prevent its apoprotein (in the case of rhodopsin, this is ‘opsin’) from being activated (11). 
 
In the dark, a resting potential is generated in the photoreceptor cell due to open cyclic guanosine 
monophosphate (cGMP) -gated sodium (Na+) channels (see figure 3), also known as cyclic nucleotide-
gated (CNG) channels that are located in the outer membrane of the rod cell (9). The CNG channel is 
made up of 4 sub-units (3 sub-units of α1 and a single sub-unit of β1). When cGMP is available it binds to 
these sub-units and opens the central pore in the channel thus allowing Na+ and calcium (Ca2+) to enter 
thus depolarising the cell membrane. The internal membrane voltage is negative.  
 
 
Figure 3: Phototransduction activation in a rod photoreceptor. Taken from Burns et al. (2005) (12). The 
upper picture is demonstrating phototransduction activation. Photoexcited rhodopsin (R*) activates 
transducin (Gtα, Gtβ and Gtγ sub-units) and PDE (α-, β- and γ- sub-units). cGMP synthesised by guanylate 
cyclase (GC) is hydrolysed by activated PDE. Phototransduction deactivation in a rod photoreceptor. R* 
is quenched by phosphorylation by rhodopsin kinase followed by arrestin (Arr) binding. Transducin and 
PDE are deactivated by the RGS9-1-GβS-L.R9AP complex, which accelerates the rate of GTP hydrolysis on 
Gα.cGMP synthesis by GC restores cGMP to its dark level (13).  
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Phototranduction activation (see figure 3) consists of the following steps: 
 
1) Rhodopsin activation: When a photon of light strikes rhodopsin, it is absorbed by an electron in 
the 11-12 double bond position within 11-cis-retinal, which is promoted to a higher energy level. 
The pie bond is disrupted and the chain can rotate about a single axis of the sigma bond. The 
result is that the chain is temporarily free for rotation and isomerisation to its preferable 
‘straight’ position before the double bond is re-established. All-trans-retinal triggers a cascade 
of conformational changes in the opsin, allowing rhodopsin to transition through its 
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intermediate forms: photorhodopsin, bathorhodopsin, lumirhodopsin and metarhodopsin I with 
ultimate production of meta-rhodopsin II*.  
 
2) Transducin activation: Meta-rhodopsin II* is the activated form of rhodopsin that contains a 
structural pocket anatomically to enable the accessibility and coupling of transducin (Gt) – a 
trimeric G-protein attached to the cell membrane to maintain proximity with rhodopsin. 
Transducin is made up of α, β and γ sub-units found at a ratio of around 1:10 relative to 
rhodopsin (9). In its inactive form, a molecule of Guanosine di-phosphate (GDP) is found in 
association with the α sub-unit. When rhodopsin becomes active, a process called ‘nucleotide 
exchange’ occurs whereby a molecule of GDP is exchanged for Guanosine tri-phosphate (GTP) 
thus allowing separation and activation of the α sub-unit (9). One rhodopsin molecule activates 
as many as 200-400 transducin molecules per second (14).  
 
3) Phosphodiesterase activation: The α sub-unit moves away to another membrane-bound 
protein called phosphodiesterase (PDE). PDE is a cyclic nucleotide consisting of 4 sub-units (1 α, 
1 β and 2 γ sub-units) whose function is to hydrolyse cGMP. It is present at a ratio of 
approximately 1:100 relative to rhodopsin (9). The γ sub-units of PDE act to maintain its 
inactivation. The binding of transducin to the γ sub-units of PDE disrupts their function and 
subsequent activation of the α and β sub-units occurs to produce the active effector complex 
Gtα-PDE* (15).  
 
4) Hydrolysis of cyclic GMP: Gtα-PDE* is able to convert the available supply of cGMP to its non-
cyclic form 5 prime GMP (5‘GMP) via hydrolysis. The end result is a reduction in the 
concentration of cGMP and increase in the concentration of 5‘GMP (9). 
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5) Cyclic nucleotide channel closure: A decrease in the level of cGMP results in closure of CNG 
channels since cGMP is no longer bound to its sub-units and the central pore created cannot be 
maintained. When Na+ and Ca2+ cations are no longer able to enter the cell, hyperpolarisation 
occurs due to voltage changes becoming more negative (16). This signals to its synaptic terminal 
to reduce the rate of glutamate release, thereby activating the ‘on’-centre bipolar cell. This 
small change initiates the cellular events leading to vision. When rods turn off, ‘on’-centre 
bipolar cells turn on. This activates retinal ganglion cells, which send axons to the optic nerve 
and then the brain (9). 
 
 
1.2.2 De-activation of the phototransduction cascade  
 
Phototranduction de-activation (see figure 3) consists of the following steps: 
 
1) Deactivation of R* must occur: After photoisomerisation, the addition of 3 phosphates to R*’s C-
terminal residues (phosphorylation) are essential for normal response recovery and must be 
mediated by rhodopsin kinase (GRK1) within 100ms of a flash (16). This allows for the protein Arr to 
bind with high affinity to phosphorylated rhodopsin in order to prevent further activation of Gt 
molecules and thus assist with the process of deactivation (16).  
 
2) cGMP hydrolysis by PDE must reduce: Transducin remains active until GTP is hydrolysed – a 
process of catalysation involving a triumvirate complex of proteins including RGS9-1, Gbeta5-L, and 
R9AP (known as the RGS9 complex) (13).  
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3) cGMP-dependent CNG channels must re-open in order for electrical response to recover:  
GC  is a lyase enzyme located in the disc membrane that continuously generates cGMP in order to 
allow opening of CNG channels and depolarisation of the cell membrane following 
phototransduction. The activity of GC is controlled by GC-activating proteins (GCAPs) and its activity 
is dependent on the level of Ca2+ present. When phototransduction takes place, CNG channels close 
and Ca2+ influx is reduced. The resultant fall in Ca2+ activates GC-1 and GC-2 through GCAPs in order 
to produce more cGMP (16). In the dark, GC has low level activity with low cGMP to maintain the 
cell’s resting potential. 
 
 
1.2.3 Photoresponse recovery 
 
Once a photon has been detected by rhodopsin, the molecule is unable to detect a subsequent photon 
until the pigment has been reset to its ground state (17). The by-product all-trans-retinal must be 
converted back into 11-cis-retinal in order to allow for photoresponse recovery. 
 
The re-cycling process begins with release of all-trans-retinal from the activated opsin into the inner leaf 
of the disc bi-layer to form a complex with phosphatidylethanolamine. This complex is transported to 
the cytoplasmic disc surface by the retina specific adenosine triphosphate (ATP) binding cassette 
transporter (ABCR), and released into the cytoplasm (18). Here, the enzyme all-trans-retinol 
dehydrogenase acts to reduce all-trans-retinal to all-trans-retinol (vitamin A). The subsequent binding of 
all-trans-retinol to interphotoreceptor retinoid binding protein (IRBP), enables exportation from the 
photoreceptor outer segment to the adjacent layer of the RPE (17).  
In the RPE, all-trans-retinol is used to generate all-trans retinyl-esters with Lecithin retinol 
acyltransferase (LRAT). These esters serve as the substrate for an isomerohydrolase reaction, likely 
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catalysed by RPE65, which generates the visual chromophore precursor 11-cis retinol (8). Oxidation of 
11-cis-retinol, by 11 cis-specific retinal dehydrogenase, yields 11-cis-retinal, which is transferred from 
apical processes of the RPE to photoreceptor OS where it combines with the appropriate opsins to 
regenerate photosensitive visual pigment (See figure 2) (8).  
 
All-trans-retinal cannot be synthesised by humans and further stores of vitamin A must therefore be 
ingested in order to keep up supplies. This can subsequently be retrieved from the blood and 
transferred to the RPE where conversion to all-trans-retinyl esters takes place via LRAT (8). When 
required, these stores can be mobilised and catalysed by the RPE-specific protein, RPE65 (8). Deficiency 
of vitamin A can lead to night blindness. 
 
 
1.3 Inherited Retinal Disorders 
 
1.3.1 Overview of Inherited Retinal Disease 
 
Inherited Retinal Disease (IRD) is the leading cause of blindness certification in the working age 
population (age 16-64 years) in England and Wales (19) and the second most common cause of 
blindness certification in childhood (20).  
 
The term IRD incorporates a large group of disorders that are clinically and genetically heterogeneous 
(20). Whilst we have the added advantage of genetic testing to confirm many IRDs, definitive diagnosis 
based on the history and clinical examination alone can often be challenging due to overlapping 
phenotypes and unclear inheritance patterns. For example, it is possible for disease-causing variants 
within the same gene to result in varying phenotypes, yet may occur within different genes and result in 
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more similar phenotypes (21). To complicate matters further, family members may carry identical 
genetic disease-causing variants yet vary in expressivity of phenotype (22). This, together with the large 
number of genes that have been identified in IRDs (>250) can make it challenging to diagnose a patient 
with a specific disorder (22).  
 
When attempting to make a diagnosis of IRD, several factors are taken into consideration in order to 
steer the diagnosis in the right direction: 
 
 Identification of cell type affected: This can be identified through detailed history taking, clinical 
examination, imaging and electrophysiological assessment. A rod dystrophy affects rod 
photoreceptors. A cone dystrophy affects cone photoreceptors. When both types of 
photoreceptor are involved the nomenclature reflects the order in which the photoreceptors 
are affected, for example, rod-cone dystrophies affect the rods prior to the cones (23).  
 
 Distribution of retinal involvement: This will reflect the cell type involved and may be described 
as central, peri-central, sector or peripheral (24). 
 
 Natural history: IRDs are described as ‘predominantly stationary’ if the condition is present at 
birth or from early infancy and tends to remain stable throughout life. A ‘progressive’ IRD tends 
to present in the first or second decades of life and worsens over time.  
 
 Inheritance: IRDs may be inherited in an autosomal dominant (AD), autosomal recessive (AR), X-
linked (XL) or mitochondrial manner (23). Digenic inheritance refers to the situation where 
disease-causing variants are required in two genes in order for the disease to be expressed (23). 
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Female carriers of XL variants may be unaffected or show less severe symptoms than an 
affected age-matched male (23).  
 
 Systemic involvement present or absent: IRDs may have isolated ocular features, termed ‘non-
syndromic’ or the addition of systemic features termed ‘syndromic’ (22). 
 
 Regional distribution: IRDs may demonstrate regional distribution of retinal degeneration, for 
example, sectoral RP. 
 
 
1.3.2 Mechanisms of photoreceptor cell death 
 
Disease-causing variants triggering photoreceptor degeneration often affect the visual cycle or 
phototransduction cascade (25). Apoptosis is a form of programmed cell death considered to be the 
main pathway by which photoreceptors and/or RPE cells die (26). It is an active process provided with 
energy from mitochondria whereby a sequence of events triggered by the cell itself enables its removal 
without damaging adjacent healthy tissue (25). Enzyme activation is required in order to breakdown 
cellular deoxyribonucleic acid (DNA) and auto-digest intracellular components. A family of cysteine 
proteases known as caspases often drive these processes, leading to morphological changes such as: 
membrane blebbing, condensation of the nuclear chromatin and cytoplasm, fragmentation of the 
nucleus, and budding of the whole cell to produce membrane-bound bodies in which organelles are 
initially intact (25). These bodies are subsequently disposed of without inducing inflammation (25).  
 
Necrosis is another pathway by which photoreceptor loss can occur. Whereas apoptosis uses signal 
transduction pathways to result in orderly cell death, necrosis results in a premature death following 
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exposure to pathogens such as toxins, trauma, ischemia and infection (26). This leads to an unregulated 
digestion of cellular components. Necroptosis also results in necrotic cell death, however, unlike 
necrosis it is carried out in a regulated way. Similar to apoptosis, necroptosis begins with the binding of 
tumour necrosis factor (TNF)-α and Fas ligand to their respective cell surface receptors. This kick-starts a 
signal transduction pathway that relies on the following critical mediators: receptor interacting protein 
(RIP)-1 kinase, RIP3 and mixed lineage kinase domain-like protein (27).  
 
IRBP is an inter-photoreceptor matrix glycol-lipoprotein secreted by photoreceptors. It is known to play 
a pivotal role in photoreceptor survival, however, the mechanism by which this occurs is poorly 
understood. A variant in the human IRBP has been linked to RP. Animal models using IRBP -/- retinas 
have observed increased levels of RIP1, RIP3 and TNF-α receptor 1, an important membrane death 
receptor that mediates both programmed apoptosis and necrosis (28).  
 
Oxidative stress is another major factor considered to trigger photoreceptor apoptosis in a variety of 
retinal diseases (29). Photoreceptor cells accumulate reactive oxygen species (ROS) and oxidative stress 
that is usually balanced by antioxidant defences. Photoreceptor degeneration is likely to happen if the 
balance is tipped in favour of ROS. The Forkhead box O (FoxO) proteins include transcription factors that 
promote oxidative stress resistance by binding to promoters of genes encoding manganese superoxide 
dismutase, catalase, and autophagyrelated proteins (29). This pathway is emerging as an important 
family of proteins that modulate the expression of genes in the regulation of a variety of cellular 
processes including cell cycle, apoptosis, DNA repair, stress resistance, and metabolism (29) . These 
scavenger proteins are therefore considered to play an essential role in oxidative detoxification in 
mammals (29). 
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Inflammation is also becoming a better understood pathway by which retinal cell death can occur.  
Cubilla et al. observed increased photoreceptor apoptosis under basal, non-stress conditions using sub-
cutaneous mifepristone - an antagonist of the glucocorticoid receptor - suggesting that glucocorticoids 
play a critical role in basal photoreceptor survival (26).  
Selected IRDs will be discussed below to briefly illustrate the wide breadth of phenotypes and exemplify 
the application of clinical assessments in diagnosis and management: 
 
 
1.3.3 Retinitis Pigmentosa 
 
1.3.3.1 Overview 
 
Retinitis Pigmentosa (RP), classified as a rod-cone dystrophy, is a genetically heterogeneous disorder 
considered to be a final common pathway arising from rod photoreceptor degeneration and RPE 
abnormalities (30). With an incidence of 1 : 3,500 – 1 : 4,000 in the USA and Europe, RP is the most 
common form of IRD (22).  
 
Over 60 genes are known to cause RP and inheritance can be either AD, AR,XL or mitochondrial (10). AR 
inheritance accounts for 5 - 20% of RP and of these, 10-15% are due to variants in the USH2A gene (31, 
32). AD inheritance accounts for 15-20% of RP and of these, 20-30% are due to variants in the Rhodopsin 
(RHO) gene (31, 32). XL inheritance is considered to be the most severe form of RP with onset in 
childhood and accounting for 5 - 15% of RP (31, 32). Of these, 70-90% are due to variants in the RP 
GTPase regulator (RPGR) gene. There is no known family history in 40-50% of patients, with the majority 
of these have AR RP (31). A rare form of RP known as ‘digenic’ occurs when simultaneous variants arise 
in both PRPH2 (previously known as RDS) and ROM1 genes (33).  
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Additional terminology includes ‘simplex’ where an isolated case of RP occurs with an absence of family 
history and ‘multiplex’ where RP occurs in 2 or more family members (such as siblings) with no pre-
existing family history (24).   
 
1.3.3.2 Features 
 
The classic ophthalmoscopic triad of RP (see figure 4) includes:  
1) Attenuation of artery vessel calibre that occurs from vasoconstriction following vessel exposure 
to increased oxygen tension due to retinal thinning. 
2) Pallor of the optic disc referred to as ‘waxy pallor’ or ‘chamois yellow’.  
3) Bone-spicule retinal pigmentation. This represents a diffuse abiotrophic process where 
disruption of the RPE allows pigment to migrate along the course of the vessels, which tend to 
become obliterated following hyaline degeneration (34).  
 
Figure 4: Fundus photograph of a patient with retinitis pigmentosa.. 
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Another sign that can be easily seen on spectral-domain optical coherence tomography (SDOCT) 
(Spectralis, Heidelberg Engineering Ltd, Heidelberg, Germany) imaging is a change of retinal architecture 
whereby the degeneration of photoreceptors causes the ellipsoid zone, also known as the 
photoreceptor inner segment/outer segment (IS/OS) junction, to become indistinct (see figure 5) 
instead of being a clear, highly reflective line. 
 
Symptoms such as nyctalopia and progressive concentric (centripetal) visual field (VF) loss vary widely 
between patients depending on the type and location of a variant. For example, a patient is more likely 
to retain better visual acuity (VA) and improved dark light adaptation if a variant affects amino acids in 
the parts of rhodopsin located in the intradiscal space rather than the cytoplasmic space (36). Genetic 
modifiers and/or environmental factors account for phenotypic variation seen within families that share 
a common disease-causing variant (37). 
 
Other clinical signs associated with RP include: cataract (typically posterior sub-capsular), dust-like 
particles in the vitreous, cystoid macular oedema, white dots deep within the retina and hyaline bodies 
affecting the optic nerve (10). 
 
Triolo et al. (2013) reported choroidal neovascularisation (NV) in 3 of 176 eyes (2%) with RP (38). 
 
Figure 5: SDOCT images centered on the macula taken from a patient without RP (A) and a patient with 
RP (B). Red arrow: External limiting membrane (ELM); Yellow arrow: Ellipsoid zone (IS/OS junction); Blue 
arrow: Outer retinal layer thinning. Used with permission. 
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1.3.3.3 Associations 
 
Examples of syndromic RP include:  
 
 Usher syndrome: This is the most common syndromic form of RP, which is inherited in an AR 
manner (39). Usher Syndrome can be classified into 3 groups: Type 1 is the most common type 
(accounting for approximately 70% of patients with Usher Syndrome) comprising of profound 
congenital sensorineural hearing loss, absent vestibular function and RP (39). The RP typically 
occurs by the age of 10 years and progression is slow (39). Type 2 accounts for approximately 
26% of patients with Usher Syndrome and comprises of moderate to severe congenital 
sensorineural hearing loss (predominantly for higher frequencies), normal vestibular function, 
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and RP with onset by the age of 20 years (39). Type 3 accounts for approximately 4% of all 
patients with Usher Syndrome and comprises of progressive sensorineural hearing loss and RP 
with onset in second decade (39). Vestibular function may, or may not be affected. 
 
 Bardet Biedl syndrome: AR condition characterised by the association of RP, obesity, learning 
difficulties, polydactyly, hypogenitalism and renal abnormalities (40). 
 
 Kearns-Sayre syndrome: Mitochondrial inheritance with RP, external ophthalmoplegia, ataxia 
and heart block (41). 
 
 Bassen-Kornzweig syndrome (also known as Abetalipoproteinemia): This is a condition 
involving malformation of red blood cells with associated neuromuscular disturbances such as 
progressive ataxia. There is also associated fat malabsorption and subsequent reduction of fat-
soluble vitamin absorption (A, E and K) leading to clotting abnormalities and RP (24). 
 
 Mucopolysaccharidoses types I-III: This is a group of conditions characterised by RP in 
associated with facial and bony changes, learning difficulties and corneal clouding (42).   
 
1.3.4 Leber Congenital Amaurosis 
 
1.3.4.1 Overview 
 
Leber Congenital Amaurosis (LCA) accounts for around 5% of all IRD (43). This heterogenous recessive 
disease is considered to be the most severe form of IRD with an incidence of 3 per 100 000 births (44) 
and prevalence of 1 : 30 000 (45) to 1 : 81 000 (44). Disease-causing variants have been identified in 25 
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genes, the most common of which include: GUCY2D (6-21%), CEP290 (20%) and CRB1 (9-13%), however, 
approximately 30% of LCA patients remain without a molecularly proven diagnosis (43).  
 
1.3.4.2 Features 
 
Patients present in the first year of life with profound vision loss (typically ranging from 20/200 to no 
perception of light), roving nystagmus and amaurotic pupils (30, 43). Fundus examination ranges from a 
normal appearance to signs including maculopathy, bone-spicule pigment migration (see figure 6) and 
white flecks/dots (43).   
 
Figure 6: Fundus photograph of a patient with Leber Congenital Amaurosis (LCA) caused by a GUCY2D 
variant.  
 
 
Additional signs and symptoms include: hypermetropia (or less often myopia), photophobia, nyctalopia, 
Franceschetti’s oculodigital sign where a patient will repeatedly poke and rub their eyes, olfactory 
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dysfunction, keratoconus and cataract (43). These latter two signs may be associated with variants in the 
AIPL1 and CRB1 genes (43). Most cases are isolated, uncommonly LCA is part of a syndrome such as 
Senior-Loken or Joubert Syndrome. 
 
1.3.4.3 Imaging and electrophysiology 
 
OCT may demonstrate macular atrophy/thinning (43). Electroretinogram (ERG) is typically sub-normal or 
non-detectable and considered essential in the of diagnosis of LCA (43). It is also helpful in distinguishing 
LCA from conditions such as achromatopsia (ACHM) and congenital stationary night blindness (CSNB) 
that also present with poor vision, nystagmus and a normal-looking fundus (43). 
 
1.3.4.4 Natural history 
 
The cumulative data from several studies observing the natural history of LCA found that across 90 
patients, 15% demonstrated deterioration of vision, 75% demonstrated stability of vision and 10% 
demonstrated appreciable improvement of vision (44, 46-48). Indeed, it seems that certain variants in 
specific LCA genes demonstrate distinctive VA among the different LCA sub-types (43). 
 
 
1.3.5 Stargardt Disease 
 
1.3.5.1 Overview 
 
Stargardt disease (STGD) is the most common inherited macular dystrophy across all ages with a 
prevalence of 1 in 8 000 to 1: 10 000 (49-51). The most common form of disease is known as STGD1, 
which is associated with variants in the ABCA4 gene (50). Dysfunctional ABCA4 protein results in toxic 
accumulation of lipofuscin - a major component of which is the bis-retinoid N-retinylidene-N-
retinylethanolamine (A2E) - within RPE cells and subsequent photoreceptor cell death (23). Over 1000 
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disease-causing sequence variants have been identified in the ABCA4 gene alone (49, 52) and the carrier 
frequency is thought to be anywhere up to 1 : 20 (53). Whilst STGD1 demonstrates AR inheritance, there 
is also a rare dominantly inherited form of STGD known as STGD3 arising from variants in the ELOV4 
gene. 
 
1.3.5.2 Features 
 
Due to the large number of disease-causing sequence variants, there is marked phenotypic 
heterogeneity amongst patients with STGD1 with variable age of onset and severity of disease. It is 
thought that the more severe sequence variants, such as nonsense variants cause earlier presentation of 
disease with increased severity; whereas adult onset/foveal-sparing disease is more frequently due to 
missense variants (50, 54-57).  
 
Patients often present with bilateral central visual loss including dyschromatopsia and central scotomata 
(50).  
 
On examination, features range anywhere from a normal fundus appearance and/or subtle loss of foveal 
reflex and/or RPE changes seen in early disease to the characteristic yellow-white flecks and/or macular 
atrophy associated with a bull’s eye or beaten bronze appearance seen with advancing disease (23). See 
figure 7 for illustrative examples of eyes with different grades of visual impairment according to World 
Health Organization Criteria. 
 
Figure 7: Illustrative examples of eyes with different grades of visual impairment according to World 
Health Organization Criteria. A = no visual impairment; best corrected visual acuity (BCVA) 20/16. B = 
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mild visual impairment; BCVA 20/32. C = moderate visual impairment; BCVA VA 20/120. D = Blindness; 
BCVA VA 20/400. Taken from Kong et al. (2016) (58).
 
 
 
1.3.5.3 Imaging and electrophysiology 
 
Imaging, such as fundus autofluorescence (FAF) and SDOCT together with electrophysiological 
assessment, is of great benefit in assisting with the diagnosis of STGD in those who present without 
typical fundus features and in monitoring disease progression. 
 
Fortunately, lipofuscin is a pigment that is able to demonstrate autofluorescence. As such, RPE with 
greater amounts of lipofuscin within its cells will appear as areas of increased signal on FAF (See figure 8 
and 9). These areas of increased autofluorescence are at risk of photoreceptor cell loss (49). Prior to 
FAF, fundus fluorescein angiography (FFA) was helpful in demonstrating a dark (or ‘silent’) choroid - 
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occurring due to the blockage of choroidal fluorescence by lipofuscin within RPE, however, not all 
patients with STGD would demonstrate this feature (50, 55). 
 
Figure 8: FAF image taken from a patient with Stargardt disease. Please note the characteristic 
autofluorescent flecks seen throughout the retina. Used with permission.           
 
 
 
 
 
 
 
 
 
Figure 9: FAF image centred on the macula taken from a patient with Stargardt disease. Please note the 
characteristic areas of increased and decreased autofluorescence. Used with permission.           
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SDOCT is useful at highlighting areas where there has been loss of outer retinal architecture at the 
central macula (59).  
 
Electrophysiology is useful for both diagnosis and prognosis. Lois et al. (2001) established the following 
classification system (60):  
 Group 1: Normal full-field ERG (ffERG) in the presence of a diminished or undetectable pattern 
ERG (pERG) 
 Group 2: Reduced cone function on ffERG in the presence of a diminished or undetectable pERG 
 Group 3: Reduced road and cone function on ffERG in the presence of a diminished or 
undetectable pERG 
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Fujinami et al. (2013) performed a longitudinal study of patients with Stargardt disease and found that 
prognosis seemed dependent on the presence (or absence) of initial rod involvement. All patients with 
initial rod ERG involvement demonstrated clinically significant electrophysiological deterioration (Group 
3) (51). However, in direct contrast, clinically significant progression was observed in only 20% of 
patients with normal ffERG’s at baseline (Group 1) (51). 
 
1.3.5.4 Natural history 
 
While STGD is considered a progressive disorder, patients may also experience a plateau of symptoms 
(60).  
 
In the largest series to date (n = 68), Fujinami et al. (2013) retrospectively classified patients with STGD1 
into 3 groups based on their baseline FAF and evaluated longitudinal FAF changes and patterns over a 
mean average of 9.1 years (51): 
 
 Type 1: Localised low signal at the fovea with surrounding homogenous background 
demonstrated rate of atrophy enlargement as 0.06mm2/year. 
 Type 2: Localised low signal at the macula with surrounding heterogenous background with 
numerous foci of abnormal signal demonstrated rate of atrophy enlargement as 
0.67mm2/year. 
 Type 3: Multiple low signal areas at the posterior pole with a heterogenous background 
demonstrated rate of atrophy enlargement as 4.37mm2/year. 
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1.3.6 Achromatopsia 
 
1.3.6.1 Overview 
 
Achromatopsia (ACHM), also known as rod monochromatism, is an AR disorder affecting S, M and L 
cone photoreceptors (61-66). The prevalence of ACHM is 1 : 30,000 – 1 : 50,000 (61). Around 80% of 
ACHM can be attributed to variants within the CNGA3 and CNGB3 genes, affecting phototransduction 
through dysfunction of the α and β sub-units of CNG channels, respectively (67). Less common causes of 
ACHM include variants within the GNAT2, PDE6C and PDE6H genes, affecting phototransduction through 
dysfunction of the α sub-unit of Gt and the α and γ sub-units of cGMP-phosphodiesterase, respectively 
(67). More recently variants within the activating transcription factor 6 (ATF6) gene have been identified 
and are believed to affect the maintenance of endoplasmic reticulum and cellular homeostasis (68). 
 
1.3.6.2 Features 
 
Two forms of ACHM exist – complete and incomplete: 
 
Complete ACHM results from complete functional loss of cone photoreceptors. Patients typically 
present at birth or by early infancy with poor vision (20/200 or worse), pendular nystagmus, 
photophobia/photoaversion and reduced or absent colour vision (6, 69).  
 
Patients with incomplete ACHM (far less common) tend to have similar, but milder clinical findings than 
those with complete ACHM (6). This occurs due to partial impairment of cone photoreceptors. Patients 
with incomplete ACHM may thus retain a degree of colour vision and demonstrate VA as good as 20/80 
(6, 70).  
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The fundus appearance in ACHM may reveal macular changes and vessel narrowing, however, most 
commonly it looks entirely normal (6).  
 
1.3.6.3 Imaging and electrophysiology 
 
Imaging remains an important adjunct in the classification of ACHM. Sundaram et al. (2014) describe a 
method of classifying outer retinal findings using SDOCT in patients with ACHM (See Figure 10) as 
follows (67): 
 
1) Continuous inner segment ellipsoid (Ise) 
2) Ise disruption 
3) Absent Ise 
4) Foveal hyporeflective zone 
5) Outer retinal atrophy  
 
Figure 10: SDOCT images of 5 patients with achromatopsia (ACHM) demonstrating various phenotypes. 
Taken from Sundaram et al. (2014) (67). (i) continuous ISe band, (ii) ISe disruption, (iii) ISe absence, (iv) 
hyporeflective zone present, and (v) outer retinal atrophy. 
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Electrophysiological testing demonstrates absent or markedly reduced cone responses, with normal rod 
responses, and is valuable in helping to distinguish from LCA (71).  
 
1.3.6.4 Natural history 
 
There is inconsistency between data published regarding the progressive nature of ACHM (6). Whilst 
ACHM is considered by many to be a stable condition, Thomas et al. (2012) observed progressive 
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changes in retinal morphology over time in children with ACHM (72) and other studies have 
demonstrated loss of cone photoreceptors over time (72, 73). Newer techniques of imaging such as 
adaptive optics (AO) are able to produce images that can be used to quantify cone photoreceptors. 
However, in order to better explore the natural history of ACHM, larger numbers of patients, assessed 
over longer periods of time will be needed. 
 
1.3.7 X-linked Retinoschisis 
 
1.3.7.1 Overview 
 
X-linked retinoschisis (XLRS) is a condition resulting in abnormal splitting of the layers within the 
neurosensory retina. It has a prevalence between 1 : 5,000 – 1 : 20,000 people worldwide (74).   
 
In 1997, Sauer et al. identified the gene responsible for XLRS known as RS1 (75). When functioning, RS1 
is responsible for producing a protein called retinoschisin that binds to the surface of photoreceptors 
and bipolar cells in order to promote cell adhesion (69). Disease-causing variants within the RS1 gene 
therefore result in dysfunctional retinoschisin and loss of retinal layer integrity (69). To date, over 190 
disease-causing variants of the RS1 gene have been identified (69).   
 
1.3.7.2 Features 
 
While penetrance is complete, clinical expression is variable in males. Foveal retinoschisis (see figure 11) 
is commonly seen in patients with XLRS and therefore reduction of central vision to various extents is 
typically present. If onset occurs at birth or in infancy, presenting features may include strabismus 
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and/or nystagmus. In those that present later (around school age) bilateral central visual loss is typically 
the presenting feature (69). In adulthood, macular atrophy may occur (76). . Peripheral retinoschisis may 
also be seen in up to 50% of individuals and is typically located in the infero-temporal fundus (69). 
Hyperopia is also frequently seen (69). Complications such as retinal detachment (RD) or vitreous 
haemorrhage (VH) tend to occur within the first or second decade of life, and are associated with a poor 
prognosis (69). Female carriers have normal retinal structure and function (77).  
 
1.3.7.3 Imaging and electrophysiology 
 
SDOCT is an extremely useful tool that can demonstrate the presence of schisis even from a single line 
scan, for example, in an uncooperative child (69). The characteristic cartwheel pattern produced can 
also be demonstrated on FAF and is seen radiating out from the fovea, which occurs due to altered light 
transmission and is observed very commonly in XLRS (69, 74).  
 
Electrophysiological testing typically identifies an ‘electronegative’ ERG: reduced b-wave (with preserved 
a-wave) that occurs due to inner retina dysfunction (76).  
 
Figure 11: SDOCT image centered on the macula taken from a patient with retinoschisis. A: spokewheel-
like maculopathy. B: retinoschisis as seen at the level of the green line observed in A. Used with 
permission. 
 
A 
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1.3.7.4 Prognosis 
 
RD and/or VH are complications of XLRS that tend to occur within the first or second decade of life. Most 
RDs are rhegmatogenous in origin and occur in up to 20% of patients whilst VH is seen in up to a third of 
patients (78, 79).  
 
1.4 Update on Structural, Functional and Molecular assessment of IRD 
 
1.4.1 Structural assessment of IRD 
 
Over the years, imaging techniques such as SDOCT, FAF and AO scanning laser ophthalmoscopy (AOSLO) 
have been developed to provide adjuvant assessment of the retina in addition to history and clinical 
examination. Their role include:  
 To provide early detection of disease as clinical assessment may initially appear normal.  
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 To provide serial data in order to monitor disease progression (50).  
 
SDOCT is a rapidly evolving, non-invasive technique that uses simultaneous multiple wavelengths of 
reflected light to compile images of retinal architecture (23). This technique produces high resolution 
cross-sectional images that are able to detect signs such as outer retinal loss, retinoschisis and ELM 
thickening (59). ELM thickening that occurs prior to the development of atrophy in STGD has been 
detected in children as young as 5 years of age using SDOCT (23, 80). SDOCT has also been used to 
demonstrate that cataract surgery is safe and effective for patients with RP and that it does not seem to 
be associated with faster disease progression (81). 
 
FAF is based on the property of ‘autofluorescence’ – a physiological phenomenon where certain 
molecules are able to emit light at a longer wavelength than that with which they were stimulated. 
Lipofuscin is a by-product of cell function that demonstrates autofluorescence and is thus able to be 
detected within RPE cells (59). Increased amounts of lipofuscin and other related metabolites within RPE 
cells therefore appear as areas of ‘increased autofluorescence’. Whilst areas of reduced 
autofluorescence can be attributed to lower levels of RPE-containing lipofuscin, it may also represent 
areas of RPE and/or photoreceptor cell loss or atrophy. This test is particularly useful in STGD, where 
increased autofluorescence may highlight areas at risk of subsequent photoreceptor cell loss (23, 59).  
 
AOSLO is a non-invasive technique that makes use of scanning laser ophthalmoscopy to produce high 
resolution photoreceptor and RPE mosaics in both normal and diseased eyes in vivo (23). To enhance 
the images obtained by this method, AO uses a wave-front corrector, usually a deformable mirror, to 
remove higher-order optical aberrations of the eye (23). Images are montaged by piecing together the 
best frame acquired from each video clip taken at various locations of the retina (see figure 12). The 
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locations are denoted by X and Y co-ordinates, for example central would be 0,0 and 1 degrees 
temporally and superiorly would be noted as 1S,1T. This process is usually undertaken manually, 
however computer based programmes have now been created to assist with this process.  
 
Figure 12: Montage of the right macula of a patient with STGD created by myself using images acquired 
by AOSLO. Please note the black patches represent areas where either the image quality was too poor 
to include, or video clips did not overlap adequately to provide information for these segments.  
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1.4.2 Functional assessment of IRD  
 
Accurate baseline assessment of visual function is crucial in patients with IRD in order to help diagnose 
and stage the disease, aid with providing an initial prognosis and for subsequent monitoring of disease 
progression. There are a variety of methods that can be employed to achieve this: 
 
 Visual acuity: 
VA is defined as “the relative ability of the visual organ to resolve detail that is usually expressed as the 
reciprocal of the minimum angular separation in minutes of two lines just resolvable as separate and 
that forms in the average human eye an angle of one minute” (82). VA is considered to have 3 
components: 1) Spatial acuity is the ability to resolve two points in space. This is higher at the fovea than 
the periphery due to the difference in distribution of rods and cones. Increasing brightness also enables 
more cones to become responsible for VA and the ability to resolve a gap at the fovea increases (83). 2) 
Temporal acuity is the ability to distinguish visual events in time. Cones have a higher critical fusion 
frequency than rods at deciphering a flashing light from a continuous one (83). 3) Spectral acuity is the 
ability to distinguish differences in the wavelength of stimuli. Pilots exploit this natural phenomenon, for 
example, by using a background of red light in the cockpit; allowing high acuity tasks to be performed 
with stimulation of cones without bleaching the rods (83). 
 
Numerous methods of VA testing are available. The Snellen and logMAR chart are two examples of 
methods used to test VA in adults. Preferential looking tests such as Keeler cards can be used to make 
an assessment of VA in pre-verbal children. Other examples for testing VA in older children include: the 
Kay picture test where pictures children are asked to name pictures presented to them that they are 
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familiar with and the Sheridan-Gardner test where the patient uses an identification card to match up 
the letter presented to them.  
 
 
 Contrast sensitivity 
Contrast sensitivity measures the ability to distinguish between finer and finer increments of light versus 
dark (84). It is related to the number of photoreceptor cells in a given area. It is possible for a patient 
with IRD to have a normal VA but reduced contrast sensitivity thus impacting on their quality of life 
(QOL). The Pelli-Robson chart is an example of a test that measures contrast sensitivity; it is carried out 
by asking the patient to read increasingly pale grey letters on a white background. 
 
 
 Colour vision: 
Colour is detected by short, middle and long (s, m and l)-wavelength sensitive cone photoreceptors in 
the macula. Dyschromatopsia is observed when IRD affects the macula. Pinkers et al. (1993), however, 
observed that the presence of CMO in RP affects mainly VA and not colour vision (85).  
 
 
 Visual field testing: 
VF testing (VFT) is a non-invasive technique designed to detect peripheral and/or central defects (23). It 
requires the patient to focus on a central target whilst lights of varying size and intensity are presented 
in different parts of the VF. ‘Static perimetry’ presents light stimuli as stationary targets and is typically 
performed by an automated machine such as the ‘Octopus’. ‘Kinetic perimetry’ relies on an examiner to 
move a light stimulus from a non-seeing area to a seeing area. In either situation, a button is pressed by 
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the patient to inform the examiner (or computer) that they have seen the light. VFT is useful at baseline 
as well as at subsequent visits to help monitor progression of IRD.  
 
 Microperimetry: 
Microperimetry targets the central VF whilst simultaneously observing each point of retinal stimulation 
(86). Before the test begins, an infrared camera is used to define a reference frame. The stimulus 
position on the display can then be subsequently corrected if any eye movement is detected during the 
test. This produces information on how well a patient can fixate as well as allowing comparison of 
retinal sensitivity with retinal structure. Microperimetry is suggested to be a good measure for retinal 
function in IRD because retinal sensitivity in the macula correlates well with outer retinal thickness (86).  
 
 ‘Hill-of-vision’:  
‘Hill-of-vision’ (HOV) is a function of retinal sensitivity based on information acquired from VFT and 
microperimetry. On a topographical map, the highest peak represents an area of highest sensitivity, 
which is usually the fovea in eyes without disease. VF Modelling and Analysis (VFMA) is an innovative 
software currently being used to create detailed HOV maps that allow for a more thorough assessment 
of vision in IRD (23, 87).   
 
 
1.4.3 Molecular assessment of IRD 
 
Whilst construction of a family pedigree aids prediction of the inheritance pattern of a disease, 
confirmation of a mode of inheritance and identification of the specific underlying genetic variant(s) is 
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now possible with the help of molecular genetic testing. This is particularly useful when clinical diagnosis 
is uncertain, for example, in conditions with marked phenotypic variability.  
 
Methods of molecular genetic testing include: single gene testing, which is useful for conditions with 
strong phenotype and genotype correlations, for example, XLRS (RS1 gene) and STGD (ABCA4 gene) (88).   
 
Other methods of testing such as APEX genotyping microarray chips can detect a fixed number of known 
variants from a fixed number of genes, however, as many of the IRD variants are novel this is not ideal 
for retinal dystrophies (10). 
 
Next-generation sequencing (NGS) allows for large numbers of genes to be examined in a single 
sequencing assay in a relatively cheap and timely manner (10). This technique is employed for large 
gene panel testing, which is more appropriate for conditions such as RP where a large variety of genes 
can be responsible for the phenotypic picture (88). Panel testing also has the advantage over single gene 
testing in being able to detect modifiers, digenic variants, and multiallelic interactions that may 
complicate genetic diagnosis (88). 
 
Despite these excellent techniques, the overall disease-causing variant detection rate of molecular 
diagnosis remains around 60% (22). In those patients where a molecular genetic diagnosis is confirmed, 
genetic counselling is tailored to provide information such as prognosis of their disease, considerations 
when starting a family as well as potential participation in studies and clinical trials (89). Factors such as 
the large numbers of genes responsible, variable expression, incomplete penetrance and oligogenic 
inheritance can make obtaining molecular diagnosis quite challenging (10). Genetic heterogeneity 
further complicates matters as some genes are implicated in other forms of retinal disease (10). Whole 
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exome sequencing, and to a greater extent whole genome sequencing, is now improving the rate of 
molecular diagnosis, and is now approaching 80%. 
 
 
 
1.5 RP-associated cystoid macular oedema (RP-CMO) 
 
1.5.1 Pathogenesis of RP-CMO 
 
RP-associated CMO (RP-CMO) may complicate RP and has been reported to occur in 10 - 50% of patients 
(90-93). Patients with RP-CMO may experience reduction of central vision either from the presence of 
fluid itself, or from underlying degeneration of retinal neurons due to their compression by the fluid 
(94). Whilst the literature does not confirm a single aetiology as cause for the pathogenesis of RP-CMO, 
several mechanisms have been proposed. It is plausible that RP-CMO may result from one, or a 
combination of these to a greater or lesser extent, depending on the genetic variant associated with RP.  
 
1.5.1.1   Breakdown of the blood-retinal barrier 
The blood-retinal barrier (BRB) exists to maintain homeostasis via the highly selective diffusion and 
active transport of molecules into and out of the retina thus preventing extravascular accumulation of 
fluid within the retina (95). This is achieved in two ways (see figure 13): (i) an outer barrier of apical tight 
junctions between RPE cells (96, 97), and (ii) an inner barrier of tight junctions between vascular 
endothelial cells (98). CMO can occur from BRB breakdown secondary to RPE and/or endothelial 
damage/dysfunction.   
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Figure 13: Schematic illustration of the blood-retina barrier (BRB). The outer barrier is composed of tight 
junctions between retinal pigment epithelial (RPE) cells. The inner barrier is composed of tight junctions 
between retinal capillary endothelial cells, however, glial cells and Müller cells surrounding blood 
capillaries also contribute to the formation of barrier properties. Taken from Cascio et al. (2015) (99). 
 
 
Factors such as diabetes mellitus (DM), hypertension (HTN), aging and uveitis are known to cause 
weakening of the BRB (100). Indeed, the release of ‘toxic products’ released from the degenerating 
retina/RPE in RP may also cause weakening of the BRB and RP-CMO (101). These toxic products include: 
vascular endothelial growth factor (VEGF), adenosine (95), prostaglandins (PG) (100), histamine (102), 
Insulin-like growth factor-1 (IGF-1) (103), tumour necrosis factor alpha and interleukin 1 alpha and beta 
(104).  
 
Vinores et al. (1995) performed a study using immunolocalisation of endogenous albumin to identify 
whether extravasation was greater from the inner or outer barrier in eyes with RP compared to normal 
eyes (105). In eyes with RP alone, albumin leakage was greatest from the inner barrier (105). In RP 
associated with other ocular complications (e.g. aphakia, glaucoma), leakage varied between the inner 
and outer barriers. No correlation was found between severity of photoreceptor degeneration and 
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albumin leakage (105) suggesting that therapies for RP-CMO could be used regardless of underlying 
disease status. 
 
1.5.1.2 Failure (or dysfunction) of the pumping mechanism in the RPE 
The RPE constitutes a layer of cuboidal cells located directly underneath the photoreceptor cells, with 
extensions of microvilli from the apical surface that envelop their outer segments (see figure 14) (106). 
This single layer of cells has a variety of essential functions in order to help maintain vision, including: 
the conversion and storage of retinoid, the phagocytosis of shed photoreceptor OS membrane, the 
absorption of scattered light, ion and fluid transport and RPE-photoreceptor apposition (106). This latter 
function is achieved by pumping fluid out from the sub-retinal space in order to maintain negative 
hydrostatic pressure (107).  
 
Figure 14: Schematic illustration of the retinal pigment epithelium (RPE). Taken from Beranova-
Giorgianni and Giorgiani (2018) (108). 
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RPE cells exhibit polarity, whereby cell components are asymmetrically distributed in apical or 
basolateral domains of the cell (106). Unlike other epithelia, the Na+/K+-ATPase pump is expressed 
apically in the RPE cell. Under normal conditions, Cl- enters the RPE cell via this pump and exits via Cl- 
channels on the basolateral membrane that are modulated by intracellular Ca2+(106). It is this active 
transport that drives water through aquaporin channels from the sub-retinal space into the 
choriocapillaris. Failure (or dysfunction) of this pumping mechanism may occur in RP, which could result 
in RP-CMO. Furthermore, the presence of CMO has been suggested to result in loss of polarised 
distribution of membrane-bound carbonic anhydrase (CA) IV in the RPE, thus further contributing to RP-
CMO (98).  
 
 1.5.1.3 Muller cell oedema and dysfunction  
Regardless of the underlying pathogenesis, chronic CMO occurs only when the rate of fluid entry into 
the retina exceeds the rate of fluid absorption.  
 
Fluid entry into the retina can either be directly from the blood, coupled to glucose up-take and/or as a 
by-product of aerobic metabolism; with the bidirectional movement of water osmotically coupled to the 
transport of osmolytes such as potassium (K+) (See figure 15) (94). Whilst sub-retinal fluid absorption 
from the retina is via the RPE cell, the inner retina itself is dehydrated by the Muller cell. The Muller cell 
therefore not only plays an essential role in visual transduction but also in retinal homeostasis (fluid 
dynamics, ions, neurotransmitter molecules and pH) (94).  
 
Under normal circumstances, K+ released by activated retinal neurons are passively taken up by the 
Muller cells to prevent a build-up and potential excito-toxicity. This occurs via inwardly-rectifying 
channels (Kir), specifically Kir2.1, located in membranes with close proximity to the retinal neurons (94). 
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Release of K+ occurs via Kir4.1 channels located in membranes with close contact to structures such as 
blood vessels (94). Kir channels consist of two transmembrane regions with cytosolic NH2 and COOH 
termini connected by a pore-forming loop. Molecules such as magnesium (Mg2+) and polyamines are 
able to physically block the Kir4.1 channel pore from allowing outward movement of K+, while still able 
to accept inwards movement of K+ (109). In addition, under pathological conditions such as 
inflammation and oxidative stress, Kir4.1 channels redistribute, becoming more evenly spread 
throughout the Muller cell and moving away from sites where ion and fluid release takes place. Kir2.1 
channels, however, do not redistribute. Continued inward movement of K+ therefore results in 
intracellular K+ overload, increased osmotic pressure within the Muller cell, reduction in water efflux and 
ultimate Muller cell swelling (109). Indeed, it may be that the Muller Cell undergoes these changes and 
resultant swelling in retinal degenerative diseases such as RP. 
 
Figure 15: Water fluxes through the retina. Taken from Reichenbach et al. (2007) (94). AQP1 = 
aquaporin1 channel. ATP = adenosine 5′-triphosphate.  Kir4.1 = Inward rectifying potassium channel.  
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Makiyama et al. (2014) used OCT to investigate the prevalence and spatial distribution of cystoid spaces 
(CS) in patients with RP. Seventy-four of 275 patients (27%) demonstrated RP-CMO in at least one eye. 
INL CS were observed in 99% of eyes with CMO. The ONL/OPL was involved in 28% and GCL involved in 
7% (110). These findings indirectly support the hypothesis of Muller cell swelling and dysfunction since 
CS were most frequently observed in the INL, which is where Muller cell bodies reside. It is also 
interesting to note that 79% of CS were located in areas of relatively well-preserved outer retina (110); 
in keeping with the observation that CMO is seen more commonly in less advanced RP compared to late 
stage RP.   
 
Muller cells also release factors such as VEGF in response to hypoxic, inflammatory or glucose-deprived 
conditions thus contributing further to breakdown of the BRB and increased vascular permeability (94).  
 
 
 1.5.1.4 Anti-retinal antibodies 
In 1970, Rahi demonstrated that photoreceptors of the retina are antigenic using haemagglutination and 
precipitation techniques (111). This raised the possibility that retinal degeneration could be wholly or 
partly due to immunologic injury (112).  
 
Rahi (1973) subsequently managed to quantitatively estimate serum levels of immunoglobulin (Ig) G, A 
and M in 52 patients with RP compared to 40 controls (112). Significantly higher levels of IgM were 
found in a proportion of patients with RP as compared to controls, however, the exact role IgM plays in 
retinal degeneration could not be confirmed (112).  
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Spiro et al. (1978) investigated this further with genetic analysis to see whether a specific genetic class 
of RP had raised IgM levels. Unlike Rahi (1973), no difference in serum IgM levels was found between 75 
patients with RP and 51 controls. Neither was there a difference between genetic classes of RP patients 
detected (113). Disagreement of results between these studies may have occurred due to variation of 
method/techniques used, environmental factors such as viral illness, or differences in RP patient 
population recruited (113). 
 
Spalton et al. performed immunological studies on 17 RP patients with central and/or peripheral 
vascular leakage observed on FFA. IgG levels as well as complement C3 and its breakdown product levels 
were within normal limits in all patients. Similar to Rahi (1973), 5 out of 17 patients had raised IgM 
unrelated to degree of vascular leakage. All patients demonstrated positive immunofluorescence to rat 
photoreceptors at 1:5 dilution of serum, however, this could be attributed to cross reactivity of smooth 
muscle antibodies with photoreceptor contractile organelles (101).  
 
Anti-retinal antibodies have been prospectively studied by Heckenlively et al. (1996) in 30 RP patients 
with CMO compared to 30 RP patients without CMO. Anti-retinal antibodies were found in 27 of 30 RP-
CMO patients compared to 4 of 30 RP patients without CMO (114). The most common retinal proteins 
showing antigenicity were CA II (30 kD) and enolase (46 kD) both occurring in 17 (63%) of 27 patients 
(114). In 1985, Chant et al. screened sera by indirect immunofluorescence on normal donor human eye 
sections to detect antibodies to human retinal antigens. They found 43 (37%) of 116 patients with RP to 
have binding of serum antibodies to normal donor retina compared to only 1 in 42 (2%) in the control 
group (115). Nevertheless, the role of anti-retinal antibodies in RP progression or RP-CMO remains 
unclear, with many unanswered questions including whether they are a secondary consequence of the 
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degenerative process, the wide range of auto-antibodies identified, and the high prevalence in normal 
controls (114, 115).  
 
Whilst anti-retinal antibodies may play a role in RP-CMO, the exact mechanism through which this 
occurs is not fully understood. 
 
 1.5.1.5 Vitreous traction 
It has been suggested that vitreous traction and epiretinal membrane (ERM) may contribute to RP-CMO 
by causing mechanical damage to Muller cells via an inflammatory reaction with subsequent capillary 
dilatation and leakage (116, 117). Schepens et al. and Takezawa et al. have reported cases of RP-CMO in 
the presence of vitreous traction (see figure 16) (117, 118). Interestingly, vitrectomy with posterior 
hyaloid removal has been seen to improve cases of diabetic macular oedema (DMO) whether or not 
there is presence of posterior vitreoretinal traction (119). Improvement of CMO in eyes with chronic 
uveitis has also been observed following vitrectomy (120).  
 
Figure 16: Example of a patient with RP-CMO in the presence of vitreous traction. Taken from Takezawa 
et al. (2011) (118). Spectral domain optical coherence tomography images of the right A) and left B) 
eyes. In the right eye, cystoid macular oedema (CMO) at the fovea and posterior vitreoschisis (arrow) in 
the nasal quadrant is seen without a posterior vitreous detachment (PVD). In the left eye, minimal CMO 
at the fovea with a focal PVD (arrowhead) and posterior vitreoschisis (arrow) in the nasal quadrant are 
seen. 
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1.5.2 Diagnosis and monitoring of RP-CMO 
 
Prior to the advent of OCT, monitoring of RP-CMO included slit-lamp biomicroscopy together with FFA. 
OCT has since been shown to be more sensitive in detecting CMO compared to biomicroscopy in 
patients with diabetic retinopathy and RP-CMO (121, 122). OCT can detect CS in RP-CMO even when 
little, or no leakage is demonstrated on FFA (122, 123) and being non-invasive is ideal for monitoring RP-
CMO. No studies have been performed using OCT-angiography (OCT-A) to investigate RP-CMO. 
 
RP-CMO is not always associated with a reduction in VA (124). In 2009, Oishi et al. published a 
retrospective cross-sectional study carried out on 41 eyes of 25 patients with centre-involving RP-CMO. 
Cross-sectional scans obtained using Stratus OCT were reviewed to obtain information regarding foveal 
thickness, transverse/vertical lengths of foveal CS and photoreceptor layer thickness. These results were 
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compared with logMAR VA to see if there was a correlation with macular morphology. No correlation 
was found between VA and foveal thickness, photoreceptor layer thickness or vertical length of the CS. 
Whilst transverse length of CS demonstrated some statistical significance, the correlation coefficient was 
weak (125). The integrity of the IS/OS, however, has been shown to correlate well with VA and inform 
the likely prognosis (124-126).   
 
Reduced VA in patients with RP-CMO may therefore be due to underlying retinal atrophy in addition to, 
or instead of from increased foveal thickness (127). Underlying retinal dysfunction/loss should therefore 
be considered when anatomical improvement is observed without complementary improvement of VA. 
Automated static perimetry may also be useful for monitoring RP-CMO given the documented 
correlation between changes in retinal thickness due to CMO and retinal sensitivity (128-130).  
 
 
1.5.3 Inheritance patterns and specific associations with RP-CMO 
 
A detailed clinical history together with construction of a pedigree chart can help provide insight into 
the mode of inheritance a patient with RP has. However, definitive conclusion can only be made with a 
molecular diagnosis.  
 
In 1978, Spalton et al. investigated 25 patients with RP-CMO and concluded that oedema was no more 
common in any of the genetic groups when compared with any other: 6 patients with AD inheritance, 4 
males with XL inheritance and 1 female heterozygote with the XL gene (131). Two other patients had a 
family history of RP but not enough information for formal classification. The remaining patients were 
classified as sporadic or AR (131).  
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Hajali et al. (2008) investigated 124 patients aged between 8 – 71 years-old with RP and found CMO in 
at least one eye to be most prevalent in the AD group (52%), followed by the AR group (39%), isolated 
group (39%) and Usher II group (35%), however, this was not statistically significant (91). RP-CMO also 
did not appear to be related to age-related, however, the numbers of patients within the youngest and 
oldest age groups were small (91). 
 
Testa et al. (2014) carried out a retrospective cohort study involving 1161 eyes of 581 Italian patients 
with RP to assess for the presence of macular abnormalities. Data was collected using OCT images and 
medical records and found CMO to be the most frequent macular abnormality observed in 237/1161 
(20.4%) eyes from 133/581 (23%) patients. This was significantly more frequent in females (27.5%) than 
in males (19.1%) and in the AD inherited pattern (34.1%) compared to the AR (13.9%) and XL (7.1%) 
groups (93). ERM was the next most frequent macular abnormality, observed in 181/1161 (15.6%) eyes 
from 115/581 (19.8%) patients (93).  
 
In contrast, Liew et al. (2015) constructed pedigrees for RP-CMO patients in a retrospective cohort and 
found 55/81 (68%) patients with AR inheritance (4 of whom were molecularly proven), 25/81 (31%) 
patients with AD inheritance (16 of whom were molecularly proven) and 1/81 (1%) patients with XL 
inheritance (132).  
 
A Korean family with AD-RP associated with the p.P347L variant in RHO has been reported, where all 
four children had bilateral CMO, suggesting this RHO variant may be associated with early-onset CMO 
(133). Despite severe bilateral CMO in all four children (aged between 11 - …), VA remained good with 
preservation of the IS/OS line as confirmed by OCT. The mother (aged 44-years), however, had VA of 
light perception (PL) associated with marked foveal atrophy and a disruption of the IS/OS line confirmed 
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by OCT. The report suggests that early-onset CMO associated with the p.P347L variant in RHO may 
account for the severe visual prognosis (133).  
 
In a recent cross-section prevalence study published by Liew et al. (2018), 338 eyes of 169 patients with 
RP were evaluated using SDOCT for CMO and/or ERM. CMO was observed in 50.9% of eyes, which was 
associated with younger age but not with gender (134). Patients with ERM and cataract/pseudophakia 
were less likely to have CMO (134). CMO was most prevalent in patients with AD inheritance (71.4% 
with CMO in at least one eye), followed by AR/sporadic inheritance (58.9%) and XL inheritance (12.5%) 
(134). ERM was found in 22.8% of eyes (134).  
 
 
1.5.4 Avenues of intervention for RP-CMO 
1.5.4.1 Pharmacological 
 
 Carbonic Anhydrase Inhibitors: Oral and Topical 
CA is an enzyme involved in hydrogen (H+) ion transport located in various parts of the body (34). It 
increases renal elimination of Na2+/HCO3- and K+, which results in a reduction of plasma bicarbonate and 
resulting metabolic acidosis (34). In the presence of CMO, membrane-bound CA IV is thought to lose its 
polarised distribution in the RPE. Inhibition of this enzyme results in acidification of the sub-retinal 
space, increased Cl- transport, with subsequent movement of water across the RPE into the choroid (98). 
In addition, inhibition of CA increases tissue carbon dioxide (CO2) concentrations and/or lowers tissue 
pH, resulting in vascular dilation and increased blood flow (135). Transvitreal placement of a 
polarographic oxygen electrode in anaesthetised pigs observed an increase in oxygen tension and 
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dilation of retinal arterioles and venules 30 minutes after intravenous injection of 500mg dorzolamide 
(136).  
 
CAIs are often used for the treatment of RP-CMO despite no randomised controlled trials (RCTs) 
(comparing CAI with placebo) being published to provide evidence for their safety and efficacy. 
Notwithstanding this, several studies of varying quality have been published documenting response of 
RP-CMO following treatment with CAIs. The typical outcome measures used include central macular 
thickness (CMT) and VA. 
 
A recent systematic review published by Bakthavatchalam et al. including 23 studies concluded that 
whilst both oral and topical CAIs are “effective first-line treatments” for RP-CMO, oral acetazolamide is 
superior to topical dorzolamide (137). The paper recommended that oral acetazolamide therefore be 
considered as first-line treatment for RP-CMO unless its adverse effects cannot be tolerated in which 
case topical dorzolamide can be used (137). Intravitreal steroids, oral corticosteroid, intravitreal anti-
VEGF, grid laser photocoagulation, pars plana vitrectomy, or ketorolac were also deemed to be effective 
in improving RP-CMO for patients unresponsive to CAI treatment (137). Regardless of the type of 
therapy used, CMO recurrence was commonly seen long term (137).  
 
The largest retrospective study to date was carried out by Liew et al. in 2015. One hundred and fifty 
seven eyes of 81 patients with RP-CMO were investigated with SDOCT before, and after treatment with 
CAIs. Eyes were considered as ‘responders’ if CMT decreased by at least 11% following treatment (132). 
Sixty four out of 81 (79%) patients were treated with 2% dorzolamide topically. Of these 125 eyes, 40.0% 
were deemed as ‘responders’ to treatment with a mean reduction CMT of 105 microns (µm). Mean VA 
improved from 6/15 at baseline to 6/12 after a median time on treatment of 3 months. Patients with AR 
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inheritance were found to be more likely to respond to topical dorzolamide treatment than those with 
AD inheritance. Seventeen out of 81 (21%) patients were treated oral acetazolamide. Of these 32 eyes, 
28.1% were deemed as ‘responders’ to treatment with a mean reduction CMT of 115 µm. Mean VA 
improved from 6/15 at baseline to 6/ 12 over a median time on treatment of 4 months (132). Better 
response to treatment was observed in those patients with higher baseline CMT values. See figure 17 
demonstrating examples of patients who have demonstrated response to topical or oral CAIs. 
 
Figure 17: SDOCT of three patients with RP-CMO showing response to carbonic anhydrase inhibitors. B = 
Patient with USH2A-associated AR-RP; visual acuity 1/60 prior to treatment, C = The same patient after 9 
months of treatment with topical dorzolamide three times a day showing marked improvement in 
cystoid macular oedema but without any improvement in visual acuity. E = Patient with Ushers 
syndrome type 1-associated AR-RP, F = The same patient after 4 months of treatment with topical 
dorzolamide three times a day showing improvement of CMO; visual acuity improved to 6/12. H = 
Patient with AR-RP; visual acuity was 6/36 prior to treatment, I = The same patient after 7 months of 
treatment with 250 mg slow release oral acetazolamide twice a day and improved visual acuity of 6/18. 
Taken from Liew et al. (2015) (132). 
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Grover et al. (2006) carried out a prospective non-randomised study of 15 patients with RP-CMO where 
each patient was treated with topical dorzolamide three times daily for at least 4 weeks. Thirteen out of 
15 (87%) patients showed a reduction in CMT of at least 16% in at least one eye (138).  
 
Similar findings were observed by Fishman et al. (2007) who also carried out a prospective non-
randomised study of 8 patients with RP-CMO where each patient was treated with topical dorzolamide 
three times daily. All patients had a significant reduction of CMT after being on treatment for 1 -2 
months (139). Three out of 6 (38%) also demonstrated statistically significant improvement of VA by at 
least 7 letters on the Snellen chart, in at least one eye (139). 
 
Ikeda et al. (2013) carried out a prospective study in 10 patients with RP-CMO where each patient was 
treated with topical 1% dorzolamide three times daily for 18 months. Within 6 months, 9 out of 18 (50%) 
eyes demonstrated near complete resolution of CMO and another 5 out of 18 (28%) eyes demonstrated 
more than 20% reduction of CMT from baseline but this was not enough to classify them as near 
complete resolution (140). Improvement was sustained in 8 out of 9 (88.9%) eyes where near resolution 
of CMO was observed (140). Macular sensitivity improved by 18 months in all eyes in which initial CMO 
demonstrated near complete resolution (140).  
 
Fishman et al. (1994) carried out a prospective, double-masked, crossover study using oral 
methazolamide 50mg twice daily versus placebo. A wash-out period of at least 28 days was included in 
between trialling each substance. Nine out of 17 (53%) patients using oral methazolamide demonstrated 
angiographic improvement of CMO, however, VA improved in at least one eye, by at least 2 lines in only 
3 patients (141).  
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Fishman et al. (1989) also carried out a prospective, masked, crossover study using oral acetazolamide 
versus placebo for 2 week periods. VA improvement of at least one line, in at least one eye was 
observed in 10 out of 12 (83%) patients. However, 3 of these patients initiated on placebo demonstrated 
improvement only once switched to acetazolamide (142). Six out of 12 (50%) patients showed reduced 
leakage on FFA (142). 
 
A recent meta-analysis published by Huang et al. (2017) included 11 studies where patients with RP-
CMO had received topical or oral CAI therapy. Mean reduction in CMT was 46.02 μm, which was 
statistically significant. All but 3 studies demonstrated improvements in VA following CAI treatment 
(143). 
 
Effect of location of CS on response to CAIs 
Location of CS in RP-CMO may influence response to treatment with CAIs. Acetazolamide cannot readily 
enter the neurosensory retina making it potentially less effective at reducing INL CS (144). However, 
with good access to the RPE basolateral membrane (145), acetazolamide may be more effective at 
reducing ONL CS (146).  
 
After gathering information from the above studies, I designed a retrospective cohort series entitled 
‘Carbonic Anhydrase inhibitors for Retinitis Pigmentosa And Macular oEdema in various Layers (the 
CARAMEL study)’ using SDOCT to: 1) detect which layer(s) CS’s are present within in patients with RP-
CMO, and 2) to review the effect that topical versus oral CAIs have on these CS’s to see if there is a 
difference noted between treatments.  
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RP-CMO recurrence 
Rebound CMO has been observed after stopping CAIs.  
 
Grover et al. (2006) observed worsening of CMO with continued topical 2% dorzolamide three times 
daily treatment in 4 out of 13 (31%) patients demonstrating initial improvement (138).  
 
Similarly, Fishman et al. (2007) describe worsening of CMO in both eyes of 2 patients who initially 
improved using topical 2% dorzolamide three times daily treatment (139).  
 
Ikeda et al. (2013) observed RP-CMO recurrence in 4 out of 5 (80%) eyes by 18 months where an initial 
reduction of CMT by at least 20% from baseline had been observed within the first 6 months (140).  
 
Thobani and Fishman (2011) carried out a retrospective chart review on 3 patients (1 patient with type 2 
Usher syndrome, 1 patient with AD-RP and 1 patient with XLRS) using CAI therapy for CMO. All 3 
patients experienced a recurrence of CMO whilst on CAI medication, which was thus discontinued. After 
a discontinuation period of between 1 – 6 months, all 3 patients demonstrated improvement of CMO 
following re-introduction of CAI treatment (147). 
 
Side-effects: 
Unfortunately, systemic absorption of CAIs can result in side-effects such as fatigue, loss of appetite, 
limb paraesthesia, kidney stones, aplastic anaemia and electrolyte disturbance including hypokalaemia 
with potential associated cardiac arrhythmia (148). Fortunately, topical CAIs are available with both 
liposolubility and hydrophilia to allow the easy passing of the drug through the cornea, together with 
high affinity for the enzyme allowing 98% of CA inhibition (34). Side-effects are greatly reduced if using 
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topical treatment due to less systemic absorption. It can, however, lead to a bitter taste in the mouth 
due to inhibition of CA in the taste buds (139). Lacrimal sac compression during usage can lessen this 
effect.  
 
Several studies have compared efficacy of topical versus oral CAI therapy as it would appear optimal to 
use topical therapy to lessen the risk of side-effects: 
 
Grover et al. (1997) carried out a prospective, double-masked, cross-over study on 5 patients with RP-
CMO who were randomised to receive either topical 2% dorzolamide or placebo eye-drops three times 
daily for 4 weeks. This was followed by a 4 week wash out period before receiving the alternative eye-
drop for another 4 weeks. Following a second wash out period of 4 weeks, patients were treated with 
oral acetazolamide 500mg daily for 2 weeks. No objective improvement of VA was found in patients 
using topical 2% dorzolamide, however, 2 out of 5 (40%) patients had reduction of leakage seen on FFA. 
In comparison, an improvement of VA by 7 ETDRS letters or more was observed in 3 out of 5 (60%) 
patients when taking oral acetazolamide, with improvement of leakage documented by FFA in all 
patients (149). 
 
In contrast to this, a more recent publication by Pacella et al. (2014) described 3 case reports of patients 
with RP-CMO using topical 2% dorzolamide versus oral acetazolamide. It is important to note that only 
patients 1 and 2 were treated with three times daily topical 2% dorzolamide following discontinuation of 
oral acetazolamide due to side-effects and insufficient quantitative data is provided overall in order to 
allow direct comparison between these treatments: Patient 1 had an initially good response to once 
daily oral acetazolamide 250mg with resolution of CMO and improvement of VA from 4/10 at baseline 
to 8/10 in the right eye (RE) and 3/10 at baseline to 7/10 in the left eye (LE). Due to renal colic, this was 
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stopped and replaced with three times daily topical 2% dorzolamide after relapse of CMO. Reduction 
(but not resolution) of CMO was observed after 7 days of use as documented by Spectralis HRA-OCT. 
Images and figures are provided for the RE only; baseline CMT 551µm, 3 weeks after starting treatment 
CMT 401µm, 6 months after starting treatment CMT 376µm (34). Patient 2 was also initiated on three 
times daily ‘half a tablet’ oral acetazolamide. After 7 days, resolution of CMO and improvement of vision 
from 5/10 at baseline to 8/10 was observed in the RE, with reduction of CMO and improvement of vision 
from 3/10 at baseline to 6/10 in the LE. Treatment was stopped due to paraesthesia and asthenia and 
replaced with topical three times daily 2% dorzolamide in each eye following recurrence of CMO. 
According to the paper, “considerable improvement” of the oedema (RE more than LE) was observed, 
however, images and figures were provided for the LE only; baseline CMT 463µm, 3 weeks after starting 
treatment CMT 330µm, 6 months after starting treatment CMT 322µm. The third patient had a history 
of renal calculi so was initiated on three times daily topical 2% dorzolamide. Significant reductions of 
CMT were observed: Baseline median 459µm, range 449 – 551µm; 3 weeks after starting treatment 
median 373µm, range 318 – 410µm; 6 months after starting treatment median 348µm, range 270 – 
395µm (P = 0.002), however, no significant improvement of BCVA was observed in either eye (34). 
 
 Steroids: Oral, Periocular and Intravitreal   
Steroids inhibit production of arachidonate indirectly through the induction of lipocortin synthesis and 
subsequent inhibition of phospholipase resulting in reduced synthesis and release of pro-inflammatory 
cytokines, including: PG’s, leukotrienes, VEGF and intercellular adhesion molecule 1 (150-154). An 
additional action of steroids that non-steroidal anti-inflammatories (NSAIDs) are not able to do, includes 
the ability to reduce the migration of macrophages and neutrophils, thereby reducing vascular 
permeability (155). This results in an improvement of BRB function and reduction of CMO, which has 
been documented in several intraocular neovascular, proliferative and oedematous diseases (92, 156-
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171). Triamcinolone has also been shown to resolve CMO by preventing osmotic swelling of Muller cells. 
It achieves this by inducing the release of endogenous adenosine and subsequent A1 receptor 
activation, thus enabling the opening of ion channels (94). 
 
- Oral deflazacort 
Deflazacort is a third generation synthetic glucocorticoid with fewer side effects than prednisolone 
and longer immunomodulating and anti-inflammatory effects (160). Giusti et al. (2002) undertook a 1 
year pilot study using oral deflazacort in 10 patients with RP-CMO. The treatment regime included the 
following: 30 milligrams (mg)/day for a week, 15 mg/day for two weeks, 6 mg/day for one month, 6 mg 
every other day for two months, 6 mg/day every three days for four months, 6 mg/day every three days 
for four more months. Significant improvements in near VA, retinal sensitivity, and angiographic findings 
were observed within 4 months of treatment with no ocular or systemic side-effects recorded (160). 
Despite some recurrence of CMO that persisted throughout the study, 47% of patients had reduced 
leakage on FFA compared to baseline, at the end of the study (160). 
 
- Topical betamethasone 
Kitahata et al. (2018) carried out a retrospective cohort study including 16 eyes of 10 patients with RP-
CMO in whom treatment response with CAIs had been unsatisfactory. Topical 0.1% betamethasone was 
given daily following a 3-month course of topical brinzolamide in 14 patients and topical 2% dorzolamide 
in 2 patients. Mean CMT decreased over the first 7 months, but not thereafter compared to baseline. No 
statistically significant improvement of BCVA was demonstrated throughout the course of the study 
(172). Treatment was stopped in 3 patients in whom IOP was elevated.   
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- Intravitreal triamcinolone acetonide (IVTA) 
Five patients aged 25 – 41 years (mean 33.2 years) with RP-CMO that had failed treatment with 250mg 
oral acetazolamide twice daily for 1 month underwent unilateral intravitreal injection of 4mg (0.1ml) of 
triamcinolone acetonide. Oral acetazolamide was stopped once the injection had been received. CMT 
improved from 418µm (range 376–626µm) at baseline, to 224µm (range 214–326µm) at 1 month post-
injection, 275µm (range 215–584µm) at 3 months post-injection and 312µm (range 239–521µm) at 6 
months post-injection. VA improved in 2 patients by 1 month post-injection but was not maintained. IOP 
measurement did not exceed 21 mmHg during the follow-up period. Re-treatment was performed 
where CMO recurrence occurred in 1 patient at 3 months post-injection and in another 2 patients at 6 
months post-injection (92).   
 
Scorolli et al. (2007) carried out a prospective, non-randomised trial comparing 20 eyes of 20 patients 
with RP-CMO treated with 0.1ml IVTA with 20 eyes of 20 RP-CMO patients who declined treatment 
(controls). All treated patients demonstrated anatomical improvement, which was greatest at 3-months 
post-injection. No statistical improvement in VA was observed. At day-1 post-IVTA, 10 eyes (50%) had a 
raised IOP (>21mmHg) including 2 patients (10%) measuring between 30-35mmHg.  All IOPs returned to 
baseline within 6 months (168).  
 
A case report published by Barge et al. (2013) describes a 32-year-old male with bilateral RP-CMO 
refractory to oral acetazolamide and topical ketoralac, who received bilateral IVTA. VA improved from 
20/50 at baseline in the RE to 20/40 and 20/100 at baseline in the LE to 20/50 at 1 week post- injection 
with bilateral resolution of CMO (158). A rise in IOP was noted at 1 month post-injection in both eyes, 
which was controlled with topical timolol and brimonidine (158). At 2- and 5- months post-injection in 
the RE and LE respectively, VA reduced secondary to CMO recurrence. A second IVTA was performed in 
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the LE with resultant improvement of VA and CMO, however, CMO recurrence happened again. Bilateral 
sub-tenon injections of triamcinolone (40mg) were performed, again, resulting in improvement of VA 
and CMO. However, CMO recurrence occurred in the LE at 3 months (158).  
 
A case report published by Saraiva et al. (2003) describes a 30-year-old male with bilateral RP-CMO, 
treated with bilateral 0.1 mL IVTA (0.4%) solution following treatment failure with oral acetazolamide. In 
the RE, baseline BCVA remained unchanged from 20/40 despite resolution of CMO. In the LE, baseline 
BCVA improved from 20/80 to 20/50 with resolution of CMO. It should be noted that the paper does not 
state the exact timeframe at which these results were obtained post-injection. It does confirm, however, 
that any visual improvement gained was lost by 6 months post-injection due to recurrence of CMO 
(166).  
 
- Intravitreal dexamethasone 
Intravitreal dexamethasone (DEX implant; Ozurdex, Allergan, Inc., Irvine, CA) has also been used in 4 
eyes of 3 patients with RP-CMO refractory to oral CAI’s and/or sub-tenon triamcinolone and/or topical 
NSAID. Mean CMT improved from 443μm at baseline, to 234μm at 1 month post-injection. Mean BCVA 
improved from 20/160 (range 20/50–20/200) at baseline, to 20/100 (range 20/40–20/125) at 1 month 
post-injection. At 3 months post-injection, mean CMT was 332μm and BCVA was 20/125 (range 20/100–
20/200), requiring re-treatment in 2 patients due to CMO recurrence. No serious ocular or systemic 
adverse events (SAE) occurred (169).  
 
Another case report published in 2013 had similar outcomes; a 36-year-old male showing no VA 
improvement whilst using topical 2% dorzolamide three times daily received bilateral 0.7mg DEX 
implants. Complete resolution of CMO was documented in both eyes at 1 week post-injection and VA 
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improved from 2/10 at baseline, to 4/10 at 1 week post-injection in both eyes. Unfortunately, 
recurrence of CMO occurred at 2- and 3-months post-injection in the LE and RE respectively (164).  
 
- Limitations to the use of steroids 
Whilst the incidence of side-effects relating to the use of steroids in RP-CMO is unknown, common side-
effects ‘seen in more than 1 patient in 10’ following DEX implant, include: IOP rise, conjunctival bleeding 
and cataract (see figure 18). DEX implant appears, however, to have a lower incidence of cataract and 
raised IOP compared to IVTA in treatment of retinal vein occlusion (RVO)-CMO (173, 174). There has 
been one reported case of central serous retinopathy following DEX implant in a 46-year-old suffering 
from DMO (175). The regular use of steroids for RP-CMO will therefore be significantly limited by its 
side-effect profile. 
 
Figure 18: Mild sub-capsular cataract in the left eye. Taken from Barge et al. (2013) (158).  
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 Topical Non-Steroidal Anti-Inflammatory  
 
NSAIDs act by inhibiting cyclo-oxygenase (COX) thus reducing the formation of PG’s (154). Additional 
anti-inflammatory actions include suppression of polymorphonuclear cell locomotion and chemotaxis, 
reduced expression of inflammatory cytokines and the ability to act as free radical scavengers (176-178). 
 
RP-CMO is not a common condition and the majority of research on the mechanism behind CMO 
generation has therefore been in association with cataract and intra-ocular lens (IOL) surgeries (100). 
Increased levels of PG’s have been demonstrated in the aqueous following stimulation of the iris or 
other structures during surgery (100) and are highest when vitreous loss occurs (179). It is hypothesised 
that these PG’s diffuse into the vitreous causing breakdown of the BRB and resultant CMO. Results from 
a meta-analysis undertaken in 1998 confirmed that fluorescein-angiographic CMO can be prevented by 
pre- and post-operative use of the topical NSAID, indomethacin (180).  
 
With this in mind, NSAIDs have been trialled for use in RP-CMO (albeit minimally), which may arise from 
similar pathology of BRB breakdown. Non-selective COX inhibitors for ophthalmic use include indole, 
phenylacetic and phenylalkanoic acids, which are compounds easily converted into eye-drop 
formulation due to their highly water-soluble nature (177). Other chemical classes of NSAID, such as 
salicylates, fenamates and pyrazolone derivatives are considered too toxic to be used in the eye (177).  
Local side-effects from topical NSAID usage include stinging and conjunctival hyperaemia, however, 
systemic absorption is also possible (177). Studies in rabbits have found that up to 74% of the 
administered topical dose reaches the systemic circulation through absorption by nasolacrimal drainage 
(181). Effects such as exacerbation of bronchial asthma need to therefore be considered before 
initiating this treatment (182).  
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In 2015, a 12-month prospective and randomised study compared the topical effect of topical 
dorzolamide versus topical ketorolac on 28 eyes of 18 patients with RP or Usher syndrome-associated 
CMO. No significant change in CMT was observed in either group. VA improved in both groups at 6 
months, however, this improvement was lost in the dorzolamide group by 12 months (183). Sample size 
was a limitation to the study.  
 
 Combination of topical NSAID together with topical steroid or topical CAI 
 
A case report by Park et al. (2013) describes an 85-year-old lady with unilateral RP-CMO in whom CAI 
usage was contraindicated due to a history of chronic renal impairment. As an alternative option, topical 
steroid (prednisolone acetate 1%) together with topical NSAID (ketorolac trometamol 0.5%) was 
prescribed four times daily in the LE only. Complete resolution of CMO was observed on SDOCT and 
BCVA improved from 20/200 at baseline to 20/60 at 3 months in the LE. Medication was stopped, 
however, 6 months following cessation, re-treatment was required. Again, this resulted in complete 
resolution of CMO and improvement of vision from 20/120 at the start of treatment to 20/80 after 3 
months in the LE (184). 
 
 Intravitreal Anti-Vascular Endothelial Growth Factor (anti-VEGF) 
 
The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PIGF) (185). In 
addition to promoting angiogenesis, VEGF-A reduces endothelial barrier function and increases 
permeability of choroidal vessels, both of which cause CMO (185). Indeed, anti-VEGF agents are 
routinely used to treat CMO and NV in a variety of retinal diseases such as age-related macular 
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degeneration (AMD), RVO and DMO. The following anti-VEGF agents will be discussed in detail regarding 
treatment for RP-CMO: pegaptanib sodium, bevacizumab, ranibizumab and aflibercept (see figure 19). 
 
Whilst no studies have assessed vitreous levels of VEGF in patients with RP or RP-CMO, anatomical 
and/or functional improvement of RP-CMO has been observed following intravitreal anti-VEGF 
medication (3, 4, 186-189), which would support the hypothesis that VEGF contributes to RP-CMO 
formation. 
 
Salom et al. (2008), however, identified markedly lower levels of VEGF-A in the aqueous humour of 16 
eyes of 16 patients with RP (94.9 +/- 99.8 (mean +/- standard deviation (SD) picogram per millilitre 
(pg/mL)) compared to the same number of controls (336.5 +/- 116.8 pg/mL). Relative hyperoxia of the 
inner retina due to photoreceptor cell death may reduce VEGF production from retinal cells such as 
pericytes, endothelial cells, glial cells, Muller cells, and ganglion cells (190). The potential complications 
associated with the use of anti-VEGF therapy must therefore be considered. 
 
- Pegaptanib sodium 
Querques et al. (2009) published a case report regarding a 33-year-old male with RP-CMO refractory to 
treatment with oral acetazolamide in whom a single intravitreal injection of 0.3mg pegaptanib sodium 
(Macugen, Eyetech Pharmaceuticals, Inc. and Pfizer Inc, New York, NY) was trialled in the LE. Oral 
acetazolamide 500mg daily was continued throughout and stopped 1 month post-injection. BCVA 
improved from 2/200 at baseline to 20/40 in the LE and complete resolution of CMO was observed on 
OCT (no quantitative measurements of CMT are provided in the paper). Improvement of CMT and VA 
was maintained at 4 months post-injection despite withdrawal of oral acetazolamide (187). 
 
86 
 
Figure 19: Molecular properties of anti-VEGF agents. Taken from Klufas and D’Amico (2018) (191). 
 
 
 
- Bevacizumab 
Bevacizumab (Avastin, Genentech/Roche, South San Francisco, California) has been used off-label to 
treat RP-CMO with varying results.  
 
In 2007, Melo et al. observed neither anatomical nor functional improvement in 2 eyes of 2 patients 
following treatment of RP-CMO with a single injection of intravitreal 1.25mg bevacizumab: Case 1 
maintained VA of 20/200 both pre- and post-bevacizumab injection with no further improvement 
following IVTA. No significant difference was observed in CMT; pre-injection 524µm versus 529µm at 1 
month post-injection. Case 2 had a baseline VA of 20/100, which worsened at 1 month post-injection to 
20/200. No significant difference was observed in CMT; pre-injection 282µm versus 299µm at 1 month 
post-injection. Due to worsening cataract, the second patient subsequently underwent 
phacoemulsification plus IVTA and VA at 3 months post-injection improved to 20/25 (192).  
 
More optimistic results were seen, however, in 2009 when Yuzbasioglu et al. treated 13 eyes of 7 
patients with RP-CMO with an average of 3.3 (range, 1-8) injections of 1.25mg bevacizumab over 10.3 
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(range, 6-14) months. CMT reduced from 370.15µm (range, 245-603µm) at baseline to 142.53µm 
(range, 124-168µm). Pre- and post-treatment VA ranged from 5/400 - 20/100 and 20/200 - 20/63, 
respectively (189). 
 
Whilst choroidal NV is rare in RP, it is of interest to note that intravitreal bevacizumab has also been 
observed to improve RP-choroidal NV (193, 194).  
 
- Ranibizumab  
In 2009, a cohort study using off-label 0.5mg intravitreal ranibizumab (LUCENTIS; Genetech, South San 
Francisco, California, USA) was performed by Artunay et al. Thirty eyes of 30 patients with RP-CMO 
refractory to treatment with oral acetazolamide for at least 6 months were enrolled. Fifteen eyes of 15 
patients were treated with a single intravitreal injection of 0.5mg ranibizumab. Fifteen eyes of 15 
patients that declined intravitreal ranibizumab were used as a control group. Thirteen out of 15 eyes 
(87%) in the treatment group demonstrated a significant reduction of CMO at 6 months post-injection. 
No statistically significant difference in VA was seen between the groups (186).  
 
- Aflibercept  
Aflibercept (EYLEA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA and Bayer Healthcare 
Pharmaceuticals, Berlin, Germany) may be superior to other anti-VEGF medications due to its 
intermediate size (115 kilodaltons (kDa)) and higher binding affinity (3). Its longer duration of action 
compared to other anti-VEGF medications is of interest as the frequency of repeat injections may be 
reduced (195). Whilst aflibercept is currently approved by the US Food and Drug Administration (FDA) 
for the management of neovascular AMD (nAMD) (2011), DMO (2014) and RVO-CMO (2014), it is not 
yet approved for usage in RP-CMO as the evidence surrounding its ability to treat RP-CMO is lacking (4).  
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A case report published in 2015 demonstrated improvement of CMT and VA following a single unilateral 
intravitreal injection of aflibercept in a 52-year-old Caucasian man with RP-CMO (4). At baseline, the 
vision in the RE was 3/10. One month post-injection, vision improved to 4/10 and the CMO resolved. 
Documented visual improvement was maintained at both the 2- and 6-month reviews.  (4).  
 
Our group subsequently published a case report regarding a 52-year-old male patient from Dubai, 
United Arab Emirates, who presented to the UK with a 3-year history of bilateral RP-CMO. Previous 
treatment had been with topical 2% dorzolamide, oral acetazolamide, and intravitreal ranibizumab, 
which had demonstrated only minimal reduction of CMO. Following re-confirmation of the diagnosis by 
clinical examination and OCT imaging, bilateral loading doses of intravitreal aflibercept were given (see 
figure 20). CMT reduced and the patient returned to Dubai. After 6 months, the patient was treated with 
intravitreal ranibizumab due to re-accumulation of fluid and unavailability of aflibercept in Dubai. Only 
minimal reduction of CMT was observed. Once available in Dubai, intravitreal aflibercept was 
administered bilaterally with further reduction of CMT observed. VA remained stable throughout (3).  
 
Figure 20: OCT of both eyes before and after intravitreal injections of aflibercept given in the UK. OCT in 
the right eye before injection of aflibercept (A), 1 month after the first injection of aflibercept (B), 1 
month after the second injection of aflibercept (C), and 8 weeks after the third injection of aflibercept 
(D). OCT in the left eye before injection of aflibercept (E), 1 month after the first injection of aflibercept 
(F), 1 month after the second injection of aflibercept (G), and 8 weeks after the third injection of 
aflibercept (H). Taken from Strong et al. (2016) (3). 
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Having demonstrated potential to treat RP-CMO following injection(s) with intravitreal aflibercept, my 
research group commenced a 12-month prospective study entitled ‘Aflibercept for Macular oedema in 
underlying retinitis pigmentosa (AMOUR)’ to determine the safety and efficacy of intravitreal aflibercept 
in RP-CMO using a ‘treat and extend’ regime (ClinicalTrials.gov identifier NCT02661711).  
90 
 
- Long-term safety of anti-VEGF  
 
Miyata et al. (2018) published an article demonstrating no negative effects related to the progression of 
VF loss during continuous treatment with anti-VEGF agents (34 injections received in total; bevacizumab 
× 2, pegaptanib × 2, ranibizumab × 11, aflibercept × 19 ) for 8 years in a 56-year-old patient with 
choroidal neovascular membrane (CNV) associated with RP (196). 
 
  
1.5.4.2 Nutritional 
 
 Oral Lutein 
Lutein and zeaxanthin are carotenoid pigments that contribute to the formation of macular pigment 
(MP). MP is thought to be protective against oxidative damage being most densely packed within the 
central 1° to 2° and located in the receptor axon layer (197).  
 
Adackapara et al. (2008) published a 48-week study using lutein supplementation for 77 eyes of 39 
patients with RP over 11 months. OCT scans were carried out every 6 weeks together with clinical 
examination. CMO was present in 19 out of 39 (49%) patients, which was bilateral in 17 out of 19 
(89.5%) of these patients. Interestingly, baseline VA did not differ significantly between the groups of 
patients with and without CMO. Lutein was found to have no statistically significant effect on CMT in 
patients with RP either with, or without CMO (90).   
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 Oral Iodine 
Iodine has been shown to promote tight junctions between RPE cells. Theoretically, it is possible that 
increasing iodine intake could improve RP-CMO by improving outer BRB integrity and fluid absorption 
(198). To date, however, there are no prospective trials using oral iodine for RP-CMO. This may be partly 
due to previous studies in mammals documenting RPE toxicity in sufficient concentrations (198). 
However, at a low intravenous concentrations, iodine has been observed to enhance RPE integrity in 
albino and pigmented rabbits (199).  
 
Sandberg et al. (2014) performed a cross-sectional observational study of 212 non-smoking patients 
aged 18 to 69 years with RP to determine whether CMT in the presence of CMO is related to dietary 
iodine intake inferred from urinary iodine concentration (UIC). A total of 201 patients returned sufficient 
urine samples, however, 2 of these samples contained outliers for UIC and were not considered in the 
analysis. CMO was detected in at least one eye in 72 out of 199 (36.2%) of patients.  
 
Higher UIC levels have been observed to be significantly associated with reduced CMT in non-smoking 
adults with RP-CMO (198). Although many patients were also taking vitamin A and/or docosahexaenoic 
(DHA) supplements throughout the study, further analysis found no confounding effect on the 
relationship of CMT and UIC. It would be interesting to perform a prospective randomised trial to review 
the effect of oral iodine on patients with RP and CMO versus those with RP without CMO. 
 
 Laser 
The retina receives oxygen and nutrients from the choriocapillaris via diffusion. In order for this to reach 
the inner retina, molecules must first pass through the outer retina where photoreceptors reside with a 
very high density of mitochondria and high oxygen consumption. Laser acts by causing thermal 
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destruction to both the RPE and adjacent photoreceptor cells with replacement by glia. This reduces 
oxygen consumption and allows oxygen to diffuse more easily from the choroid through the 
photoreceptor layer into the inner retina (200). Improved oxygenation of the inner retina should lead to 
constriction of retinal vessels (autoregulation) with decreased blood flow following laser treatment 
(200). According to Poiseuille’s law, vessel resistance is inversely proportional to the radius to the fourth 
power. Vasoconstriction thus causes an increase in resistance and reduction of hydrostatic pressure 
downstream. As per Starling’s law, this should reduce water flux from the vessel into the tissue allowing 
the oncotic pressure to drive water back into the vessels thus reducing CMO (200). In addition, the 
removal of hypoxic degenerating retina by laser reduces levels of VEGF and may improve leakage of fluid 
from vessels. 
 
In 1987, grid laser photocoagulation was undertaken in one eye of 16 patients with bilateral RP-CMO. 
Six treated eyes gained one or more lines of vision, while none of the untreated eyes did. Seven 
untreated eyes lost one or more lines of vision, while none of the treated eyes did. Thirteen of 16 eyes 
showed decreased fluorescein leakage after treatment (201).  
 
 Vitrectomy 
In 2003, Garcia-Arumi et al. published a prospective non-randomised case series evaluating vitrectomy 
combined with inner limiting membrane (ILM) peel in 12 eyes of 8 patients with RP-CMO. All patients 
had been deemed refractory to treatment with acetazolamide. The presence or absence of pre-
operative vitreo-macular traction (VMT), however, was not confirmed. All patients had surgery 
performed by the same surgeon. Mean CMT improved from 478µm (range, 380 - 570µm) pre-
operatively to 342µm (range, 310–432µm) at 3 months post-vitrectomy and 260µm (range, 177 - 
424µm) at 6 months post-vitrectomy. Mean VA improved from 20/115 (range, 20/60 – 20/400) pre-
93 
 
operatively to 20/45 (range, 20/30 – 20/100) at 6 months post-vitrectomy (116). These results suggest 
that vitrectomy combined with ILM peel may reduce CMT with improvement of vision in patients with 
RP-CMO. 
 
1.6 Approaches to therapy for IRDs 
 
There are currently no cures for IRD. However, research is underway to better understand these 
diseases and to offer potential therapies that may slow or stop disease progression and/or reverse sight 
loss in people with IRD (20).  
 
1.6.1 Supportive management of IRD 
 
1.6.1.1 Visual rehabilitation 
Various types of visual rehabilitation are available for patients depending on their type and extent of 
visual impairment. Chotikavanich et al. (2018) recently published a 5-year retrospective record review of 
hospital-based low-vision rehabilitation in Thailand. It comprised of 992 patient records, of which 760 
were aged over 15 years (“adults”) and 232 were 115 years or younger (“children”) (202). Problems 
affecting the retina affected 534 out of 760 (70.3%) adults and 100 out of 232 (41.3%) children. RP was 
the most common ocular cause of vision loss in adults accounting for 215 out of 760 (28.3%). This study 
is interesting because it highlights QOL-related goals and what services patients are accessing for visual 
rehabilitation. Adults most commonly wished to be able to ‘read, write, and perform near tasks’ (503 
out of 1,449 (34.7%) eyes), and to have ‘independent mobility’ (309 out of 1,449 (21.3%) eyes), whereas 
children wished to have ‘visual and developmental stimulation’ (134 out of 349 (38.4%) eyes) (202). The 
services most commonly accessed by adults included ‘visual aid devices’ 436 out of 842 (51.8%) services 
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provided and ‘orientation and mobility training’ 343 out of 842 (40.7%) services provided, whereas 
children mainly received ‘visual and developmental stimulation’ by multidisciplinary teams 125 out of 
273 (33.8%) services provided (202). Studies such as this can help to guide future low-vision patient care 
and rehabilitation services.  
 
Common visual aid devices such as glasses, contact lenses and magnifying glasses can improve the use 
of residual vision. Computers (including specialised computer software) allow patients to easily adjust 
their screen display and text size as well as offering additional features such as speech synthesis and 
portable Braille devices.  
 
Photophobia may also be lessened through the use of dark or special filtered glasses or red-tinted 
contact lenses (6).  
 
‘Eccentric fixation’ is a technique adopted by patients with central vision loss; fixation occurs at the edge 
of the lesion within a normal area of retina instead of at the fovea (203). Although resolution is reduced, 
magnifying aids can be used to compensate for this. Whilst many patients naturally adopt the use of 
eccentric fixation, training is available if desired for patients who continue to fixate centrally (203).  
 
The history of the invention of Braille dates back to the early 1800’s. Charles Barbier, a man serving in 
Napoleon Bonaparte’s French army, wished to create a method of communication between soldiers that 
could not be easily intercepted by the enemy - as opposed to previous visual methods of communication 
using lamps that drew attention to their position (204). The system created was thus tactile-based, using 
a 12-dot cell, which had two dots across and six dots down. Unfortunately, it was deemed too complex 
for use in the battlefield, however, Barbier believed there was a place for his system amongst civilians. A 
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lecture Barbier gave at the Royal Institute for Blind Youths in Paris in 1821 was attended by Louis Braille 
(see figure 21), a boy born in 1809, who had lost his vision after accidentally stabbing himself in the eye 
with his father’s awl (a gadget used to create holes in leather goods). Braille was inspired by Barbier’s 
military code and spent time thereafter creating a more simplified version based on a 6-cell dot system, 
known as ‘Braille’, which to date is available in over 120 languages (see figure 22) (204).  
Figure 21: Portrait of Louis Braille by Lucienne Filipi (Braille Museum, France). Taken from Jimenez et al. 
(2009) (205). 
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Figure 22: Braille alphabet as it currently exists. Taken from Jimenez et al. (2009) (205). 
 
 
 
 
 
Guide dog services are provided by ‘Guide Dogs’, which is solely charity based (206). There are 
approximately 5000 guide dogs in the UK (206). Guide dogs have been demonstrated to reduce journey 
avoidance in patients with visual impairment; a study by Lloyd et al. (2008) noted 34 out of 50 (68%) 
participants avoided one or more journeys (i.e., environments, routes and destinations) before they 
received a guide dog (207). Common advantages for having a guide dog as reported by participants, 
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included: Facilitates independent mobility, Obstacle avoidance, Safer travel, Can dispense with cane 
(stigmatising through sight and sound, and prods abdomen) and Dignified travel (less stumbling) (207). 
Common disadvantages for having a guide dog as reported by participants, included: Previous cane skills 
deteriorate, Less safe/efficient or disorienting if dog is not working well, Obstacles are not located or 
identified and Mobility is reduced as dog ages/slows down or becomes sick (207). 
 
There are two types of cane used by patients with visual impairment: The ‘symbol or identification’ cane 
is made from a series of white aluminium tubes connected together with an elastic cord, which is mainly 
used to make others aware that the person carrying it has a mobility disability (208). The ‘long’ cane is a 
longer white cane with a plastic ball at the bottom end, used in a sweeping motion from side-to-side to 
identify obstacles along someone’s path (208). Advantages for using a cane, include: being easily 
replaceable, affordable and allowing a person to receive tactile information about the environment 
around them. Disadvantages for using a cane, include: getting caught, for example, in cracks along the 
road and being negatively affected by adverse weather conditions such as snow. 
 
 
1.6.2 Prevention of cell death (retinal neuroprotection) 
 
As mentioned in section 1.3.2 Mechanisms of photoreceptor death, apoptosis plays a significant role in 
IRD and is considered the main pathway by which photoreceptors and/or RPE cells die (26). Various 
retinal disease models have therefore looked at novel ways of directly inhibiting apoptosis: 
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1.6.2.1 Growth factors 
Neurotrophic factors have the ability to inhibit the apoptotic cascade and are therefore of interest as 
potential therapies for IRD (209).  
 
Pharmacological treatment with nerve growth factor (NGF) has been trialled and shown to promote 
photoreceptor survival in animal models of RP (210).  
A pilot study published by Falcini et al. (2016) administered daily murine NGF eye-drops for 10 days in 16 
eyes of 8 patients with RP. Whilst some mild corneal irritation was noted, no SAEs were reported. No 
significant visual loss was observed as measured by flicker electroretinogram (fERG) and BCVA (209). 
Three patients reported subjective improvement of vision that was associated with temporary 
enlargement of the VF with improved fERG (209).  
 
A multicenter, sham-controlled study published in 2016 by Birch et al. evaluated the long-term efficacy 
of ciliary neurotrophic factor (CNTF) delivered via an intraocular encapsulated cell implant for the 
treatment of RP (211). Thirty-six patients at 3 CNTF4 sites were randomised to receive a high- or low-
dose implant in 1 eye and sham surgery in the fellow eye. Eyes retaining the implant showed 
significantly greater VF loss from baseline than either explanted eyes or sham eyes by 42 months (211). 
By 60 months and continuing through 96 months, VF loss was comparable among sham-treated eyes, 
eyes retaining the implant, and explanted eyes, as was VA and macular volume (211).  
 
This reduction of photoreceptor function associated with the use of neurotrophic factors occurs due to 
the down-regulation of phototransduction cascade enzymes (209). It would therefore only be clinically 
useful if its benefits outweighed these risks. 
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1.6.2.2 Neuroprotective peptides 
Somatostatin is an endogenous neuroprotective peptide produced in large quantities by the retina, most 
specifically the RPE (212). It acts as a neuromodulator through pathways such as: intracellular Ca2+ 
signalling, nitric oxide function, and glutamate release from photoreceptors (212). In addition to 
neuroprotection, somatostatin has potent anti-angiogenic properties and regulates various ion/water 
transport systems (212). Topical somatostatin has been observed to reduce ERG abnormalities and glial 
activation as well as reduction of photoreceptor apoptosis (212).  
 
Akiyama et al. (2012) analysed the effect of pigment epithelium-derived factor-impregnated 
nanoparticles (PEDF-NPs) on photoreceptors in a retinal degeneration model using rats. At 8 weeks post-
intravitreal injection, significantly increased numbers of cells in the ONL (due to inhibition of apoptosis) 
with preservation of a- and b-wave amplitudes in ERG studies were observed in eyes treated with PEDF-
NP, compared to those treated with PEDF alone (213). This suggests that nanoparticles could be used as 
a long-term delivery system for growth factors to delay photoreceptor degeneration (213). Careful 
quantification of neuroprotective peptide is essential since the overexpression of IGF-1 in a mouse 
model resulted in loss of photoreceptors, bipolar, ganglion and amacrine cells (214).  
 
 
1.6.2.3 Antioxidants 
 
- Studies using RD models 
Studies using RD models may provide insight for the treatment of IRD since RD also generates ROS that 
leads to photoreceptor apoptosis. This occurs when the physical separation of photoreceptors from 
underlying RPE leads to reduced oxygen and nutrient supply to photoreceptor OS (29). Resveratrol is a 
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potent antioxidant and small molecule activator of the FoxO pathway – affecting the cell cycle, 
apoptosis, DNA repair, stress resistance, metabolism and oxidative stress (215). Huang et al. (2013) 
observed that resveratrol given via intraperitoneal injection was able to reduce caspase activation and 
photoreceptor apoptosis in a RD model (29).  
 
- Studies using glaucoma models 
Studies using glaucoma models may provide insight for the treatment of IRD since glaucoma is another 
ocular condition associated with apoptosis (of retinal ganglion cells) leading to progressive loss of vision 
(215). Lulli et al. (2012) observed that topical administration of coenzyme Q10 in a mouse model was 
capable of penetrating through to the retina to provide a neuroprotective effect against apoptosis of 
retinal ganglion cells (215). 
 
Berson et al. (2010) carried out a randomised, controlled, double-masked trial to evaluate the effect of 
lutein supplementation on the VF of patients with RP. The trial involved 225 non-smoking patients who 
received either 12mg of lutein or a control tablet daily over a 4-year period. All patients were given 15 
000 International units (IU)/day of vitamin A palmitate. Total point score for the Humphrey Field 
Analyzer (HFA) was used as the primary outcome measure. Mean decline with the 60-4 programme was 
slower among those with the highest serum lutein levels. Lutein may therefore offer protection from 
oxidative damage and supplementation of 12 mg/day has been observed to slow loss of mid-peripheral 
VF in non-smoking adults with RP taking vitamin A (216). 
 
- Oral lutein 
In 2000, Danelie et al. published a study using lutein supplementation for a total of 26-weeks in 13 
patients with RP as well as 3 patients with other retinal degenerations. Dosage was initiated at 
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40mg/day for 9 weeks and reduced to 20mg/day thereafter. Ten patients taking vitamin A and/or beta-
carotene before the study commenced, continued this throughout. VA was tested by the patients 
themselves using a computer; Mean VA improved by 0.7 decibels (dB) but gains were most notable in 
those patients with blue eyes. Central VF area was tested by the patients themselves using a wall-chart; 
Mean VF area improved by 0.35dB but gains were most notable in those patients who received previous 
supplements. This short-term improvement plateaued at 6 to 14 weeks (217).  
 
In 2001, Aleman et al. used heterochromatic flicker photometry to measure MP optical density profiles 
of 47 patients with clinically diagnosed RP, 11 patients with Usher syndrome and 29 controls. Following 
this, a subset of patients (23 with retinal degeneration versus 8 controls) were provided with 20mg/day 
lutein supplementation over a 6-month period to determine whether baseline serum and MP density 
could be modified (197).  It should be noted that this study was neither masked nor placebo-controlled. 
Thirteen out of 58 (22.4%) of patients with retinal degeneration were taking vitamin A orally at 15,000 
IU/day before the study commenced and were encouraged to continue taking this throughout. No 
difference in MP density levels were found between patients with retinal degeneration and controls. 
Lutein supplementation had no significant effect, positive or negative, towards foveal vision parameters 
(197).  
 
- Systemic edaravone 
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, MCI186, Radicut) is a free radical scavenger with 
antiapoptotic and anti-inflammatory effects (218). It has been used via intravenous infusion to treat 
acute ischemic stroke and has been found to be effective in mouse models against retinal degeneration 
both in vivo and in vitro (219, 220).  
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1.6.2.4 Inhibition of necrosis 
 
Inhibition of RIP1 has been observed to be successful in preventing cone and rod photoreceptor 
degeneration. RIP3 kinase inhibition has been observed to prevent cone necrosis. Inhibition of the RIP 
pathway could therefore be a therapeutic target to prevent retinal degeneration, at least in some 
disease models (28).  
 
1.6.2.5 Anti-inflammatory mediators 
Various anti-inflammatory mediators such as steroids have been studied as potential therapies for IRD. 
Mo et al. (2013) reported that intravitreal 17 beta-estradiol significantly reduced neuronal apoptosis in a 
light-induced model (221).  
Cubilla et al. (2013) found that sub-cutaneous injections of mifepristone, an antagonist of the 
glucocorticoid receptor, caused increased apoptotic signals in retinal extracts and apoptosis of the 
photoreceptors under basal, non-stress conditions (222). This suggests that glucocorticoids play a critical 
role in basal photoreceptor survival. 
 
 
1.6.2.6 Other pharmacological therapies 
Valproic acid (VPA) is a potent inhibitor of histone deacetylase and the inflammatory response pathway 
via apoptosis of microglial cells. It can also down-regulate complement proteins and increase levels of 
various neurotrophic factors (223). It is currently prescribed as an anti-convulsant, mood stabiliser and 
for the prevention of migraine but has shown neuroprotective potential for IRD. Clemson et al. (2011) 
carried out a retrospective chart review of 13 eyes of 7 patients with RP who had taken between 500 - 
750 mg/day of VPA for 2 – 6 months. Statistically significant improvement of Goldman VF was observed 
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in 9 eyes. Two eyes had decreased VF and 2 eyes demonstrated no change. All 13 eyes demonstrated 
statistically significant improvement of BCVA (223).  
 
Unoprostone isopropyl is a large-conductance Ca2+-activated K+ channel inhibitor currently used in 
topical form as a treatment for glaucoma. Due to its neuroprotective mechanism and ability to improve 
macular blood flow, unoprostone isopropyl shows potential as a therapeutic treatment for patients with 
RP (224). A phase III, multicenter trial carried out in Japan reviewed the efficacy and safety of 
unoprostone in the treatment of RP. The primary endpoint, however, found no significant difference in 
the value of mean retinal sensitivity at four central points through HFA (10-2) compared with placebo 
(clinicaltrials.gov identifier NCT01786395). 
 
Brimonidine is a topical alpha2-agonist that may offer neuroprotection by slowing the progression of VF 
loss in patients with RP. Merin et al. (2008) carried out a placebo-controlled, double-masked, 
randomised study in 26 patients with retinal dystrophies. One eye received brimonidine tartrate 0.2% 
twice-daily whilst the other eye received artificial tears. Only 17 patients out of 26 (65%) completed 
follow-up. Whilst no difference was observed in VA, colour vision, or contrast sensitivity between the 
treated and placebo eyes, a trend toward a lesser degree of VF loss was found in the brimonidine-
treated eyes (most strongly observed in a subgroup of patients with RP) (225). An exploratory, 12-
month, ascending-dose study has also been carried out to evaluate the safety and efficacy on visual 
function following a single injection of brimonidine intravitreal implant in one eye of patients with RP 
(clinicaltrials.gov identifier NCT00661479). Details of statistical analysis are pending. 
 
Fenretinide is a synthetic derivative of vitamin A that can be taken orally. It forms a complex with retinal 
binding protein (RBP), which is then excreted in the urine. With reduced levels of circulating RBP, 
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Vitamin A (retinol) is unable to bind to form the vitamin RBP-retinol complex resulting in decreased 
vitamin A concentrations in the eye and deceleration of A2E formation (226). Fenretinide has been 
demonstrated to reduce A2E production in the eye in knockout (KO) mice (ABCA4 -/-) thus offering a 
potential therapy for STGD (226). This is of particular interest for a subset of patients with AR-RP due to 
variants in the ABCA4 gene (227).  
 
QLT091001 is a synthetic retinoid replacement for 11-cis-retinal that has the potential to improve visual 
function by restoring this key component of the visual cycle. Wen and Birch (2015) carried out a phase I 
study to evaluate whether once-daily treatment with oral QLT091001 for 7 days can improve visual 
function in 14 patients with LCA and 18 patients with RP due to RPE65 or LRAT variants (228). Nineteen 
of 28 eyes (68%) with LCA and 13 of 36 eyes (36%) with RP were classed as ‘responders’, whereby 
improvement of Goldmann VF retinal area of the primary isopter by ≥20% was observed at two 
consecutive study visits starting within 2 months of treatment (228). Baseline thickness of the OS layer 
in responders was 13.5µm in those with LCA and 11.7µm in those with RP. Baseline thickness of the OS 
layer in non-responders was less than 4.6µm in both groups. This suggests that patients with a greater 
baseline outer segment thickness are more likely to respond to treatment with QLT091001. 
 
CU239 is non-retinoid compound able to specifically target and inhibit RPE65, a key enzyme in the visual 
cycle. Shin et al. (2018) observed a protective effect on the retina by CU239 in a light-induced retinal 
damage murine model (229).  
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1.6.2.7 Gene therapy 
Gene therapy describes a technique whereby a defective gene creating an abnormal or deficient 
product is replaced with a functioning gene. It is more applicable to the earlier stages of disease before 
significant retinal deterioration has occurred (20).  
 
Common viral vectors used include adeno-associated virus (AAV) and lentivirus. AAV is a small, non-
enveloped virus consisting of a protein shell surrounding and protecting a small, single-stranded DNA 
genome of approximately 4.8 kilobases (kb) (230). They are particularly useful as a viral vector (see 
figure 23) as they are: non-pathogenic, provide long-term transgene expression, produce minimal host 
immune response, and infect both dividing and quiescent cells (230). 
 
Figure 23: Gene therapy using an adenovirus vector. Taken from Strong and Michaelides (2017) (231). 
The defective gene creating an abnormal or deficient product is replaced with a functioning gene. 
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Animal models of IRD have enabled significant progress to be made in the field of gene therapy. They 
have provided insight into the specific gene defects causing retinal disease and the mechanisms 
involved, as well as aiding the design of molecules for translational research and gene-based therapy 
(230). Mice are the most popular models as transgenic technology is far advanced and animal housing is 
inexpensive (230).  
 
The eye is considered an excellent organ for gene therapy. This is for several reasons: 1) Its immune 
privilege created by the BRB prevents a florid inflammatory reaction following introduction of a vector, 
2) The organ is of small size, which minimises the amount of vector required, 3) The eye has easy access 
and compartmentalisation allowing treatment to be given using a variety of techniques, including: 
intravitreal, intracameral, subretinal or suprachoroidal (232). The contralateral eye can also serve as a 
control, which is useful when undertaking RCTs (5). 
 
While sub-retinal injection following PPV and retinotomy causes a temporary focal separation of the 
neurosensory retina from RPE that spontaneously resolves, complications such as macular holes, sub-
retinal haemorrhage, sub-retinal fibrosis, RD and rarely extension of the vector to other sites can occur 
(232). Intravitreal injection is more cost-effective and indeed safer, although endophthalmitis and RD 
remain a risk factor and the vector may struggle to enter the retina. This can be improved using 
techniques such as preliminary argon laser to initially disrupt the ILM (232). The suprachoroidal space 
can be reached via microneedle puncture of the sclera but has only been performed in rabbits (233). 
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Selected gene therapy trials for IRD 
 LCA 
Several trials for LCA have assessed viral vectors to induce transduction in the RPE65 gene:  
 
LUXTURNA™, also known as voretigene neparvovec (AAV2-hRPE65v2) has been recently FDA and 
European Medicines Agency (EMA)-approved following a randomised, controlled, open-label, phase 3, 
clinical trial published by Spark Therapeutics Inc. in 2017 using bilateral, sub-retinal injections of 
LUXTURNA™ for patients with RPE65-related IRD, including LCA and RP (234). Significant improvement 
of light sensitivity, VFs and navigational ability under dim lighting conditions were observed in the 
intervention group versus the control group (234). No product-related serious adverse events or 
immune responses occurred (234).  
 
Bainbridge et al. (2015) published a phase 1/2, open-label, dose-escalation study using recombinant AAV 
2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA for patients with LCA. Although no 
improvement was observed on ERG, an improvement of retinal sensitivity was found in 6 patients, 
peaking at 6 - 12 months, which lasted for up to 3 years (235). 
 
A longer-term follow-up study for patients who have been administered AAV2/5-OPTIRPE65 in the 
phase I/II, open label, non-randomised, two-centre, dose escalation trial in adults and children with LCA 
associated with defects in RPE65 is currently underway (ClinicalTrials.gov Identifier: NCT02946879).  
 
A phase III study evaluating sub-retinal injection of SPK-RPE65 in patients with LCA (an AAV2 gene 
therapy that delivers the RPE65 gene) observed statistically significant improvement in full-field light 
sensitivity threshold testing as well as ability to navigate a mobility course under various lighting 
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conditions in 21 treated patients compared with 10 controls (236). Unfortunately, no significant 
improvement of VA was observed. 
 
 STGD 
SAR422459, formerly known as StarGen™, is a gene-based therapy using the lentivirus vector to deliver 
a corrected ABCR gene via sub-retinal injection in patients with STGD. A pre-clinical 6-month study has 
demonstrated efficacy following a single administration. A phase I/IIa, dose-escalation study 
investigating the safety and efficacy of SAR422459 in STGD1 over a 48-week follow-up period is being 
undertaken (NCT01367444 results pending). There have been no safety concerns in the first three 
cohorts of subjects with relatively advanced disease, and no definite evidence of efficacy. Another 
cohort with less severe disease is also being recruited and may indeed show greater potential to benefit 
(231, 237).  
ABCA4−/− mice have been studied as a model for STGD1 in which rAAV-mediated delivery of a 
complement negative regulatory protein, known as complement receptor 1-like protein y (CRRY) into 
the subretinal space resulted in: reduced complement factors C3/C3b in the RPE, a two-fold reduction in 
bis-retinoid accumulation and 30% fewer lipofuscin granules/increased photoreceptor nuclei in the ONL 
compared to sham-injected ABCA4−/− mice after 1 year (238). 
 
 
 Retinitis Pigmentosa 
 
A dose escalation, phase 1/2 clinical trial of retinal gene therapy for XLRP using an AAV-encoding RPGR is 
currently recruiting 24 patients at Manchester and Oxford Eye Hospital (ClinicalTrials.gov Identifier: 
NCT03116113). 
109 
 
 
Another open label, multi-centre, phase I/II dose escalation trial of a rAAV (AAV2/5-hRKp.RPGR) for gene 
therapy of adults and children with XL-RP owing to defects in RPGR is currently recruiting 36 patients at 
Moorfields Eye Hospital, London (ClinicalTrials.gov Identifier: NCT03252847). 
 
 XLRS 
rAAV-mediated delivery of the normal RS1 gene to the retina of young KO mice has demonstrated long-
term retinoschisin expression and rescue of the retinal structure and function (69, 231). There are 
currently two phase I/II trials assessing the safety and tolerability of a two virus vectors delivered 
intravitreally specifically targeting RS1 gene to express retinoschisin (clinicaltrials.gov identifier 
NCT02416622 and NCT02317887) (232).  
1.6.3 Tissue replacement:  
 
1.6.3.1 Retinal stem cells and transplantation 
 
Two scientists, John B. Gurdon and Shinya Yamanaka, were jointly awarded ‘The Nobel Prize in 
Physiology or Medicine 2012’ following their discovery that mature, specialised cells can be 
reprogrammed to become immature cells capable of developing into all tissues of the body.  
 
In 1962, John B. Gurdon was able to replace the immature cell nucleus of an egg cell from a frog with 
the nucleus of a mature intestinal cell (239). A survey of over 150 frogs was performed obtained by the 
transplantation of donors ranging from late blastulae to swimming tadpoles (239). His results 
demonstrated at least 30% of blastula nuclei and at least 4% of hatched tadpole gut-cell nuclei 
contained a complete range of the genetic information required for formation and functioning of a 
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normal frog (239). Another observation noted was that transplant frogs derived from nuclei of 
differentiating cells were more often abnormal than those from embryonic cell nuclei (239).  
Embryonic stem cells (ESCs), obtained from the inner cell mass of blastocysts, are pluripotent meaning 
they can potentially give rise to cells from all three germ layers including ectoderm, endoderm and 
mesoderm (240). In 1981, Evans and Kauffman were the first to discover how to culture ESCs from 
mouse blastocysts (241). In 1998, Thomson et al. published the first report regarding the successful 
isolation of human embryonic stem cells (hESCs) from human blastocysts (242). This generated much 
controversy due to this process involving the destruction of human embryos. 
 
The ability to isolate hESCs (see figure 24) means that, theoretically, transplantion of specialised cells in 
order to replace damaged tissue in patients suffering from various degenerative diseases, is possible. 
However, the signalling mechanisms involved in lineage restriction of ESC to adopt various cellular 
phenotypes are still under investigation (243). Furthermore, for progression of hESC-based therapies 
towards clinical applications, appropriate culture conditions must be developed to generate genetically 
stable homogenous populations of cells, to avoid possible adverse effects following transplantation 
(243).  
 
In 2006, Takahashi and Yamanaka’s ground-breaking research demonstrated that adult somatic cells 
(using mouse fibroblasts) can be reprogrammed to generate induced pluripotent stem cells (iPSCs), 
using specific factors, back into an embryonic stem cell-like state (244). By using fibroblasts - the most 
commonly used primary somatic cell type for the generation of iPSCs - many of the ethical and technical 
hurdles associated with obtaining ESCs have been overcome.  
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Patient-specific iPSCs have since enabled scientists to investigate specific disease-causing variants and 
their associated pathophysiologic mechanisms, evaluate novel gene augmentation, gene silencing, small 
molecule therapies, and restore function through the transplantation of manufactured cells and tissues 
(231, 245).  
 
One major advantage of iPSCs is the high availability of fibroblasts which can be easily isolated from skin 
biopsies. Being derived directly from adult tissue, other advantages of iPSCs include: reduced risk of host 
immune system rejection and the need for embryos can be bypassed. Due to the plasticity of stem cells 
and their unlimited capacity for self-renewal, however, adverse events (AE) such as tumour formation, 
immune rejection, and the risk of differentiating into unwanted cell types are possible (7, 231). Studies 
to date have therefore mainly focused on the safety and tolerability. 
 
The first-in-human, phase I/IIa, open-label, prospective study of the safety and tolerability of sub-
retinally transplanted human retinal progenitor cells (hRPC), created by ReNeuron, is being carried out 
in 15 patients with RP in the USA (clinicaltrials.gov identifier NCT02464436) (231). This followed on from 
rat model studies where treatment with hRPCs resulted in better VA compared with untreated eyes and 
greater preservation of the ONL on histological analysis (231, 246). ReNeuron claim that their hRPCs 
offer low immunogenicity and the potential for large-scale production using a patented and highly 
efficient cell expansion process (231, 246). 
  
Studies such as Lund et al. (2006) have demonstrated extensive photoreceptor rescue in an animal 
model of retinal disease following sub-retinal transplantation of hESC-derived RPE (see figure 25)  (247). 
In 2015, Scwartz et al. published the results of two phase I/II, open-label, multi-centre, prospective 
studies carried out to determine the safety and tolerability of sub-retinal transplantation of hESC-
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derived RPE cells in patients with STGD and atrophic AMD (7, 231). hESC-derived cells were well 
tolerated for up to 37 months after transplantation in patients with either disease. No evidence of 
adverse proliferation, rejection, or serious ocular or systemic safety issues related to the transplanted 
tissue were found (7). The AEs, such as Staphylococcus Epidermidis-related endophthalmitis 
experienced in 1 patient, were specifically associated with vitreoretinal surgery and immunosuppression 
(7). 
 
Figure 24: hESC-derived cone cells. Image provided by Dr. Anai Gonzalez Cordero at The UCL Institute of 
Ophthalmology, London, UK. Used with permission. 
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Figure 25: hESC-derived RPE cells. Image provided by Dr. Anai Gonzalez Cordero at The UCL Institute of 
Ophthalmology, London, UK. Used with permission. 
 
 
 
 
1.6.4 Artificial Vision - Retinal Implants 
 
Medical devices aim to improve quality of vision for patients with IRD. The restoration of useful vision 
can be achieved by bypassing diseased retina and sending signals directly to the brain, or by improving 
the clarity and magnification of patients’ surroundings (231). Current devices for patients with RP that 
are European conformity (CE) marked and available for use in the UK, include (20):  
 
 
The Alpha IMS is a 3.2 x 3.1mm2 wireless sub-retinal microchip containing 1500 electrodes contained in 
a 50 x 50µm square arrangement. The device is able to capture light, stimulate the optic nerve and 
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deliver signals to the brain. The device is powered by a wireless pocket battery and patients adjust the 
brightness using a dial fitted behind the ear. A clinical trial interim report suggests that sub-retinal 
implants can restore very-low vision or low vision in IRD patients with PL vision or worse (248). The cost 
of the Alpha IMS device together with the surgical implantation is estimated at $130,000. 
 
A Clinical trial interim report published by Stingl et al. (2015) referred to 29 blind patients with outer 
retinal degeneration in whom the Alpha IMS device had been implanted (248). The results of this 
international, multicenter clinical trial found that almost half of the patients could recognise object 
shapes and detail in daily life and almost three-quarters could localise high-contrast objects (248). The 
Alpha IMS is therefore able to restore low, but useful vision, in patients blind from hereditary 
degenerations of the photoreceptors with VAs up to 20/546 (249). 
 
The durability and longevity of the Alpha IMS, however, was sub-optimal, mainly due to technical 
failures which occurred in some implants within the 12 month clinical trial observation period. A newer 
device, known as the Alpha AMS (see figure 26), was therefore created to address these technical 
glitches with improved materials and design (249). The Alpha AMS is a 3.2 x 4.0mm2 wireless sub-retinal 
microchip containing 1600 electrodes in a 30µm round arrangement. 
 
The results of 15 blind patients in whom the Alpha AMS was implanted in one eye, were published in 
2017. This 12-month study, carried out at four sites, was not only found to be reliable, well tolerated 
and able to restore limited visual functions in blind patients with retinal degeneration, but 
demonstrated improved longevity compared to its predecessor, the Alpha IMS device (249).  
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Figure 26: The Alpha AMS device. Taken from RETINA IMPLANT. Used with permission. A colour fundus 
photograph of the RE demonstrating the sub-retinal visual implant. 
 
 
 
 
 
The Argus® II device (see figure 27), CE marked in 2011 and approved for use by the FDA in 2013, acts in 
place of degenerated outer retina i.e. photoreceptors by direct stimulation of the relatively preserved 
inner retina via epiretinal microelectrodes (250). The device aims to facilitate patients with: a) form 
discrimination/recognition; b) target localisation; c) motion detection; and d) navigation (250). A small 
camera mounted on a pair of glasses captures images, which are subsequently converted to a pixelated 
image by an external video processing unit (250). A wireless sub-retinal receiver receives these signals at 
the macula and is able to transmit directly to the visual cortex where they are interpreted as visual 
images. The cost of the device alone is $100,000. 
 
The International, multi-centre, phase II, Argus® II Retinal Prosthesis System clinical trial began in 2006 
and has since implanted the device in 30 patients with profound visual loss from conditions such as RP, 
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choroideraemia and geographic atrophy secondary to AMD (251). Three devices have since been 
explanted, for example, following a SAE involving hypotony with 360 degree choroidal effusions and RD. 
Twenty-four of the remaining 27 patients remained implanted with functioning Argus® II Systems at 5 
years post-implant (251). Patients performed significantly better on all visual function tests and 
functional vision tasks when the with the Argus® II System was ‘on’ as opposed to being ‘off’ (251). 
 
Figure 27: The Argus® II Retinal Prosthesis System. Taken from Second Sight Medical Products. Used 
with permission. A = Placement of the electronic implant in and around the eye; B = Fundus photograph 
demonstrating the implant in-situ; C = A miniature video camera is mounted on a pair of glasses, which 
sends information to the video processing unit (VPU) via a cable. The VPU processes the information and 
sends instructions back to the glasses via a cable. Theses instructions are transmitted wirelessly to an 
antenna in the retinal implant; D = Model demonstrating how the device is worn. 
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2.0 The AMOUR study 
 
2.1 Methods  
 
2.1.1 Overview  
 
The AMOUR study stands for ‘Aflibercept for Macular Oedema in Underlying Retinitis Pigmentosa’. This 
is a prospective, non-randomised, exploratory, phase II study to assess the safety and efficacy of 
aflibercept in RP-CMO. 
 
As discussed in section 1.5.4 Avenues of intervention, CAIs are the mainstay of treatment for RP-CMO, 
however, varying levels of response to treatment have been published. Anti-VEGF medication is 
currently licenced for use in neovascular age-related macular degeneration (AMD), macular oedema 
following retinal vein occlusion (RVO), diabetic macular oedema (DMO), and diabetic retinopathy (DR) in 
patients with DMO. Since VEGF has also been proposed as one of the toxic products released from 
degenerating retina that may contribute to weakening of the BRB and RP-CMO, the idea for a study 
using anti-VEGF for RP-CMO came about. Bayer LTD were approached and agreed to fund the study 
using aflibercept. 
The protocol of the study adhered to the provisions of the Declaration of Helsinki. This was submitted by 
the PI Professor Michel Michaelides and Miss. Stacey Andrea Strong (SAS). SAS attended the  local ethics 
committee meeting, which took place in Brighton and thereafter the study was approved.  Informed 
consent was obtained from all patients. The study was undertaken at Moorfields Eye Hospital NHS 
Foundation Trust, London, United Kingdom. The study was registered with ClinicalTrials.gov and 
assigned the following unique identifier: NCT02661711.  
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2.1.2 Inclusion criteria 
 
 CMO in association with RP 
 At least 16 years of age 
 Uni- or bilateral CMO (where patients have bilateral CMO, the worse eye only will be treated – 
defined as the eye with a greater CMT on OCT) 
 No previous oral treatment for CMO for last 3 months 
 No previous peribulbar or intravitreal treatment for CMO in the study eye for last 3 months 
 No previous topical treatment for CMO in the study eye for last 1 month  
 Central visual impairment that in the view of the principal investigator (PI) is due to CMO 
 BCVA better than 3m/60 
2.1.3 Exclusion criteria 
 
 Insufficient patient cooperation or media clarity to allow adequate fundus imaging 
 Evidence of visually significant VMT or ERM on OCT that in the PI’s opinion is highly likely to 
significantly limit the efficacy of intravitreal therapy  
 History of cataract surgery within prior 3 months or cataract surgery anticipated within 6 
months of starting the study 
 Any anti-VEGF treatment to study eye within 3 months 
 History of YAG capsulotomy performed within 3 months 
 Uncontrolled IOP > = 24 mmHg for ocular hypertension (on topical IOP lowering medications) 
 Advanced glaucoma (in the opinion of a glaucoma specialist)  
 Patients with active or suspected ocular or periocular infections 
 Patients with active severe intraocular inflammation 
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 Patients with a new, untreated retinal tear or RD 
 Patients with a stage 3 or 4 macular hole 
 Thromboembolic event (myocardial infarction (MI)/cerebrovascular accident (CVA)/Unstable 
Angina) within 6 months 
 Pregnancy or family planned within 15 months 
 Females who are breast feeding 
 Known allergy or hypersensitivity to anti-VEGF products 
 
 
2.1.4 Name of committees involved in the study 
 
Several committees were put in place as part of this study:  
 The Trial Management Group (TMG) was responsible for overseeing recruitment and data 
management.   
 
 The Trial Steering Committee (TSC) provided overall supervision of the study (including 
monitoring trial progress and conduct, checking of protocol compliance during the trial and 
deciding if the trial should be stopped early for safety or efficacy reasons).  
 
 The Independent Data Monitoring Commmittee (IDMC) was responsible for ensuring that the 
risk-benefit ratio of the study was appropriate for all patients involved and that the scientific 
integrity of the trial was maintained throughout.  
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2.1.5 Patients and methods  
 
2.1.5.1 Identification of patients 
 
An electronic search was performed to identify all patients seen at Moorfields Eye Hospital NHS 
Foundation Trust, London, UK, between 1st December 2012 and 30th November 2015 with the phrases 
‘retinitis pigmentosa’ and ‘cystoid macular oedema’ appearing in their electronic patient record (EPR). 
This time period was chosen as it was deemed a manageable period of time and number of patients’ 
notes/images to review in the first instance. This initial search identified 295 patients; however, after 
review of each EPR, 165 patients were excluded from the study for the following reasons: no/minimal 
CMO (111), visually significant ERM (17), VA too poor (24), VA too good (4), macular hole (2), visually 
significant cataract (2), under 16 years of age (4) and pregnant (1).  
A total of 130 patients were therefore found to be potentially suitable for the study. Patients were then 
contacted by the research fellow, Dr. Stacey Andrea Strong (SAS), carrying out the clinical trial either in 
person at the medical retina clinic, by telephone or letter. The aims, methods, anticipated benefits and 
potential hazards of the study were explained to each patient and a patient information sheet (PIS) was 
provided. Patients were given a minimum of 24 hours to consider whether they wished to attend a 
baseline evaluation/screening visit. The patients were informed that they were under no obligation to 
enter the trial and that they could withdraw at any time during the trial, without having to give a reason. 
 
Out of 130 patients found to be suitable to enter the trial: 18 could not be contacted/did not reply, 1 
was found to be deceased, 32 wished to be in the study and 79 declined to participate for reasons 
including: did not wish to have injections into their eye, happy with their current treatment and/or 
vision, or unable to commit to the study visits (due to distance from the hospital or concerns about the 
impact it would have on their job). 
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Fifteen patients were being treated with topical CAI (dorzolamide or brinzolamide) at point of contact, 
which was required to be stopped in the study eye for at least 1 month prior to arranging their screening 
appointment. Five patients were being treated with oral CAI (acetazolamide) at point of contact, which 
was required to be stopped at least 3 months prior to arranging their screening appointment. Ten 
patients were not using any treatment at point of contact and were able to attend a screening visit at 
their earliest convenience. 
 
 
2.1.5.2 Screening and recruitment of patients  
 
Within a week of being approached either at medical retina clinics or by telephone and having been 
provided with information about the trial, our research manager contacted the patient and invited them 
to attend a screening appointment. Screening appointments occurred within 28 days of being 
contacted, unless there was a reason that the patient could not attend, for example, they were abroad. 
If the patient was deemed ineligible, for example, because they were being treated with an oral carbonic 
anhydrase inhibitor (CAI), they were contacted again to re-check eligibility and a screening appointment 
was booked within 28 days.  
At the screening appointment, patients had the opportunity to ask any further questions before 
informed consent was taken, their medical/drug history reviewed and vital signs including blood 
pressure (BP), heart rate (HR) and temperature measured. If they were deemed fit to enter the trial, the 
patient was ‘recruited’ and their 1st aflibercept intravitreal injection was given on the same day (‘Visit 
1’). All patients were recruited over a 6 month period. 
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2.1.5.3 Follow-up visits  
 
At each follow-up visit, patients had their vital signs checked and a medication review performed. Tests 
of visual function carried out at every visit included: BCVA, colour vision, contrast sensitivity and SDOCT. 
In addition, microperimetry and FAF were also undertaken at the 6- and 12- month (exit) visits. Please 
refer to table 1 for an overview of the steps taken during study visits. 
 
Table 1: An overview of the steps taken during study visits 
 
Patient demographics confirmed (at all scheduled visits) 
General medical and ocular history (taken at baseline only) 
Medication review (at all scheduled visits) 
Pregnancy status confirmed (taken at baseline only) 
Eligibility check (taken at baseline only)  
Informed consent (taken at baseline only) 
Vital signs including: BP, HR and temperature (at all scheduled visits) 
BCVA (at all scheduled visits) 
Refracted BCVA (Baseline, 6 and 12 months) 
Colour vision (at all scheduled visits) 
Contrast Sensitivity (at all scheduled visits) 
Microperimetry (Baseline, 6 and 12 months) 
Dilation of the patient (at all scheduled visits) 
Slit lamp examination to check for cataract (at all scheduled visits) 
Pre-injection IOP check (at all scheduled visits) 
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SDOCT (at all scheduled visits)  
FAF Imaging (at all scheduled visits) 
Administration of Eylea (at all scheduled visits) 
Post-injection IOP check (at all scheduled visits) 
 
 
The ‘treat and extend’ regime is selected in clinical trials in order to simulate achieving optimal visual 
outcomes whilst simultaneously balancing the burden of long-term, frequent and high-cost treatment. 
Studies such as ‘PrONTO’, whereby anti-VEGF was used for the treatment of neovascular AMD, 
increased intervals between appointments by 2 weeks when no activity was present, for example, a new 
haemorrhage. There is no universally accepted treat and extend regimen, however, for AMD and a treat 
and extend regime for RP-CMO is not directly comparable with AMD. The AMOUR study therefore 
included the following protocol for its treatment regime as guided by the PI: IvA was administered every 
four weeks for the first three months (loading phase), followed by a treat and extend protocol up to 12 
months. Extension from monthly to 6, 8, 10 and 12 week follow-up occurred when there was no 
reduction in macular oedema compared with the previous visit.  
 
A consort flow diagram has been constructed to illustrate the flow of patients throughout the study (See 
Figure 28). Please refer to table 2 for a schedule of assessments. 
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Figure 28: Consort flow diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=295) 
Excluded  (n=263) 
 Did not meet inclusion criteria (n= 165) 
 Unable to contact / did not reply (n= 18) 
 Deceased (n= 1) 
 Declined to participate (n= 79) 
Lost to follow-up (give reasons) (n= 1) 
- Patient withdrew consent 
Allocated to intervention (n=30) 
Enrolled (n=30) 
Patients who completed study (n=29) 
 
Screened (n=32) 
Excluded  (n=2) 
 No Cystoid Macular Edema (n= 2) 
 
125 
 
Table 2: Schedule of assessments 
 Screening 
and 
Baseline 
Treatment phase and follow-up* 
Visit number 1 2 3 4 5 6 7 8    9 10 11 12 13 
Weeks 0 wks 4 wks 
post 
baseli
ne 
8 wks 
post 
baseli
ne 
4 - 12 
wks 
post 
visit 3  
4 - 12 
wks 
post 
visit 4 
4 - 12 
wks 
post 
visit 5 
4 - 12 
wks 
post 
visit 6 
4 - 12 
wks 
post 
visit 7 
4 - 12 
wks 
post 
visit 8 
4 - 12 
wks 
post 
visit 9 
4 - 12 
wks 
post 
visit 10 
4 - 12 
wks 
post 
visit 11 
4 - 12 
wks 
post 
visit 12 
Patient demographics 
confirmed 
X X x X x x X x x x x x X 
General medical and 
ocular history 
X             
Medication review X x x x x x X x x x x x X 
Pregnancy status 
confirmed 
 
X 
            
Eligibility check X             
Informed Consent X             
Vital signs: Blood 
pressure, heart rate and 
temperature 
X X x X x x X x x x x x X 
Best corrected 
ETDRS visual acuity 
X X X X x x X x x x x x x 
Refracted best 
corrected ETDRS visual 
acuity 
X     X ( at 6 
months) 
      X (at 12 
months) 
Colour vision X X X X x x X x x x x x x 
Contrast sensitivity X X X X x x X x x x x x x 
Microperimetry X     X ( at 6 
months) 
      X (at 12 
months) 
Dilation of the patient X X X X x x X x x x x x x 
Slit lamp 
examination 
X X X X x x X x x x x x x 
IOP check (pre- 
injection) 
X X X X x x X x x x x x x 
SDOCT  in both eyes X X X X x x X x x x x x x 
Fundus 
Autofluorescence X X X X x x X x x x x x x 
Administration of Eylea  Possibly X X X x x X x x x x x x 
IOP check (post- 
injection) 
X X X X x x X x x x x x x 
   *Number of total visits will vary between patients as follow-up appointments will be any time   
    between 4 – 12 weeks.  
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2.1.5.4 Informed consent  
 
SAS was delegated the duty of taking informed consent by the PI, Professor Michel Michaelides. If 
patients were deemed suitable to participate in the trial at the end of their screening visit, written 
informed consent was obtained from each subject prior to participation in the trial. This took place 
following adequate explanation of the aims, methods, anticipated benefits and potential hazards of the 
study. Consent did not denote enrolment into trial. Patients were informed that they could withdraw at 
any time during the trial, without having to give a reason. A copy of the signed consent form was given 
to each participant. The original signed form was retained at the study site and a copy placed in the 
medical notes. 
 
It was discussed that if new safety information resulted in significant changes in the risk/benefit 
assessment during the study period, the consent form would be reviewed and updated if necessary and 
subjects would be re-consented as appropriate. 
 
2.1.5.5 Randomisation  
 
The study consisted of only 1-arm and all trial patients received the active drug, aflibercept via 
intravitreal injection. Whilst the study in 2009 carried out by Artunay et al. included 15 patients who 
declined to undertake intravitreal injections of ranibizumab as controls, the AMOUR study was an 
exploratory study using descriptive statistics only that therefore did not require controls.  
2.1.5.6 Study size  
 
Artunay et al. (2009) included 30 patients in a study using anti-VEGF for RP-CMO, however, only a single 
injection of ranibizumab was given to 15 patients (the other 15 patients had declined treatment and 
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were hence used as controls). No previous studies using anti-VEGF for RP-CMO have therefore been 
published using a treat and extend regime for which the sample size could be powered on. Our team of 
statisticians felt a sample size of 30 patients was therefore justified on the basis that 30 subjects will 
provide an estimate of the mean change in CMT from baseline to 12 months with reasonable precision 
as advocated by Browne (1995)(252) and Hertzog (2008) (253). 
 
2.1.5.7 Masking  
 
This was an open-label study and therefore no masking took place. 
 
 
2.1.5.8 Discontinuation/withdrawal of participants and stopping rules  
 
Circumstances in which subjects would have been withdrawn from the trial, included: mortality, 
CVA/transient ischaemic attack (TIA)/MI/unstable angina, hypersensitivity/allergy to anti-VEGF and if for 
any reason the patient no longer wished to be involved with the trial. This would have been confirmed 
in writing and documentation sent to both patient and GP informing them why they were withdrawn 
from the trial and thanking them for their participation up to that point.  
Withdrawn subjects would only have been replaced if their withdrawal was deemed unrelated to the 
trial, for example, if a patient needed to relocate for work purposes/sick family member and could no 
longer physically attend their appointments. Replacement patients would have been recruited in an 
identical fashion to those who originally enrolled in the study. Recruitment of these patients would have 
been required to occur within the designated 8 month recruitment period.  Patients who may have 
withdrawn for reasons deemed related to the trial e.g. intolerable side effects, would not have been 
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replaced. Patients who may have withdrawn from the study would have been asked to attend an exit 
follow-up review at 12 months, which would have involved the same tests to be undertaken as those 
still remaining in the study.  In the event of a retinal tear, the dose of aflibercept would have been 
withheld and treatment not resumed until the break was adequately repaired.  
 
The trial would have been stopped prematurely if SAEs were shown to be caused by aflibercept or if the 
TSC had any safety concerns. 
 
2.1.5.9 Data management  
 
The completed paper case report forms (CRFs) were checked for completion by the research nurse / 
research manager and data officer before data entry.  All trial data were double entered by two 
independent data officers using the database created by the research and development (R&D) 
information technology (IT) team. The first and second data entries were compared for completion and 
consistency. Discrepancies were checked against the original CRF for entry errors, which were 
subsequently corrected. Sense checks, logic checks and range checks were also performed. Data queries 
were corrected and data were cleaned. The database was then locked and data transferred for data to 
be analysed by trial statisticians using statistics and data (STATA) statistical software. The data 
management process followed Moorfields Eye Hospital standard operating procedures (SOPs) for data 
management. 
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2.1.5.10 Statistical analysis  
 
The primary analysis was an available case analysis but baseline characteristics of those who were lost to 
follow up were compared with those who were not.  
 
If the findings from this study were favourable, these data would be used to plan a larger phase IIImulti-
site study based on the same anti-VEGF regime. If safety and efficacy data were deemed favourable 
following this, our hope would be for the licencing of aflibercept to be extended to include the use of 
RP-CMO. 
Descriptive statistics have been used to report the findings of this study due to its modest sample size 
and single arm design. 
 
‘Responders’ would be considered as participants demonstrating a reduction of CMT by 11% or more 
between baseline and 12 months thus allowing comparison with previous studies that used the same 
definition (138, 254). 
 
2.1.6 Name and description of all drugs used in the trial 
 
2.1.6.1 Aflibercept (Eylea) 
 
Aflibercept is currently licenced for use in nAMD and CMO secondary to RVO and DMO. It is a 
recombinant fusion protein consisting of portions of human VEGF receptor 1 and 2 extracellular 
domains fused to the Fc portion of human IgG1 (255). Aflibercept is produced in Chinese hamster ovary 
K1 cells by recombinant DNA technology. Aflibercept acts as a soluble decoy receptor that binds VEGF-A 
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and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and 
activation of these VEGF receptors (195). VEGF-A and PlGF are members of the VEGF family of 
angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for 
endothelial cells. VEGF acts via two receptor tyrosine kinases; VEGFR-1 and VEGFR-2, present on the 
surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of 
leucocytes. Excessive activation of these receptors by VEGF-A can result in pathological 
neovascularisation and excessive vascular permeability. PlGF can synergise with VEGF-A in these 
processes, and is also known to promote leucocyte infiltration and vascular inflammation.  
 
The following information has been taken from the electronic Medicines Compendium (eMC) (256): A 
total of 3,102 patients constituted the safety population of 8 phase III studies. Among those, 2,501 
patients were treated with the recommended dose of 2 mg. 
 
Serious ocular AEs related to the injection procedure have occurred in less than 1 in 1,900 intravitreal 
injections with aflibercept and included blindness, endophthalmitis, retinal detachment, cataract 
traumatic, vitreous haemorrhage, cataract, vitreous detachment, and intraocular pressure increase. The 
most frequently observed AEs – defined as occurring in at least 5% of patients treated with aflibercept – 
included: conjunctival haemorrhage (25%), VA reduction (11%), eye pain (10%), IOP increase (8%), 
vitreous detachment (7%), vitreous floaters (7%) and cataract (8%) (256).  
 
Table 3 includes safety data of all adverse events reported from 8 phase III studies in the indications wet 
AMD, CRVO, BRVO and DMO with a reasonable possibility of causality to the injection procedure or 
medicinal product. In the wet AMD phase III studies, there was an increased incidence of conjunctival 
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haemorrhage in patients receiving anti-thrombotic agents. This increased incidence was comparable 
between patients treated with ranibizumab and aflibercept.  
 
There is a theoretical risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. 
A low incidence rate of arterial thromboembolic events was observed in the aflibercept clinical trials 
involving patients with AMD, DMO, RVO and myopic CNV. Across indications no notable difference 
between the groups treated with aflibercept and the respective comparator groups were observed. 
 
As with all therapeutic proteins, there is a potential for immunogenicity with aflibercept. 
 
Table 3: Adverse drug reactions associated with the use of intravitreal aflibercept. All treatment-
emergent adverse drug reactions reported in patients in phase III studies (pooled data of the phase III 
studies for the indications wet AMD, CRVO, BRVO and DME). The adverse reactions are listed by system 
organ class and frequency using the following convention:  Very common (≥1/10), common (≥1/100 to 
<1/10), uncommon (≥1/1,000 to <1/100), rare (≥ 1/10,000 to < 1/1,000). Within each frequency 
grouping, adverse drug reactions are presented in order of decreasing seriousness (256). 
 
System Organ 
Class 
Very common Common Uncommon Rare 
Immune system 
disorders 
    Hypersensitivity***    
Eye disorders Visual acuity 
reduced,  
Conjunctival 
haemorrhage, 
Eye pain  
Retinal pigment epithelial 
tear*,  
Detachment of the retinal 
pigment epithelium,  
Retinal degeneration,  
Vitreous haemorrhage,  
Cataract,  
Cataract cortical, 
Cataract nuclear,  
Endophthalmitis**,  
Retinal detachment,  
Retinal tear,  
Iritis,  
Uveitis,  
Iridocyclitis,  
Lenticular opacities,  
Corneal epithelium 
defect,  
Blindness,  
Cataract 
traumatic,  
Vitritis  
Hypopyon  
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Cataract subcapsular,  
Corneal erosion,  
Corneal abrasion,  
Intraocular pressure 
increased,  
Vision blurred,  
Vitreous floaters,  
Vitreous detachment,  
Injection site pain,  
Foreign body sensation in 
eyes,  
Lacrimation increased,  
Eyelid oedema,  
Injection site haemorrhage,  
Punctate keratitis,  
Conjunctival hyperaemia,  
Ocular hyperaemia  
Injection site irritation,  
Abnormal sensation in 
eye,  
Eyelid irritation,  
Anterior chamber 
flare, Corneal oedema  
 
* Conditions known to be associated with wet AMD. Observed in the wet AMD studies only. 
** Culture positive and culture negative endophthalmitis 
*** including allergic reactions 
2.1.6.2 Tropicamide 1% eye drops: 
 
 
Tropicamide is an eye drop used to dilate the pupil of the eye allowing for easier retinal examination. 
Tropicamide also effects the muscle that controls the lens of the eye, resulting in reduced 
accommodation. Due to the effects of tropicamide, patients may have photophobia and visual 
disturbance following installation, which may affect their ability to drive. The effects of tropicamide are 
only temporary lasting between 4-6 hours, however, it is possible for the effects to last longer. 
 
Each carton of tropicamide contains 20 minim units, measuring approximately 0.5 millilitre (ml) of the 
active ingredient tropicamide 1%. Other ingredients include: sodium hydroxide, hydrochloric acid (for 
pH adjustment) and purified water. There is no preservative. 
 
Tropicamide should not be used in patients with known allergy to tropicamide or any of its ingredients. 
It should also not be used in patients with a history of acute angle closure glaucoma or patients with a 
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narrow anterior chamber. This can be confirmed on examination by an ophthalmologist prior to its 
usage. Tropicamide can cause temporary stinging upon administration into the eye. It is also possible for 
this medication to cause a patient to have a dry mouth.  
 
2.1.6.3 Phenylephrine 2.5% eye drops: 
 
Phenylephrine 2.5% is an eye drop used to dilate the pupil of the eye allowing for easier retinal 
examination. Due to the effects of phenylephrine, patients may have photophobia and visual 
disturbance following installation, which may affect their ability to drive. The effects of phenylephrine 
are only temporary lasting between 4-6 hours, however, it is possible for the effects to last longer. 
 
Each carton of phenylephrine 2.5% contains 20 minim units, measuring approximately 0.5ml solution of 
phenylephrine hydrochloride 2.5%. 
 
Other ingredients include: sodium metabisulphite, disodium edetate and purified water. There is no 
preservative. 
 
Phenylephrine should not be used in patients with known allergy to phenylephrine or any of its 
ingredients. It should also not be used in patients with a history of heart disease, tachycardia, raised BP, 
aneurysms or thyrotoxicosis. Caution should be taken when used in patients with asthma or DM. It 
should also not be used in patients with a history of acute angle closure glaucoma or patients with a 
narrow anterior chamber at the front of the eye. This can be confirmed on examination by an 
ophthalmologist prior to its usage. 
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2.1.6.4 Proxymetacaine eye drops: 
 
Proxymetacaine is an eye-drop used before the giving of an intravitreal injection, in order to produce an 
anaesthetic effect on the eye. Each pack contains 20 minim units containing the active ingredient 
proxymetacaine hydrochloride. Each unit contains approximately 0.5ml eye drops solution of 
proxymetacaine hydrochloride 0.5% (2.5 mg). The other ingredients include: hydrochloric acid, sodium 
hydroxide and purified water. This medicine does not contain a preservative as it is a sterile single use 
unit. 
 
Allergic reactions can occasionally occur that affect the cornea and the iris. Patients may experience the 
following symptoms before the drug wears off:  pupil dilation, reduced accommodation and conjunctival 
irritation. In rare circumstances, a defect or inflammation of the cornea and/or inflammation of the iris 
may occur. 
 
2.1.6.5 Iodine eye drops and skin preparation 
 
Iodine has a powerful bactericidal action and is used for disinfecting unbroken skin before operations. 
Iodine is active against fungi, viruses, protozoa, cysts and spores. The product is suitable for use by 
adults, children and the elderly. Excipients include: purified water and ethanol (96%). Its use is 
contraindicated in patients with hypersensitivity to iodine or iodides, newborn infants and in patients 
with thyroid disorders or those receiving lithium therapy. 
 
Allergic reactions that can occur, include: urticaria, angioedema, cutaneous haemorrhage or purpuras, 
fever, arthralgia, lymphadenopathy and eosinophilia. 
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2.1.6.6 Chloramphenicol eye drops 
 
Chloramphenicol eye-drops are used to reduce the risk of infection following intravitreal injection. It is 
contra-indicated for use in patients with a known hypersensitivity to chloramphenicol or to any other 
component of the preparation and if there is a family or personal history of blood dyscrasias including 
aplastic anaemia. 
 
Adverse local effects include sensitivity reactions such as transient irritation, burning, stinging, itching 
and dermatitis. Sometimes the eye-drops can be tasted or affect taste as they drain from the eye into 
the back of the mouth. The prolonged use of eye-drops containing phenylmercuric preservative has 
been associated with skin irritation, primary atypical band keratopathy and mercurialentis 
(pigmentation of the anterior capsule of the lens). 
 
Adverse systemic effects: Rarely cases of adverse haematological events (bone marrow depression, 
aplastic anaemia and death) have been reported following ocular use of chloramphenicol. 
 
 
2.1.7 Preparation and labelling of the investigational medicinal products 
 
Preparation and labelling of the investigational medicinal products were completed in accordance with 
the relevant GMP guidelines. Due to the primary packaging containing a small vial of medication on 
which particulars cannot be displayed, a second sheet displayed a label containing the following 
information:  
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(a) name of sponsor, or investigator 
 
(b) route of administration, the name/identifier and strength/potency 
 
(c) batch and/or code number to identify the contents and packaging operation 
 
(d) a trial reference code allowing identification of the trial, site, investigator and 
sponsor if not given elsewhere 
 
(e) the trial subject identification number/treatment number and where relevant, 
the visit number 
 
2.1.8 Protocol for intravitreal injection of aflibercept 
 
Intravitreal injections were carried out by SAS who was Good clinical practice (GCP) trained and suitably 
qualified and experienced to deliver intravitreal injections. Another locum consultant, Dr. Simona 
Esposti, was formally included on the delegation log to provide cover if SAS was absent due to annual, 
study or sick leave. 
 
Eylea 2 mg (0.05mL) was administered by intravitreal injection every 4 weeks for the first 3 injections, 
followed by 2mg once every 4 - 10 weeks depending on whether there was evidence of OCT stability in 
the view of the PI (i.e. there was no further reduction in macular fluid compared to the previous visit). 
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2.1.9 Post-intravitreal injection management 
 
Small volume injections (0.05ml) are unlikely to cause a significant rise in IOP (257). All patients were 
tested for hand movement (HM) vision immediately after injection:  
 
 If HM vision was not achieved, indirect ophthalmoscopy was performed by SAS to check for 
perfusion status of the central retinal artery (CRA). Immediate anterior chamber paracentesis 
was performed if the CRA was considered to be non-perfused. Patients were then re-tested for 
HM vision. If this was achieved, IOP was checked using Goldmann tonometry after 30 minutes. If 
this was not achieved, a second anterior chamber paracentesis would be performed and the 
above process repeated. 
 If HM vision was achieved, patients would be asked to wait for 30 minutes in the waiting area, 
after which time, IOP was re-checked using Goldmann tonometry. 
 
If post-intravitreal IOP was 30mmHg or less, patients were discharged home with instructions regarding 
topical antibiotic usage and advice about when (and how) to seek help, for example, if the eye became 
red or painful or if the vision reduced. Patients were informed, however, that some blurring of vision is 
common immediately post-injection; often described as 'seeing spots floating in the eye', which usually 
resolve after a few days to a week (257). Patients were advised not drive until their visual function had 
recovered sufficiently. 
 
Since this study was carried out, the Royal College of Ophthalmologists have published updated 
guidelines for intravitreal injection therapy. This states that “the use of peri-injection antibiotics is no 
longer recommended. There is no evidence that their use reduces the risk of post-operative 
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endophthalmitis, but there is evidence that their use can contribute to the emergence of drug-resistant 
pathogenic bacteria” (257).  
 
 
2.1.10 Outcome measures 
 
2.1.10.1 Primary outcome 
 
There were two primary outcome measures: (i) To report the safety of aflibercept throughout the study 
(17 months in total); via the documentation of AEs deemed related to the trial drug; (ii) To report the 
efficacy of aflibercept via mean CMT on SDOCT at 12 months after baseline in eyes of patients with RP-
CMO treated with three loading doses of Eylea at monthly intervals followed by a treat and extend 
protocol. 
 
2.1.10.2 Secondary outcomes 
 
To report mean CMT at 6 months as measured with SDOCT in eyes of patients with RP-CMO treated with 
three loading doses of Eylea at monthly intervals followed by a treat and extend protocol between 
baseline and 12 months. 
 
To report mean change in CMT as measured with SDOCT in eyes of patients with RP-CMO treated with 
three loading doses of Eylea at monthly intervals followed by a treat and extend protocol between 
baseline and 6 months, and baseline and 12 months. 
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To report mean BCVA ETDRS letter score at 6 and 12 months in eyes of patients with RP-CMO treated with 
three loading doses of Eylea at monthly intervals followed by a treat and extend protocol between 
baseline and 12 months. 
 
To report mean change in BCVA ETDRS letter score in eyes of patients with RP-CMO treated with three 
loading doses of Eylea at monthly intervals followed by a treat and extend protocol between baseline and 
6 months, and baseline and 12 months. 
 
To report mean macular volume at 6 and 12 months as measured with SDOCT in eyes of patients with RP-
CMO treated with three loading doses of Eylea at monthly intervals followed by a treat and extend 
protocol between baseline and 12 months. 
 
To report mean change in macular volume as measured with SDOCT in eyes of patients with RP-CMO 
treated with three loading doses of Eylea at monthly intervals followed by a treat and extend protocol 
between baseline and 6 months, and baseline and 12 months. 
 
To report all AEs and SAEs at any time point during the 12 month study of using intravitreal Eylea in eyes 
of patients with RP-CMO. 
 
To report mean retinal sensitivity at 6 and 12 months using microperimetry in eyes of patients with RP-
CMO treated with three loading doses of Eylea at monthly intervals followed by a treat and extend 
protocol between baseline and 12 months. 
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To report mean change in retinal sensitivity using microperimetry in eyes of patients with RP-CMO treated 
with three loading doses of Eylea at monthly intervals followed by a treat and extend protocol between 
baseline and 6 months, and baseline and 12 months 
 
To report mean number of intravitreal injections administered in eyes of patients with RP-CMO treated 
with three loading doses of Eylea at monthly intervals followed by a treat and extend protocol between 
baseline and 12 months. 
 
 
2.1.11 Methodology of assessments of visual function 
 
2.1.11.1 VA  
 
At the baseline, 6- and 12- month visits, all patients within the study were subjectively refracted by 
an optician in order to obtain any spectacle correction required to achieve their BCVA.  
 
At all study visits, the lens correction from the most recent subjective refraction was placed in the trial 
frame to correct for any refractive error. VA was tested using the ETDRS chart, which incorporates 
specific design criteria to make it more accurate than the Snellen VA. Two ETDRS charts were used in 
this study (chart 1 for the RE and chart 2 for the LE) that were retro-illuminated using a lightbox 
containing 2 Cool Daylight 20 watt fluorescent tubes. The room lights were turned off whilst the test 
was being performed. The RE was always tested first and the non-tested eye was occluded throughout 
the test. Each patient sat at a starting distance of 4 metres (m), however, if a patient was unable to read 
20 letters or more at this distance, the test would be repeated at 1m. In this case, only the first 6 rows 
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would be attempted. If the patient was wearing a trial frame, +0.75 dioptres sphere (DS) was added to 
the prescription to correct for the closer test distance. The VA score was the number of letters read 
correctly at 4m, plus the number of letters read correctly at 1m. If the patient did not require testing at 
1m, i.e. they read 20 or more letters at 4m, then the score was the number of letters read correctly at 
4m, plus 30.  
 
If the patient was unable to read any letters on the ETDRS chart at 1m, then their ability to count fingers, 
detect HM or PL was measured. 
 
2.1.11.2 CMT  
 
The Heidelberg Spectralis OCT was used to obtain images of macular volume in order to measure CMT. 
The scan was performed by a technician who had been approved on the delegation log. It was 
performed on patients following pharmacological dilatation, but before intravitreal injection. Patients 
were asked to look directly into the camera lens, where they saw a bright blue dot representing the 
internal fixation target. Patients were encouraged to blink regularly throughout the examination, 
however, to maintain focus on the internal fixation target at all times. The macular volume scan protocol 
took images as follows: 20°x20°, 49 Sections, High Speed, 29 Frames automatic real time (ART). The 
technician would inspect each scan after acquisition to ensure high quality images had been taken. 
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2.1.11.3 Colour vision  
 
Ishihara colour vision testing is a rapid and simple test involving the use of pseudo-isochromatic plates in 
order to measure colour vision.  
 
Before seeing trial patients, staff were required to be signed off on the delegation log by the PI. The 
protocol stipulated that patients should be tested, before being pharmacologically dilated, in an 
adequately lit room. This was achieved by using a light box, meaning that testing was performed in a 
very controlled fashion. The Ishihara book contained 17 plates. Patients were adequately corrected for 
reading vision using plus lenses if required. Each eye was tested individually in turn (monocular testing 
starting with the RE, then the LE). Plates were held at 75 cm from the patient and tilted so that the plane 
of paper was at right-angles to the line of vision. Each patient was asked to state the numeral seen on 
each plate between plates 1 - 17. The answer was only counted as correct if given without more than 
three seconds delay. The number of numerals correctly identified was recorded out of 17 plates. 
 
 
2.1.11.4 Contrast sensitivity  
 
Contrast sensitivity was performed by an optician using the Pelli-Robson chart (Clement Clarke Inc., 
Columbus, OH). The patient was seated at a distance of 1m. Each eye was tested in turn (the RE was 
tested before the LE) with the non-tested eye being patched. As a standard, +0.75DS was added to each 
patient’s refraction when performing the test. The luminance of the chart was between 80 - 120 candela 
per square metre (cd/m2).   
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The patient was asked to name each letter on the chart, starting with the high-contrast letters on the 
upper left-hand corner and reading horizontally across the entire line. As low-contrast letters can take 
some time to appear, the patient was given instructions to keep looking and not give up too soon. The 
optometrist circled each letter read correctly and crossed out any letter read incorrectly, with letters not 
attempted left unmarked. The test was completed when the patient failed to correctly identify two or 
more letters in a triplet.  
 
2.1.11.5 Retinal sensitivity  
 
Fundus-driven perimetry, commonly known as microperimetry, is a technique for measuring VF 
sensitivity, whilst simultaneously viewing the fundus (258). It is deemed superior at evaluating the 
function of the macular area in patients with unstable or extra-foveal fixation (258).  
In this study, standard mesopic microperimetry was used to test retinal sensitivity using the MP-1 
microperimeter (Nidek Instruments, Inc, Padua, Italy). At baseline, microperimetry was carried out 
twice on each eye, whereas at 6- and 12- months, microperimetry was carried out only once on each 
eye.  
 
To carry out the test, spherical error was initially accounted for in all patients using the following calculation: 
sphere + ½  cylindrical error. Patients were dark-adapted for 10 minutes before performing the test and 
throughout the test, the non-tested eye was patched. Regardless of where the fixation cross was situated, 
the grid was centred over the fovea. The microperimetry protocol included: Cross  2  degrees, 
Goldmann  Ill  Stimulus  200ms, 4-2 strategy and 30 seconds of tracked fixation. At the end of the test, 
a photograph of each eye was taken using retinography.  A  local defect map, including -9:1 setting in 
order to provide mean sensitivity and mean defect together with bivariate contour ellipse area 
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(BCEA) value (numeric and fixation), was printed off at the end of the test and placed in the patient’s 
study folder. 
 
 
2.1.11.6 FAF 
 
Autofluorescence describes the capacity for certain molecules, known as fluorophores, to emit light 
when they have been excited by suitable wavelengths (259). The endogenous fluorophores include 
the cornea, crystalline lens, RPE, uveal melanocytes and scleral collagen (259).  
 
FAF images were acquired during this study at the baseline, 6- and 12- month visits using the 
Heidelberg Spectralis OCT machine. For each eye, an infrared reflectance image and blue 
autofluorescence image of standard field 2 (centred on the fovea) was acquired. Both 30 and 55 degree 
fields were acquired using high resolution at 50 frames (ART).  
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2.2 Results  
 
2.2.1 Overview and baseline characteristics  
 
Results are summarised in tables 4 to 14.  
 
Thirty eyes of 30 patients were enrolled into the study. The first patient was recruited in March 2016 
and the final patient had their 52-week visit in August 2017. Two patients were screened who did not 
satisfy the criteria for enrolment (study ID 29 and 31); the reason being that they no longer had 
presence of CMO. The mean age of the patients was 43.3 years (SD 11.5 years, range 20 – 61 years) 
consisting of 17 male (56.7%) and 13 female (43.3%) subjects. The ethnicity of the patients in the study 
were as follows: 26 White, 1 Asian, 1 Black, 1 Mixed and 1 Other. The study eye involved the LE in 16 
(53.3%) cases and the RE in 14 (47.7%) cases. The median duration of CMO in the study eye was 252 
weeks and the interquartile range (IQR) was 156 - 296 weeks. All patients enrolled in the study received 
the active drug, aflibercept. All patients enrolled in the study received the active drug, aflibercept. The 
median number of injections given across all patients in the study was 7 (IQR 6 - 9); with the minimum 
number of injections given being 4, and the maximum number of injections given being 11.  
 
Likely disease-causing sequence variants were identified in 16 of 30 (53.3%) study participants (see 
figure 29, table 4), which included: (i) AD inheritance: neural retina leucine zipper (NRL) gene (1 patient), 
RHO gene (2 patients), pre-mRNA processing factor (PRPF) 31 gene, also known as RP-11  (3 patients), 
PRPF8 gene (1 patient), small nuclear ribonucleoprotein U5 subunit 200 (SNRNP200) gene (1 patient); (ii) 
AR inheritance: usherin 2A (USH2A) gene (3 patients including the following variants: c.1841-2A>G 
homozygous; c.11700C>A, p.Tyr3900Ter; c.4618G>A, p.Asp1540Asn; c.2299del, p.Glu767Serfs*21 hom), 
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tubby like protein 1 (TULP1) gene (1 patient), RP-1 gene (1 patient), retinol dehydrogenase (RDH)-12 
(RDH12) gene (1 patient), intraflagellar transport (IFT)-140 (IFT140) gene (1 patient); and (iii) X-linked 
inheritance: RPGR gene (1 patient). The other 14 patients were recruited into the Genomics England 
(GEL), Specialist Pathology: Evaluating Exomes in Diagnosic (SPEED) or Manchester 176 panel studies, 
however, identification of disease-causing variants remain unsolved to date. 
 
Figure 29: The known or putative localisation of proteins translated by genes associated with RP within 
the rod photoreceptor or RPE cell. Taken from Dias et al. (2018) (260). 
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Table 4: Genetic data of all patients in the study 
Study 
ID 
Symbol Protein Inheritance 
pattern 
1 PFPR31 pre-MRNA processing factor 31 AD 
2 PFPR8 pre-MRNA processing factor 8 AD 
3 USH2A 
Location: 
c.1841-2A>G 
homozygous 
usherin 2A AR 
4 Unsolved Unsolved Unsolved 
5 RP11 retinitis pigmentosa-11 AD 
6 RP1 retinitis pigmentosa-1 AD 
7 TULP1 tubby like protein 1 AR 
8 Unsolved Unsolved Unsolved 
9 NRL neural retina leucine zipper AD 
10 IFT140 intraflagellar transport-140 AR 
11 Unsolved Unsolved Unsolved 
12 RHO/RP4 Rhodopsin AD 
13 Unsolved Unsolved Unsolved 
14 Unsolved Unsolved Unsolved 
15 RHO Rhodopsin AD 
16 Unsolved Unsolved Unsolved 
17 Unsolved Unsolved Unsolved 
18 SNRNP200 small nuclear ribonucleoprotein U5 subunit 200 AR 
19 Unsolved Unsolved Unsolved 
20 USH2A  
Location: 
c.2299del, 
p.Glu767Serf
s*21 hom 
usherin 2A AR 
21 Unsolved Unsolved Unsolved 
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22 Unsolved Unsolved Unsolved 
23 Unsolved Unsolved Unsolved 
24 PRPF31 pre-MRNA processing factor 31 AD 
25 Unsolved Unsolved Unsolved 
26 Unsolved Unsolved Unsolved 
27 Unsolved Unsolved Unsolved 
28 USH2A 
Location: 
c.11700C>A, 
p.Tyr3900Ter
; c.4618G>A,
 p.Asp1540As
n 
usherin 2A AR 
29 n/a n/a n/a 
30 RPGR retinitis pigmentosa GTPase regulator XL 
31 n/a n/a n/a 
32 RDH12 retinol dehydrogenase-12 AD 
 
 
The baseline characteristics for all participants in the study are summarised in tables 5 and 6. The 
following results are representative of the study eye for the cohort overall: mean baseline ETDRS BCVA 
was 64 letters (SD 11.5 letters) with a mean CMT of 458.7µm (SD 84.6µm); median baseline macular 
volume was 8.0mm3 (IQR 7.5 – 8.8); median baseline colour vision was 15 plates (IQR 6 – 16); mean 
baseline contrast sensitivity was 1.58 log CS (SD 0.35); mean baseline IOP was 12.5mmHg (SD 2.9); mean 
baseline retinal sensitivity was 6.3 dB (SD 3.6). Twenty-four (80%) patients were phakic in their study 
eye compared with 6 (20%) patients who were pseudophakic. No patients were aphakic.  
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Table 5:  Non-Ocular Baseline Characteristics (whole cohort) 
 Aflibercept 
Number of Patients (Eyes) 30 (30) 
Male / Female, n (%) 17 (57)/ 13(43) 
Age (years),  Mean (SD) 43.3 (11.5) 
Ethnicity, n (%): 
  White 
  Asian 
  Black 
Mixed 
  Other 
 
26 (87) 
1 (3) 
1 (3) 
1 (3) 
1 (3) 
 
 
 
Table 6: Ocular Baseline Characteristics (whole cohort) 
 Aflibercept 
(n=30) 
Study Eye, Left/Right, n(%) 16 (53)/ 14 (47) 
Duration of CME (weeks), Median (IQR) 252 (156-296) 
Lens status, n (%): 
  Aphakic 
  Pseudophakic 
  Phakic 
 
0 (0) 
6 (20) 
24 (80) 
ETDRS BCVA (letters),  Mean (SD) 64 (11.5) 
Ishihara colour vision (out of 17 plates), 
Median (IQR)  
15 (6-16) 
Contrast sensitivity (cd/m2) , Mean (SD) 1.58 (0.35) 
IOP (mmHg),  Mean (SD) 12.5 (2.9) 
Central macular thickness on SDOCT (µm),  
Mean (SD) 
458.7 (84.6) 
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Macular Volume on SDOCT (mm3), Median 
(IQR) 
8.0 (7.5-8.8) 
Mean Retinal sensitivity on microperimetry 
(dB), Mean (SD) 
 
6.3 (3.6) 
CME = cystoid macular oedema; µm = microns; ETDRS = early treatment diabetic retinopathy study; BCVA 
= best corrected visual acuity; SD = standard deviation; IQR = Interquartile range; cd/m2 = candela per 
square meter; IOP = intraocular pressure; mmHg = millimetre of mercury; SDOCT = Spectral domain optical 
coherence tomography; mm3 = millimetres cubed; dB = decibels 
 
Nine of 29 (31.0%) patients were graded as having either questionable or definite presence of ERM 
within 3mm of the fovea. No patients were found to have vitreo-macular traction (VMT) on their 
baseline OCT scan. One of 29 (3.4%) patients was found to have vitreo-macular adhesion on their 
baseline OCT scan. Nine of 29 (31.0%) patients were graded as having either questionable or definite 
disruption of the ellipsoid zone within 1mm of the fovea on their baseline OCT scan. 
 
One participant did not complete 12 months of follow-up due to a relapse of mental illness and 
withdrew from the study. The GP was informed and asked to contact the patients’ social worker. This 
patient was last reviewed at visit 2 with these data being carried forward and an intention-to-treat 
analysis undertaken. The baseline characteristics for this participant who withdrew from the study were 
not different to patients who continued in the study. Twenty-nine out of 30 (96.7%) patients therefore 
completed 12 months of follow-up for the study. 
 
A post-hoc exploratory analysis of responders-only was also undertaken. Baseline characteristics for 
responders are summarised in Tables 7 and 8. Sub-group analysis of responders demonstrated similar 
baseline characteristics to the group taken as a whole, with mean baseline ETDRS BCVA of 63.6 letters 
(SD 11.3 letters), mean CMT of 489.8µm (SD 105.9µm) and median duration of CME was 264 weeks (IQR 
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228-416). The median number of injections for this group was 7 (IQR 6 - 10) where the minimum 
number of injections given was 5 and the maximum number of injections given was 11. 
 
Table 7:  Non-Ocular Baseline Characteristics (Responders only) 
 Aflibercept 
Number of Patients (Eyes) 11 (11) 
Male / Female, n (%) 8 (73)/3(27) 
Age (years),  Mean (SD) 42.7 (15.6) 
Ethnicity, n (%): 
  White 
  Asian 
  Black 
Mixed 
  Other 
 
11 (100) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
 
Table 8: Ocular Baseline Characteristics (Responders only) 
 Aflibercept 
(n=11) 
Study Eye, Left/Right, n(%) 6 (55)/5 (45) 
Duration of CME (weeks), Median (IQR) 264 (228, 416) 
Lens status, n (%): 
  Aphakic 
  Pseudophakic 
  Phakic 
 
0 (0) 
1 (9) 
10 (91) 
ETDRS BCVA (letters),  Mean (SD) 63.6 (11.3) 
Ishihara colour vision (out of 17 plates), Median (IQR)  10 (3-14) 
Contrast sensitivity (cd/m2), Mean (SD) 1.42 (0.38) 
IOP (mmHg),  Mean (SD) 12.4 (3.4) 
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Central macular thickness on SDOCT (µm),  Mean (SD) 489.8 (105.9) 
Macular Volume on SDOCT (mm3),Median (IQR) 8.9 (8.3-9.9) 
Mean Retinal sensitivity on microperimetry (dB),  
Mean (SD) 
5.8 (3.7) 
CME = cystoid macular oedema; µm = microns; ETDRS = early treatment diabetic retinopathy study; BCVA 
= best corrected visual acuity; SD = standard deviation; IQR = Interquartile range; cd/m2 = candela per 
square meter; IOP = intraocular pressure; mmHg = millimetre of mercury; SDOCT = Spectral domain optical 
coherence tomography; mm3 = millimetres cubed; dB = decibels 
 
2.2.2 Outcome measures 
 
2.2.2.1  Efficacy: analysis of all study participants  
 
The primary and secondary efficacy outcomes for all patients (responders and non-responders) within 
the study are summarised in Tables 9 and 10. Mean CMT at 12 months was 413.4µm (SD 98.2µm, 95% CI 
376.0 – 450.7µm) corresponding to a reduction in CMT of 47.6µm (SD 86.6µm, 95% CI -80.5 to -14.6µm) 
or 9.61 % (17.56 %) between baseline and 12 months. Mean macular volume at 12 months was 8.0mm3 
(SD 0.7, 95% CI 7.7 – 8.2) corresponding to a change in macular volume of -0.3mm3 (SD 0.7, 95% CI -0.6 - 
-0.1) between baseline and 12 months. Mean CMT at 6 months was similar at 414.8µm (SD 96.4µm, 95% 
CI 378.1 – 451.4µm) corresponding to a reduction in CMT of 46.2µm (SD 108.7µm, 95% CI -87.6 to -
4.9µm) or 8.13 % (23.3 %) between baseline and 6 months. Mean macular volume at 6 months was 
7.9mm3 (SD 0.6, 95% CI 7.7 – 8.2) corresponding to a change in macular volume of -0.3mm3 (SD 0.8, 95% 
CI -0.7 - 0.0) between baseline and 6 months. Figure 30 is a graph demonstrating mean change in CMT 
from baseline to 6 months, and baseline to 12 months in the group overall.  
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Table 9: Primary outcome measures 
 Aflibercept 
 (n=29) 
95% CI 
Central Macular thickness on SDOCT (µm), 
Mean (SD) at Baseline 
458.7 (84.6)  
Central Macular thickness on SDOCT (µm), 
Mean (SD) at 12 months 
 
413.4 (98.2) 
 
 
376.0 - 450.7 
 
SDOCT = Spectral domain optical coherence tomography; µm = microns; SD = standard deviation  
 
Table 10: Secondary outcome measures 
 Aflibercept 
 (n =29) 
95% CI 
Central Macular thickness on SDOCT (µm), Mean (SD) at 6 
months  
 
414.8 (96.4) 
 
378.1 – 451.4 
Change in Central Macular thickness on SDOCT (µm) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-47.6 (86.6) 
-46.2 (108.7) 
 
-80.5 - -14.6 
-87.6 - -4.9 
ETDRS BCVA (letters), Mean (SD) at 6 months  66.9 (10.6) 62.8 – 70.9 
ETDRS BCVA (letters), Mean (SD) at 12 months  68.0 (11.1) 63.8 – 72.3 
Change in ETDRS BCVA (letters) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
4.3 (6.9) 
3.1 (6.6) 
 
1.7 – 6.9 
0.6 – 5.6 
Macular Volume on SDOCT (mm3), Mean (SD) at 6 months  
 
7.9 (0.6) 7.7 – 8.2 
Macular Volume on SDOCT (mm3), Mean (SD) at 12 months  
 
8.0 (0.7) 7.7 – 8.2 
Change in Macular Volume on SDOCT (mm3) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-0.3 (0.7) 
-0.3 (0.8) 
 
-0.6 – -0.1 
-0.7 – 0.0 
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Retinal Sensitivity (dB), Mean (SD) at 6 months  
 
Missing, n(%) 
4.92 (3.49) 
 
1 (3) 
3.56 – 6.27 
Retinal Sensitivity (dB), Mean (SD) at 12 months  
 
Missing, n(%) 
4.93 (3.48) 
 
2 (6) 
3.55 – 6.31 
Change in Retinal Sensitivity (dB) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-1.09 (2.10) 
-1.23 (2.24) 
 
-1.90 - -0.27 
-2.10 - -0.37 
Total number of injections received over the study period (12 
months), Median (IQR) 
 
7 (6-9) 
 
- 
CME = cystoid macular oedema; µm = microns; ETDRS = early treatment diabetic retinopathy study; BCVA 
= best corrected visual acuity; SD = standard deviation; IQR = Interquartile range; cd/m2 = candela per 
square meter; IOP = intraocular pressure; mmHg = millimetre of mercury; SDOCT = Spectral domain optical 
coherence tomography; mm3 = millimetres cubed; dB = decibel 
 
Figure 30 : A graph demonstrating mean change in CMT from baseline to 6 months, and baseline to 12 
months in the group overall.  
 
155 
 
Mean ETDRS BCVA was 66.9 letters (SD 10.6, 95% CI 62.8 – 70.9) at 6 months and 68.0 letters (SD 11.1, 
95% CI 63.8 – 72.3) at 12 months. This equated to a gain of 3.1 letters (SD 6.6, 95% CI 0.6 – 5.6) and 4.3 
letters (SD 6.9, 95% CI 1.7 – 6.9) respectively at 6 and 12 months. No patients lost ≥30 letters. Please see 
figure 31 for box plots of change in BCVA demonstrating mean change in BCVA from baseline to 6 
months, and baseline to 12 months in the group overall.  
 
 
Figure 31 : Box plots of change in BCVA demonstrating mean change in BCVA from baseline to 6 months, 
and baseline to 12 months in the group overall.  
 
 
Mean retinal sensitivity at 6 months was 4.92 dB (SD 3.49, 95% CI 3.56 – 6.27) corresponding to a 
change in retinal sensitivity of -1.23dB (SD 2.24, 95% CI -2.1 - -0.37).  Data were missing for 1 (3%) 
patient. Mean retinal sensitivity at 12 months was 4.93 dB (SD 3.48, 95% CI 3.55 – 6.31) corresponding 
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to a change in retinal sensitivity of -1.09dB (SD 2.10, 95% CI -1.9 - -0.27). Data were missing for 2 (6%) 
patients. 
 
3.1.2.2  Efficacy: sub-group analysis of responders only 
 
The primary and secondary efficacy outcomes using descriptive statistics for sub-group analysis of 
responders within the study are provided in table 11.  
 
Table 11: Descriptive statistics for responders 
 Aflibercept 
(n=11) 
Central Macular thickness on SDOCT (µm), Mean (SD) at 12 months 350.3 (93.3) 
Central Macular thickness on SDOCT (µm), Mean (SD) at 6 months  360.7 (85.2) 
Change in Central Macular thickness on SDOCT (µm) from  
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-139.5 (65.8) 
-129.1 (125.1) 
ETDRS BCVA (letters), Mean (SD) at 6 months  67.5 (10.1) 
ETDRS BCVA (letters), Mean (SD) at 12 months  68.4 (11.8) 
Change in ETDRS BCVA (letters) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
4.7 (9.5) 
3.8 (6.8) 
Macular Volume on SDOCT (mm3), Mean (SD) at 6 months  
 
8.5 (0.6) 
Macular Volume on SDOCT (mm3), Mean (SD) at 12 months  
 
8.5 (0.8) 
Change in Macular Volume on SDOCT (mm3) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-0.6 (0.6) 
-0.6 (0.6) 
Retinal Sensitivity (dB), Mean (SD) at 6 months  4.93 (4.06) 
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Retinal Sensitivity (dB), Mean (SD) at 12 months  
 
4.48 (3.83) 
Change in Retinal Sensitivity (dB) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-0.97 (1.92) 
-0.92 (2.03) 
Total number of injections received over the study period (12 
months), Median (IQR) 
 
7 (6-10) 
CME = cystoid macular edema; µm = microns; ETDRS = early treatment diabetic retinopathy study; BCVA 
= best corrected visual acuity; SD = standard deviation; IQR = Interquartile range; cd/m2 = candela per 
square meter; IOP = intraocular pressure; mmHg = millimetre of mercury; SDOCT = Spectral domain optical 
coherence tomography; mm3 = millimetres cubed; dB = decibels 
 
Eleven out of 29 (36.7%) patients were considered responders having demonstrated a reduction in CMT 
of 11% or more at 12 months compared to baseline. These same patients were also classed as 
responders at 6 months when applying the same criteria. Please see figure 32 for 2 examples of 
responders in the study. Genetic variants were identified and confirmed in 5 of 11 (45.5%) of 
responders, which included: RPGR (1 patient), PRPF31 (1 patient), USH2A (c.11700C>A, p.Tyr3900Ter; 
c.4618G>A, p.Asp1540Asn) (1 patient), RHO (1 patient) and RDH12 (1 patient). The other 6 patients were 
recruited into the GEL or SPEED studies, however, identification of variants remain unsolved. 
 
 
Following sub-analysis of these 11 patients, mean CMT at 12 months was 350.3µm (SD 93.3µm) 
corresponding to a change in CMT of -139.5µm (SD 65.8µm) or 28.1% (12.9 %) between baseline and 12 
months. Mean macular volume at 12 months was 8.5mm3 (SD 0.8) corresponding to a change in macular 
volume of -0.6mm3 (SD 0.6) between baseline and 12 months. Mean CMT at 6 months was similar at 
360.7µm (SD 85.2µm) corresponding to a change in CMT of -129.1µm (SD 125.1µm) or 22.9% (29.7 %) 
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(See Figure 32) between baseline and 6 months. Mean macular volume at 6 months was 8.5mm3 (SD 
0.6) corresponding to a change in macular volume of -0.6mm3 (SD 0.6) between baseline and 6 months. 
Figure 33 demonstrates SDOCT images of 2 responders taken at baseline and at 1 month post-baseline 
(after having received only a single intravitreal injection of aflibercept).  
 
 
Figure 32 : A graph demonstrating mean change in CMT from baseline to 6 months, and baseline to 12 
months in responders-only.  
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Figure 33: Two representative examples of responders: 1a and 2a show SDOCT baseline images of two 
study participants (study IDs: 04 and 14); 1b and 2b are SDOCT images taken at 1 month post 1st 
aflibercept injection in the same two participants, respectively 
 
 
 
Mean ETDRS BCVA at 6 months was 67.5 letters (SD 10.1) corresponding to a gain of 3.8 letters (SD 6.8). 
Mean ETDRS BCVA at 12 months was 68.4 letters (SD 11.8) corresponding to a gain of 4.7 letters (SD 9.5) 
(see figure 34). It should be noted that 3 of 11 (27.3%) responders were graded as having disruption of 
the ellipsoid zone within 1mm of the fovea on their baseline OCT scan. No improvement of vision was 
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found in all 3 of these patients. Four of 11 (36.4%) responders were graded as having questionable 
presence of ERM within 3mm of the fovea. 
 
Figure 34: Box plots of change in BCVA demonstrating mean change in BCVA from baseline to 6 months, 
and baseline to 12 months in responders-only.  
 
 
Mean retinal sensitivity at 6 months was 4.93dB (SD 4.06) corresponding to a change in retinal 
sensitivity of -0.92dB (SD 2.03) between baseline and 6 months. Mean retinal sensitivity at 12 months 
was 4.48dB (SD 3.83) corresponding to a change in retinal sensitivity of -0.97dB (SD 1.92) between 
baseline and 12 months.  
 
The median number of injections given in responders was 7 (IQR 6 - 10). 
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3.1.2.3  Additional data of non-responders 
 
Eighteen out of 29 (62.1%) patients were classified as non-responders. Genetic variants were identified 
and confirmed in 10 of 18 (55.6%) non-responders, which included: NRL (1 patient), RHO (1 patient), 
PRPF31 (1 patient), PRPF8 (1 patient), SNRNP200 (1 patient), USH2A (2 patients), TULP1 (1 patient), RP1 
(1 patient) and IFT140 (1 patient). Six of 18 (33.3%) non-responders were graded as having disruption of 
the ellipsoid zone within 1mm of the fovea on their baseline OCT scan. 
 
 
2.2.3 Safety 
 
Ocular and non-ocular AEs and SAEs are summarised in tables 12 - 14.  
 
Table 12. Ocular and Non-Ocular Adverse Events (AEs) and Serious Adverse Events (SAEs) – 0-6 months 
after baseline 
ID Adverse Event Start Date Stop Date Severity 
Relationship 
to Study 
Treatment 
Action Taken 
with Study 
Treatment 
Outcome 
of AE Expected Serious 
1 Floater in RE 11/08/2016 05/09/2016 Mild Probably None Resolved Yes No 
2 
Sub-conjunctival 
haemorrhage 04/04/2016 05/04/2016 Mild Not Related None Resolved Yes No 
2 Blurring of vision 25/08/2016 06/09/2016 Mild Possibly None Resolved No No 
3 
Contacted by pt 
to say similar 
blurring to 1st 
injection 07/06/2016 15/06/2016 Mild Definitely  None Resolved Yes No 
3 
Corneal epithelial 
defect post 
injection 11/04/2016 12/04/2016 Mild Definitely  None Resolved Yes No 
3 
Back pain after 
bending down 10/10/2016 14/10/2016 Mild Not Related None Resolved No No 
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ID Adverse Event Start Date Stop Date Severity 
Relationship 
to Study 
Treatment 
Action Taken 
with Study 
Treatment 
Outcome 
of AE Expected Serious 
4 Dry cornea 12/08/2016 14/08/2016 Mild Definitely  None Resolved Yes No 
4 
LUL lesion 
(chalazion) 19/10/2016  On-going Mild Not Related None 
AE 
ongoing No No 
4 
Grittiness / Dry 
eye 09/07/2016 16/07/2016 Mild Probably None Resolved Yes No 
5 
Headache post - 
IVT 26/07/2016 26/07/2016 Mild Probably None Resolved Yes No 
5 Feeling lethargic 25/09/2016 30/11/2016 Mild Unlikely None 
AE 
ongoing No No 
5 
Raised IOP post - 
IVT 03/05/2016 03/05/2016 Mild Definitely  None Resolved Yes No 
5 
Sub-conjunctival 
haemorrhage (5 
days post IVT) 05/06/2016 15/06/2016 Mild Definitely  None Resolved Yes No 
5 Tinnitus 10/07/2016  On-going Mild Not Related None 
AE 
ongoing No No 
8 
Dry ocular surface 
+ pain 10/11/2016 16/11/2016 Moderate Definitely  
Discontinued 
permanently Resolved Yes No 
9 Headache 24/06/2016 26/06/2016 Mild Not Related None Resolved Yes No 
10 
Sub-conjunctival 
haemorrhage 16/05/2016 19/05/2016 Mild Definitely  None Resolved Yes No 
10 
Sub-conjunctival 
haemorrhage 22/08/2016 26/08/2016 Mild Definitely  None Resolved Yes No 
13 Bad back 15/08/2016 19/08/2016 Mild Unlikely None Resolved No No 
14 
Viral cold with 
headache 18/10/2016 27/10/2016 Mild Not Related None Resolved No No 
14 Corneal abrasion 24/06/2016 25/06/2016 Mild Definitely  None Resolved Yes No 
15 
Grittiness/Blurring 
using laptop 01/10/2016 18/10/2016 Mild Unlikely None Resolved No No 
16 
Conversion of 
prostate biopsy 
from benign to 
low-grade 
neoplasia 20/09/2016  On-going Mild Unlikely None 
AE 
ongoing No No 
16 
Vision is not as 
sharp 04/07/2016 06/12/2016 Mild Possibly None 
AE 
ongoing No No 
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ID Adverse Event Start Date Stop Date Severity 
Relationship 
to Study 
Treatment 
Action Taken 
with Study 
Treatment 
Outcome 
of AE Expected Serious 
17 Bad back 14/11/2016 01/01/2017 Mild Not Related None Resolved Yes No 
17 
Yag capsulotomy 
(on non-study eye 
LE) 28/10/2016 28/10/2016 Mild Not Related None Resolved Yes No 
17 Feeling Low 01/12/2016 01/05/2017 Mild Not Related None Resolved Yes No 
18 Viral Cold 22/09/2016 30/09/2016 Mild Not Related None Resolved No No 
19 
Grittiness both 
eyes 12/09/2016 13/09/2016 Mild Unlikely None Resolved Yes No 
20 Labyrinthitis 02/08/2016 01/04/2017 Mild Unlikely None Resolved No No 
21 
Sub-conjunctival 
haemorrhage 01/07/2016 03/07/2016 Mild Definitely  None Resolved Yes No 
21 Soreness of eye 05/10/2016 07/10/2016 Mild Definitely  None Resolved Yes No 
22 UTI 24/10/2016 28/10/2016 Mild Not Related None Resolved No No 
22 
Dry corneal 
surface 02/11/2016 03/11/2016 Mild Definitely  None Resolved Yes No 
22  Viral Illness 28/12/2016 22/01/2017 Mild Not Related None Resolved Yes No 
22 
Sub-conjunctival 
haemorrhage 04/07/2016 09/07/2016 Mild Definitely  None Resolved Yes No 
22 
Dry corneal 
surface 04/07/2016 05/07/2016 Mild Definitely  None Resolved Yes No 
22 Dry Eye 05/10/2016 30/10/2016 Mild Definitely  None Resolved Yes No 
23 
Bitten by 
mosquitto 10/08/2016 17/08/2016 Mild Not Related None Resolved No No 
24 
Flare up of mental 
health issues 15/09/2016  On-going Moderate Unlikely 
Discontinued 
permanently 
AE 
ongoing Yes No 
25 Heartburn 31/08/2016 25/09/2016 Mild Unlikely None Resolved No No 
25 
Sub-conjunctival 
haemorrhage 06/12/2016 24/12/2016 Mild Definitely  None Resolved Yes No 
26 
Viral cold (nasal 
congestion) 19/11/2016 24/12/2016 Mild Not Related 
Delayed 
Dose Resolved Yes No 
27 
Exacerbation of 
mental health 
illness 04/11/2016 17/11/2016 Mild Unlikely None Resolved No No 
27 Viral Illness 02/11/2016 09/11/2016 Mild Not Related None Resolved Yes No 
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ID Adverse Event Start Date Stop Date Severity 
Relationship 
to Study 
Treatment 
Action Taken 
with Study 
Treatment 
Outcome 
of AE Expected Serious 
27 
Punched in non-
study eye (LE) 
with bruise under 
eye 27/08/2016 31/08/2016 Mild Not Related None Resolved No No 
28 
Sub-conjunctival 
haemorrhage 05/10/2016 13/10/2016 Mild Definitely  None Resolved Yes No 
 
 
 
Table 13. Ocular and Non-Ocular Adverse Events (AEs) and Serious Adverse Events (SAEs) – 6- 12 months 
after baseline 
ID Adverse Event Start Date Stop Date Severity 
Relationship 
to Study 
Treatment 
Action Taken 
with Study 
Treatment 
Outcome 
of AE Expected 
Seriou
s 
4 
Perforated 
Ear Drum 26/02/2017 03/03/2017 Mild Not Related None Resolved No No 
4 Ear Infection 26/02/2017 03/03/2017 Mild Not Related None Resolved No No 
4 Ear Infection 03/04/2017 09/04/2017 Mild Not Related None Resolved No No 
4 Viral cold 03/12/2016 05/12/2016 Mild Not Related None Resolved No No 
4 
Vision not as 
clear 15/11/2016 06/12/2016 Mild Definitely  None Resolved Yes No 
11 
Sub-
conjunctival 
haemorrhage 14/12/2016 17/12/2016 Mild Definitely  None Resolved Yes No 
15 Low Mood 20/05/2017   On-going Mild Not Related None 
AE 
ongoing No No 
15 Viral cold 13/12/2016 18/12/2016 Mild Not Related None Resolved Yes No 
16 
Floater Right 
Eye 20/04/2017 27/04/2017 Mild Definitely  None Resolved Yes No 
16 
Grittiness 
after injection 06/02/2017 12/02/2017 Mild Definitely  None Resolved Yes No 
16 
Dry ocular 
surface 19/04/2017 20/04/2017 Mild Definitely  None Resolved Yes No 
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Table 14. Ocular and Non-Ocular Adverse Events (AEs) and Serious Adverse Events (SAEs) – More than 
12 months after baseline 
17 
Viral Gastric 
Bug 09/04/2017 11/04/2017 Mild Not Related None Resolved No No 
17 
Reduced 
central vision 
due to 
progression of 
underlying 
disease 12/05/2017  On-going Moderate Unlikely 
Discontinued 
permanently 
AE 
ongoing Yes No 
21 
Posterior 
vitreous 
detachment 17/03/2017   On-going Mild Possibly None 
AE 
ongoing Yes No 
21 Anxiety 03/03/2017   On-going Mild Not Related None 
AE 
ongoing No No 
21 
Corneal 
abrasion + dry 
cornea 13/01/2017 
 16/01/201
7 Mild Definitely  None 
AE 
ongoing Yes No 
27 
Punched in 
the face just 
below RE (no 
sequelae) 20/03/2017 20/03/2017 Mild Not Related None Resolved No No 
27 Viral illness 21/01/2017 31/01/2017 Mild Not Related None Resolved Yes No 
28 
Posterior 
vitreous 
detachment 16/02/2017   On-going Mild Possibly None 
AE 
ongoing Yes No 
28 
Vitreous 
floater 05/06/2017   On-going Mild Definitely  None 
AE 
ongoing Yes No 
30 Feeling low 17/02/2017 28/02/2017 Mild Not Related None Resolved Yes No 
30 
Right eye 
posterior sub-
capsular 
cataract (non- 
study eye) 17/02/2017   On-going Mild Not Related None 
AE 
ongoing Yes No 
 
ID Adverse Event Start Date Stop Date Severity 
Relationship 
to Study 
Treatment 
Action Taken 
with Study 
Treatment 
Outcome 
of AE Expected Serious 
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3.1.3.1  Ocular adverse events 
 
Ocular AEs included: floaters, sub-conjunctival haemorrhage, blurring/reduced/not as sharp vision, 
epithelial dystrophy/abrasion immediately following injection, grittiness, dry eye, chalazion, raised IOP 
immediately following injection, posterior vitreous detachment (PVD), yittrium aluminium garnet (YAG) 
capsulotomy on the non-study eye, cataract in the non-study eye, history of being punched in the face 
not involving the eye and history of being punched in the non-study eye. There were no cases of 
endophthalmitis or RD reported during this study.  
 
3.1.3.2  Ocular serious adverse events 
 
One participant reported sub-acute reduction of vision at week 32 despite being a ‘responder’ with 
testing demonstrating a reduction in vision of 14 ETDRS letters. This was reported as a SAE and 
injections were immediately discontinued. Further assessments were undertaken including SDOCT, FAF, 
microperimetry and OCT-A in order to help determine the cause for this reduction in vision. There was 
no demonstrable change in outer retinal lamination compared to baseline, with also no change in 
11 
Feeling tired from 
fasting 05/06/2017  06/06/2017 Mild Not Related None 
AE 
ongoing No No 
15 Vitreous Floaters 16/06/2017   On-going Mild Possibly None 
AE 
ongoing Yes No 
17 
Reduced central 
vision 25/10/2017 On-going Mild Possibly 
Discontinued 
permanently Resolved No Yes 
27 
Exacerbation of 
mental health 
illness 17/11/2017 23/11/2017 Mild Unlikely None Resolved No No 
30 Viral illness 05/12/2017 12/12/2017 Mild Not Related Delayed Dose Resolved Yes No 
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microperimetry or FAF compared to baseline, and no abnormality detected on OCT-A. The non-study 
eye had a baseline vision of 30 ETDRS letters due to advanced photoreceptor loss and it was therefore 
concluded that the reduction in vision was most likely to be secondary to progression of underlying RP 
rather than as a consequence of receiving aflibercept injections. This patient was happy to remain within 
the study and attended their 6- and 12- month follow-up appointments. 
 
3.1.3.3  Non-ocular / systemic adverse events 
 
All non-ocular/systemic AEs were reported during the study whether or not they were considered to be 
secondary to aflibercept. Non-ocular/systemic AEs included: back pain, headache, lethargy, tinnitus, 
viral cold, conversion of prostate biopsy from benign to low-grade neoplasia, feeling low/low mood, 
labyrinthitis, urinary tract infection, flare up of mental health, heartburn, perforated ear drum, ear 
infection, viral gastric illness, anxiety and mosquito bite. 
 
Whilst the participant who developed labyrinthitis during the study was reassured that it was unlikely to 
be secondary to aflibercept, they decided that they would prefer to discontinue receiving injections. This 
patient remained in the study and attended their 6- and 12- month follow-up appointments. 
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3.0 The CARAMEL study 
 
3.1 Methods  
 
3.1.1 Overview 
The CARAMEL study stands for ‘Carbonic Anhydrase-inhibitors for Retinitis-pigmentosa And Macula 
oEdema in various Layers’. This was a retrospective cohort study to determine if there was an 
association between the spatial distribution of CS in RP-CMO and response to CAIs. 
 
This study was institutional review board (IRB) approved. 
 
3.1.2 Inclusion criteria 
Patients were included in the study if they met the following inclusion criteria:  
1) Confirmed diagnosis of RP-CMO  
2) Uni- or bilateral (if bilateral, each eye was evaluated individually) 
3) Commenced on treatment with either a topical and/or oral CAI within the period 1st 
January 2013 – 31st  December 2014. Please note that this start date was selected 
because a publication by Liew et al. (2015) included patient data from the same 
institution between January and December 2012 and we did not wish for data to 
overlap. 
4) Pre-treatment OCT scan acquired within 3 months of initiating treatment AND post-
treatment OCT scan acquired between 3 – 9 months after initiation of treatment 
5) Any age 
6) Heyex machine images only 
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3.1.3 Exclusion criteria 
 
Patients were excluded if any of the following applied: 
1) A diagnosis of CMO not considered to be related to RP 
2) Treatment for RP-CMO received within 3 months of initiation of CAI e.g. IVTA/anti-VEGF 
3) Pre-treatment OCT scan not acquired within 3 months of initiating treatment 
4) Post-treatment OCT scan acquired greater than 9 months from initiation of treatment 
5) Images taken on a Topcon machine 
 
3.1.4 ROAD application form 
 
A form entitled ‘Research On Anonymised Data’ (ROAD) form was completed and submitted to the R&D 
department at Moorfields Eye Hospital before this retrospective study was carried out. Only once 
permissions were received was the study undertaken. 
 
3.1.5 Patients and methods 
 
3.1.5.1 Identification of patients 
This retrospective cohort study carried out at Moorfields Eye Hospital NHS Foundation Trust, London, 
UK between 1st January 2013 – 31st  December 2014 made use of a computer-based search to identify all 
patients with ‘retinitis pigmentosa’ and ‘cystoid macular oedema’ appearing in their EPR. This time 
period was chosen as it was deemed a manageable period of time and number of scans to analyse. This 
initial search identified 103 patients, however, after review of each patient record, 78 patients were 
excluded from the study due to having ‘no’ CMO.   
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After accounting for the inclusion and exclusion criteria, the total number of patients included in the 
study totalled 25. Of these, 18 had bilateral RP-CMO and 7 had unilateral RP-CMO; 43 eyes were 
therefore graded in total. 
 
2.2.5.2  Images and consent 
 
SDOCT was undertaken in all recruited subjects as part of a patient’s standard care at their medical 
retina clinic appointment. All patients across the cohort underwent scan acquisition according to the 
standard of care procedure used for out-patient clinics at Moorfields Eye Hospital. All images were 
anonymous therefore additional consent from individual patients was not required. 
 
2.2.5.3  Grading system 
 
Two independent graders experienced in SDOCT interpretation were selected to grade pre-and post-
treatment scans (SAS, NH). Both graders were blinded to the treatment that each patient received and 
whether they were classed as a ‘responder’ or not.  
 
Each grader began by performing re-centration of the images if deemed necessary in order to optimise 
results for the study. The following variables were graded for their presence within 3600µm of the 
foveal centre: sub-retinal fluid (SRF), INL fluid, ONL fluid, GCL fluid, ERM, vitreo-macular adhesion 
(VMA), VMT, lamellar macular hole (LMH) and full-thickness macular hole (FTMH). Each of these 
variables was graded as either: present (>90% certainty), questionably present (50-90% certainty), 
absent (<50% certainty) or ungradable. The presence of ELM within 1200µm of the foveal centre was 
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also graded and a comment made as to whether it was felt to be intact throughout or disrupted. A 
further ‘yes’ or ‘no’ response was required for the grading of whether there was felt to be intact ELM 
and/or fluid present (in any lamination) directly under the foveal centre. Pre- and post- treatment CMT 
and macular volume were also documented.  
 
If both graders agreed on a variable, the grading was complete. If the second grader (NH) disagreed with 
the first grader (SAS), adjudication was performed by a consultant retinal specialist (MM).  
CMT values were considered to be in agreement if graded within 50µm of each other. Macular volume 
values were considered to be in agreement if graded within 1.5 millimetres (mm)3 of each other. In 
total, graders 1 and 2 correlated on 1146 out of 1290 (88.8%) points thus requiring adjudication of 144 
out of 1290 (11.2%) points. The mean of the grader scores for CMT was used for analysis.  
 
2.2.5.4  Statistical analysis 
 
Descriptive statistics are used to describe the results of the CARAMEL study. For categorical variables, 
Kappa statistic was computed with respective 95% confidence interval (CI) for assessing inter-rater 
agreement as Kappa is thought to be a more robust measure than simple percent agreement (Kappa 
takes into account the possibility of agreement occurring by chance). For continuous variables Bland-
Altman agreement methods were used to quantify limits of agreement (LoA). Analysis was performed in 
STATA version 13 (STATA Corp., Texas, USA) and 95% CIs for Kappa were computed using the kapci 
package using 1000 bootstrap replicates. 
 
No natural history studies have taken place to assess change of CMT over time in patients with RP-CMO 
who are not receiving treatment. Artunay et al. (2009) demonstrated no statistical change of CMT 
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throughout the duration of their 6-month study in their control group (n = 15), however, these patients 
had still previously received acetazolamide for at least 6-months. Whilst diurnal variation in CMT 
measurements has been evaluated for conditions such as DMO, there is nothing in the literature with 
regards to RP-CMO. Patients were therefore considered to be a ‘responder’ if they demonstrated a 
reduction of CMT of at least 11% or more following treatment, thus allowing comparison with previous 
studies that used the same definition (138, 254). Please note that for the purposes of this study, all 
values over 10.5% were rounded up to 11%.  
 
 
3.1.6 Outcome measures 
 
3.1.6.1  Primary outcome measure 
 
To report mean CMT as measured with SDOCT in eyes of patients with RP-CMO acquired between 3 – 9 
months after initiation of oral or topical CAI treatment. 
 
3.1.6.2  Secondary outcome measures 
 
To report the presence of SRF within 3600µm of the foveal centre using SDOCT in eyes of patients with 
RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
 
To report the presence of INL fluid within 3600µm of the foveal centre using SDOCT in eyes of patients 
with RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
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To report the presence of ONL fluid within 3600µm of the foveal centre using SDOCT in eyes of patients 
with RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
 
To report the presence of GCL fluid within 3600µm of the foveal centre using SDOCT in eyes of patients 
with RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
 
To report the presence of ERM within 3600µm of the foveal centre using SDOCT in eyes of patients with 
RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
 
To report the presence of VMA within 3600µm of the foveal centre using SDOCT in eyes of patients with 
RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
 
To report the presence of VMT within 3600µm of the foveal centre using SDOCT in eyes of patients with 
RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
 
To report the presence of LMH or FTMH within 3600µm of the foveal centre using SDOCT in eyes of 
patients with RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
 
To report the presence of ELM within 1200µm of the foveal centre using SDOCT in eyes of patients with 
RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
 
To report the integrity of ELM within 1200µm of the foveal centre using SDOCT in eyes of patients with 
RP-CMO acquired between 3 – 9 months after initiation of oral or topical CAI treatment. 
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3.2 Results  
 
Forty three eyes (22 right; 21 left); were included in the study consisting of 18 patients with bilateral RP-
CMO and 7 patients with unilateral RP-CMO. Seventeen of these patients were male and 8 were female. 
Median age was 48 and ranged between 17 and 79 years. Four out of 43 (9.3%) eyes were treated with 
oral acetazolamide 250mg twice a day versus 39 out of 43 (90.7%) of eyes treated with topical 2% 
dorzolamide or brinzolamide three times a day. All 43 eyes in the study were graded as having INL fluid 
present on their pre-treatment OCT scan. Thirty three out of 43 eyes (76.7%) in the study demonstrated 
co-existing ONL fluid present on their pre-treatment OCT scan. Eleven out of 43 eyes (25.6%) in the 
study demonstrated co-existing GCL fluid present on their pre-treatment OCT scan. No patients 
demonstrated presence of SRF. 
 
Estimates of agreement for all variables assessed by the two graders are presented in figures 38 and 39. 
No single variable was found to have poor agreement. No evidence of bias was found in terms of inter-
rater agreement for pre-treatment CMT (see figure 35), mean difference -0.74. 95% CI (-3.12, 1.63). 
Inter-rater LoA were -16.18 to 14.69 for pre-treatment CMT and -18.36 to 21.76 for post-treatment 
CMT, which was considered by the PI to be acceptable. Inter-rater agreement was -0.91 to 1.14 for pre-
macular volume and -1.22 to 1.24 for post-macular volume, which was considered by the PI to be 
acceptable with no evidence of bias.  Figure 36 demonstrates pre-CMT and post-CMT measurements 
made by the two graders using a box plot. 
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Figure 35: Bland-Altman graph illustrative of pre-CMT inter-rater agreement. CMT = central macular 
thickness 
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Figure 36: Box plot illustrative of pre-CMT and post-CMT measurements made by the two graders. CMT 
= central macular thickness. 
 
 
 
Out of 43 eyes that were graded, 13 (30.2%) were classed as ‘responders’ having achieved a CMT 
reduction following treatment of at least 11%. All 13 responders demonstrated ONL fluid on their pre-
treatment OCT and the presence of fluid (in any layer) directly under the fovea. ERM was ‘definitely 
present’ in 8 out of 13 (61.5%) responders and ‘questionably present’ in 2 out of 13 (15.4%) responders. 
No responder demonstrated VMA, VMT or a FTMH on their pre-treatment OCT scan. ELM was 
considered to be present (intact or disrupted) within 1200µm of the fovea and present directly under 
the fovea in all but 1 responder (92.3%). BCVA improved by at least 10 ETDRS letters in 2 out of 13 
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(15.4%) responders. No responders demonstrated a loss of 10 or more ETDRS letters. The remaining 11 
out of 13 (84.6%) responders demonstrated no change in their BCVA following treatment. Interestingly, 
4 out of 13 (30.8%) responders demonstrated total clearance of ONL fluid on their post-treatment OCT 
scan whilst INL cysts remained 
 
Out of 30 non-responders, 20 (66.7%) eyes had ONL fluid on their pre-treatment OCT compared to 10 
(33.3%) eyes without ONL fluid on their pre-treatment OCT. Sixteen out of 30 (53.3%) non-responder 
eyes had fluid (in any layer) directly under the fovea. Interestingly, there were three non-responders 
that demonstrated total clearance of ONL fluid on their post-treatment OCT scan whilst INL cysts 
remained (see Figure 3). VMA was definitely present in 7 out of 30 (23.3%) non-responders and 
questionably present in 2 out of 30 (6.7%) non-responders. ELM was considered to be present (intact or 
disrupted) within 1200µm of the fovea in 26 out of 30 (86.7%) non-responder eyes, however, was only 
present directly under the fovea in 20 out of 30 (67.0%)  eyes.  BCVA improved by at least 10 ETDRS 
letters in 2 out of 30 (6.7%) non-responders. No non-responders demonstrated a loss of 10 or more 
ETDRS letters. The remaining 28 out of 30 (93.3%) non-responders demonstrated no change in their 
BCVA following treatment.  
 
Of note, all 4 patients (2 responders and 2 non-responders) who gained at least 10 ETDRS letters of 
BCVA, demonstrated ONL fluid on their pre-treatment OCT scans. 
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4.0 Discussion 
 
IRD is the leading cause of blindness certification in the working age population (age 16-64 years) in 
England and Wales, occurring from abnormalities of retinal cell structure including photoreceptors as 
well as defects in phototransduction and the visual cycle (10). RP is the most common IRD to date with 
RP-CMO being a known complication of RP. However, the exact underlying pathogenesis of RP-CMO 
remains uncertain and thus challenging to treat.  
 
A variety of treatments, including: CAI’s, steroids (topical, oral, intravitreal, sub-tenon), NSAIDs, lutein, 
laser and vitrectomy have been attempted with varying success to address various hypotheses such as 
breakdown of the BRB, failure of the RPE pump, Muller cell oedema and dysfunction, anti-retinal 
antibodies and vitreous traction. The majority of studies published provide levels of evidence between 3 
and 4; no large RCTs have been undertaken, thus the effect of known and unknown confounders cannot 
be excluded (1), many studies did not have a control group (level 4 evidence) inherently limiting the 
validity of findings (as these may be a result of natural history rather than the intervention) (1) and 
many studies were retrospective, which may thus be affected by recall bias. We therefore remain in a 
position where there are currently no studies able to provide high-level evidence for the treatment of 
RP-CMO. 
 
The release of toxic products (including VEGF) from degenerating retina/RPE in patients with RP 
contributes to weakening of the BRB and RP-CMO formation (101). Anti-VEGF is thought to act by 
reversing proliferation and cell migration stimulated by VEGF and the delocalization of tight junction 
proteins induced by VEGF 165 (261). It therefore has the potential to treat RP-CMO, however, the 
evidence for its usage in this condition is limited. 
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In view of the above, two studies were carried out and reported in this thesis in order to achieve a 
better understanding of the following: 
 
1) To explore whether an association exists between the spatial distribution of CS in RP-CMO and 
response to treatment with CAIs (the CARAMEL study) 
 
2) To explore the efficacy and safety of aflibercept as a treatment for RP-CMO (the AMOUR study) 
 
 
The CARAMEL Study 
In keeping with Makiyama et al. (2014), the CARAMEL study observed an overall higher frequency of INL 
compared to ONL fluid in patients with RP-CMO (110). This suggests that inner BRB dysfunction may 
have a greater role than the outer BRB in the development of RP-CMO (2).   
 
It was interesting to note that 100% of responders demonstrated ONL fluid on their pre-treatment OCT, 
however, not every patient with pre-treatment ONL fluid responded. The presence of ERM graded as 
either ‘questionably present’ or ‘definitely present’ was similar in both groups (10 out of 13 (77.0%) 
responder eyes versus 24 out of 30 (80.0%) non-responder eyes) and therefore does not appear to have 
significantly affected response to treatment in our cohort. In contrast, the presence of VMA graded as 
either ‘questionably present’ or ‘definitely present’ was greater in the non-responder group (0 out of 13 
(0.0%) responder eyes versus 9 out of 30 (30.0%) non-responder eyes) and may therefore play a role in 
limiting response to treatment due to its tractional component. 
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Overall, there were seven patients (including ‘responders’ and ‘non-responders’) that demonstrated 
total clearance of ONL fluid on their post-treatment OCT scan despite persistence of INL cysts. Our 
working hypothesis to explain this response includes the closer anatomical proximity of ONL fluid to the 
RPE where the action of CAIs take place. A greater percentage of eyes in the responder group 
demonstrated at least 10 ETDRS letter improvement of BCVA compared to the non-responder group 
(15.4% of responders versus 6.7% of non-responders). It is not uncommon for anatomical improvement 
to occur without significant functional improvement (125). Factors such as underlying photoreceptor 
loss and/or chronicity of RP-CMO may have an effect on visual outcome (1, 125). Whilst it was noted 
that patients with visual gain demonstrated ONL fluid on their pre-treatment OCT scans, a larger study 
with appropriate statistical analysis is required to be able to qualify whether this observation is 
significant.  
 
Although there was only a limited vision-improving effect observed in this study, we still believe in 
treating RP-CMO to achieve anatomical improvement to prevent irreversible structural damage as well 
as to potentially decelerate underlying photoreceptor loss (1). 
 
The CARAMEL study was limited due to a small cohort size. Further studies with larger patient numbers 
are required in order to support our findings of OCT phenotypes that may help predict treatment 
response. This would help better inform patient counselling and management in this highly genetically 
heterogenous retinal dystrophy. 
 
CAIs are also associated with side-effects such as: tingling/numbness of the limbs, fatigue, renal stones, 
aplastic anaemia, hypokalaemia and cardiac arrhythmia (148). To this end, it would be valuable to 
identify factors that might help predict response of RP-CMO to CAI treatment in order to tailor patient 
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care appropriately. Whilst the CARAMEL study identified the presence of ONL fluid on pre-treatment 
OCT scan to possibly be a positive prognostic factor in the treatment of RP-CMO, we are limited by 
design and numbers to be able to provide accurate statistical analysis and it must therefore be 
interpreted as observation only. 
 
Unfortunately, permission to obtain information regarding genetic data was not requested when setting 
up the CARAMEL study and therefore could not be included. This would have been an interesting area to 
explore. 
 
The AMOUR Study 
The AMOUR study is the first prospective study to obtain safety and efficacy data on the use of serial 
intravitreal injections with aflibercept for the treatment of RP-CMO, employing a monthly loading phase 
of 3 injections followed by a treat-and-extend protocol for a total of 12 months of follow-up. No 
statistically or clinically significant improvement of vision was demonstrated in this cohort as a whole, or 
in sub-group analysis of responders. Responders gained 3.8 (SD 6.8) and 4.7 (SD 9.5) ETDRS letters 
respectively at 6 and 12 months.  
 
In keeping with Moustafa and Moschos (2015), the AMOUR study observed a reduction of CMT +/- 
improvement of VA following intravitreal aflibercept within its cohort (4). When the cohort was analysed 
as a whole, the mean (SD) percentage change in CMT relative to baseline was -8.1% (23.3%) and -9.6% 
(17.6%) at 6- and 12- months respectively. In total, 11 out of 29 (37.9%) patients were classified as 
responders at both 6- and 12- months having demonstrated a reduction of at least 11% CMT on SDOCT 
compared to baseline. These patients experienced a mean percentage change in CMT relative to 
baseline of -22.9% (29.7 %) and -28.1% (12.9 %) at 6- and 12- months respectively. Responders also 
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demonstrated a greater change of macular volume over the study (-0.6mm3 at 6 and 12 months) 
compared to non-responders (-0.3mm3 at 6 and 12 months). An intriguing observation, unlike other 
disorders where anti-VEGF agents have been employed, is that all responders (n=11) achieved a notable 
reduction in CMO after their first injection ('early-responder'). There were no 'late-responders'. This is 
clinically very valuable as for the majority of patients it may be possible to decide at a very early stage 
whether injections should be pursued.  
 
 
There were no significant safety concerns and serial injections were well tolerated. 
 
Responders in this study were identified across all categories of inheritance pattern (AD, AR and XL). 
There was no association between response to anti-VEGF treatment and mode of inheritance. Whilst 
just over half of the patients in this study had a confirmed molecular diagnosis, no genotype was 
associated with response to treatment; including 1 USH2A patient responded, whilst 2 other USH2A 
patients did not, and 1 PRPF31 patient responded - whilst 2 others did not. This study included only 1 
patient with XL inheritance who was deemed a responder and we therefore cannot draw any 
comparison with other patients with XL-RP. More advanced disease, defined as disruption of the 
ellipsoid zone within 1mm of the fovea (seen in 27.3% of responders and 33.3% of non-responders) did 
not appear to affect likelihood of response to anti-VEGF.  
 
The majority of patients (26 out of 30) in the study reported their ethnicity as ‘White’. Whilst we cannot 
confirm the reason for this, it should be noted that no patient declined to be in the study based on 
religious or ethnic grounds. Since almost all patients in the study came from the medical retina clinics at 
Moorfields Eye Hospital, it would be interesting to perform an electronic search to analyse the ethnic 
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backgrounds of the patients in attendance at these clinics to see if this mirrors the patient ratios in our 
study. Unfortunately, the ethnicity of the cohort of patients included in the paper published by Liew et 
al. (2015) and Liew et al. (2018) was not reported. This would have been interesting to compare with as 
both studies were carried out at the same institution at a similar time (132, 262). 
Mean retinal sensitivity was reduced by -0.92dB (SD 2.03) and -0.97dB (SD 1.92) at 6- and 12- months 
respectively compared to baseline despite an overall improvement of CMT and BCVA.  
 
Whilst this slight reduction may be clinically significant, it should be noted that test-retest variability was 
not determined at baseline and it is therefore possible that the results remain within limits of normal 
variation.  
 
Strengths of this study included excellent patient attendance throughout its duration, with a 96.7% 
participant retention rate at 12-months. The study drug was well tolerated and no cases of 
endophthalmitis occurred. The study design including an initial loading phase followed by a treat-and-
extend regime, which allowed for the observation of both early and (potentially) late responders. Likely 
disease-causing sequence variants were also established in 16 of 30 (53.3%) study participants. 
 
One of the limitations to our study was being unable to include treatment-naive patients with shorter 
duration of CME. Many patients were deemed eligible for the study yet declined intravitreal injections 
without first trialling topical and/or oral treatment. All patients in the study had therefore used topical 
CAI medication previously; 15 of whom were using topical CAI treatment up until 1 month prior to their 
screening appointment. Five of these patients were deemed responders. Five patients in the study were 
using oral CAI treatment up until 3 months prior to their screening appointment; 1 patient withdrew 
from the study, 2 patients were deemed responders, and 2 patients did not respond. No obvious trend 
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was demonstrated to suggest whether recent use of topical or oral CAIs influences response to anti-
VEGF therapy.  
 
Long-standing CMO duration was observed in many patients within this cohort, with the median 
duration being 252 weeks (IQR, 156 - 296 weeks). An interesting observation identified from this study 
was that duration of CMO did not appear to affect anatomical response to anti-VEGF; median CMO 
duration in responders was 264 weeks (IQR 228, 416), compared to the group overall (252 weeks (IQR 
156, 296). Indeed, the patient with the longest standing CMO duration of the cohort (20 years) had 
complete resolution of CMO after a single intravitreal injection of aflibercept.  
 
As long as patients achieved a BCVA better than 20/400 at baseline, they were considered eligible for 
the study. Our study therefore included patients with fairly advanced underlying disease as 
demonstrated by photoreceptor loss and outer retinal thinning - features that have been shown to 
hinder VA improvement despite reduction of CMT (127). It was therefore unsurprising to find that all 3 
of 11 (27.3%) responders graded as having disruption of the ellipsoid zone within 1mm of the fovea on 
their baseline OCT scan demonstrated no improvement of vision. Greater improvement of VA may be 
demonstrated in patients with a relatively more intact photoreceptor layer at baseline.  
 
It would be valuable to repeat this study in a larger cohort of patients, ideally naive to other treatment 
modalities, with shorter history of CMO duration and relatively intact photoreceptor layers at baseline. 
Only including patients with a molecularly confirmed genetic diagnosis would help to determine if 
genotype has a role in predicting response to anti-VEGF treatment. Additional suggestions to consider 
when designing a future study would include: to perform fundus fluorescein angiogram (FFA) at baseline 
to see whether active leakage is present and whether FFA is predictive of which patients will/will not 
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respond to aflibercept, to take baseline samples of vitreous in order to assess levels of VEGF in this 
cohort of patients, to include a control group (possibly using placebo), to randomise patients if there is 
an option of a control/placebo group, to blind patients and/or clinicians if there is an option of a 
control/placebo group, and to include OCT-A as an additional imaging modality. 
 
This phase II exploratory study demonstrates that intravitreal aflibercept can be effective at reducing 
CMT in select patients with RP-CMO. The factors predicting who is likely to respond, however, remain to 
be clarified. Our data supports more studies to further investigate the role of VEGF blockade in RP-CMO.  
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5.0 Concluding remarks 
 
To conclude, the successful management of RP-CMO should aim to both improve both quality and 
quantity of vision in the short-term as well as slowing the rate of vision loss long-term. It appears there 
are 2 approaches to tackle RP-CMO: the first involves identifying a therapeutic agent that is able to 
pinpoint and address the exact underlying mechanism(s); the second involves treating the underlying 
condition of retinal degeneration thus preventing any related complications from arising. 
 
Unfortunately, with varying ideas regarding the mechanism of RP-CMO formation and a lack of high 
quality evidence for RP-CMO treatments, we are not yet in a position to treat RP-CMO with absolute 
clarity. We are, however, in an exciting era of opportunity to potentially address one, or both of these 
options in the future given enough time, funding and research. 
 
An extensive literature review has been provided in this thesis regarding avenues of intervention for RP-
CMO, which can be summarised as follows: 
 
 CAIs are often used for the treatment of RP-CMO despite no RCTs (comparing CAI with placebo) 
being published providing evidence for their safety and efficacy. Before treating a patient with 
CAI, consideration should be given to the possible side-effects associated with its usage. These 
can be minimised by using CAIs topically, as opposed to orally, which may be as effective (34). 
Cases of rebound CMO have been documented with prolonged use (140). 
 
 Topical use of steroid and/or NSAID can be effective at reducing CMO +/- improving vision in 
patients where CAIs are contraindicated. The effects of systemic absorption of these 
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medications need to be considered, however, and a thorough medical history should be taken 
before their usage. IOP can also rise therefore close monitoring of IOP during the course of 
steroid administration would be necessary (172). IVTA may be useful for selected cases of RP-
CMO (166). 
 
 Whilst no studies have assessed vitreous levels of VEGF in patients with RP or RP-CMO, 
anatomical and/or functional improvement of RP-CMO has been observed following intravitreal 
anti-VEGF medication (3, 4, 186-189). The high binding affinity and long duration of action of 
aflibercept may reduce the frequency of repeat injections (195). 
 
The CARAMEL study has highlighted the dilemma regarding the use of CAI treatment for RP-CMO; 
similar to Liew et al. (2015) where response to treatment with CAI was demonstrated in only 50 out of 
125 (40.0%) eyes treated with topical dorzolamide and 9 out of 32 (28.1%) eyes treated with oral 
acetazolamide, the CARAMEL study demonstrated response in only 13 out of 43 (30.2%) eyes. It has also 
drawn our attention to the trends shown towards: better improvement where pre-treatment OCT scans 
include CS in the ONL, greater chance of BCVA improvement in patients who respond and that the 
presence of ERM does not appear to significantly affect response to treatment. 
 
The AMOUR study found improvement of CMT +/- VA using descriptive statistics only in certain patients 
with RP-CMO, although we have been unable to ascertain factors that might predict treatment success. 
Where CMO and CMT was seen to improve, subsequent improvement of vision was not necessarily 
demonstrated. This is not an uncommon finding and previous studies have also demonstrated lack of 
significant improvement on multifocal ERG (4). This might be explained by other factors that influence 
VA such as: atrophy of the retina and/or RPE and scarring.  
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Whilst concrete conclusions cannot be drawn, the evidence available to us as provided in this thesis 
through a combination of literature review and consideration of the results from both the CARAMEL and 
AMOUR studies, suggests:  
1) Topical CAI may be used as a first-line approach with review of response after 4 - 6 months.  
2) a) After 4 - 6 months, if there has been minimal (but not significant) reduction of CMT or 
improvement of BCVA, consider switching to an alternative topical CAI or oral CAI.  
b) After 4 - 6 months, if there has been no reduction of CMT or improvement of BCVA or if the 
spatial distribution of cysts are located only in the INL, consideration should be given to trialling 
alternative therapeutic options, such as: topical NSAID agents or considering intravitreal anti-
VEGF (although these latter agents are currently unlicensed for RP-CMO).  
 
A better understanding of the mechanisms underlying RP-CMO will facilitate better targeted and likely 
more efficacious and durable therapies (1). 
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6.0 Future directions 
 
6.1 Diagnosis of IRD 
 
Preliminary diagnosis of IRD based on the history and clinical examination can often be tricky due to 
overlapping phenotypes and unclear inheritance patterns. Genetic testing is therefore extremely useful 
for diagnosis as well as to further our understanding of IRD genetic associations and direct appropriate 
treatments. Molecular diagnosis has also helped propel the fields of stem cell research and genome 
editing technology (10).  
 
Until recently, patients were unable to receive a molecular diagnosis due to the high level of cost and 
various inefficiencies involved in molecular genetic testing (263). Since around 2010, the development of 
NGS has offered the possibility of genome-mapping in order to help diagnose diseases such as retinal 
dystrophies (10). However, around half of all people tested remain without a molecular diagnosis. There 
are also many challenges that come with advances in genomic medicine, including (264):  
 
 Developing skills and expertise in genomics within the wider health professional workforce  
 
 Issues relating to patient communication, privacy and consent (particularly for genomic testing 
in children)  
 
 Handling uncertain, unexpected or incidental findings from genomic tests in clinical practice  
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 Implications of significant results for other family members  
 
 Bioinformatics provision and secure genomic data storage and access within the health service  
 
 Impact of genomics on current healthcare services, resources and patient pathways (including 
equity of access to genomic tests)  
 
 Developing intelligent decision support systems that allow the use of genomic and clinical 
information to aid in the prescribing of drugs at the right dose  
 
 Clarifying risks and benefits associated with using genomic tests for opportunistic screening  
 
Our hope for the future is to improve sequencing performance and interpretation while providing 
quicker turnaround times and reduction in cost (263). 
 
 
6.2 Management of IRD 
Future management of IRD will focus on identifying therapeutic options to reverse, or slow down, the 
rate of underlying retinal degeneration. This will vary according to each patient’s rate and extent of 
disease: 
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6.2.1 Management of earlier stages of disease 
 
Neuroprotection, antioxidants and other pharmacological therapies are useful for earlier stages of 
disease, being actively investigated and showing huge potential in preventing cell death. Photoreceptors 
in particular will most likely require the inhibition of both apoptosis and necroptosis (26). 
 
Gene therapy is also best placed for earlier stages of disease where the opportunity still remains to 
alleviate the underlying defect, regenerate damaged retinal cells and prevent further retinal 
deterioration (20). There are many gene therapy studies currently being undertaken in humans to 
address IRD. We will therefore focus on those studies on the horizon, specifically for RP: 
 
 At present, there are no gene therapy trials being carried out in ADRP. This is due to the greater 
complexity of gene silencing approaches needed in ADRP compared to gene supplementation 
strategies in AR/XL-RP (230). 
 
 We eagerly await the results of three AAV human trials in progress for RP caused by variants in 
the RPGR gene [NCT03116113, NCT03316560, and NCT03252847] (230). 
 
 AR-RP caused by variants in the PDE6β gene account for approximately 1–2% of all RP cases 
(230). Gene therapy using rAAV-mediated PDE6β has been demonstrated in both mouse and 
dog models to restore dim-light vision, providing great promise for human treatment, with 
anticipated clinical trials (230).  
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 Variants in cyclic nucleotide-gated channel β1(CNGB1) cause approximately 4% of AR-RP (230). 
Again, gene therapy using  an AAV vector has been demonstrated in both mouse and dog 
models to improve vision at very low light levels, with a clinical trial in development  (230).  
6.2.2 Management of more advanced stages of disease 
 
More advanced stages of disease would benefit from artificial vision and stem cell therapy. The 
indefinite self-renewal ability and plasticity of stem cells allows for in vitro generation of an unlimited 
number of distinct cell types, and has opened new avenues for regenerative medicine (243). There are 
many stem cell studies currently being undertaken in humans to address IRD including:  
 
- A first-in-human, phase I/IIa, open-label, prospective study investigating the safety and 
tolerability of sub-retinally transplanted hRPC in patients with RP is currently recruiting in the 
USA (ClinicalTrials.gov Identifier: NCT02464436). The primary outcome measure is safety and 
secondary outcome measure is efficacy via VA, VF sensitivity, retinal photography, FAF and 
SDOCT.  
 
Retinal implants or prosthetics rely on a patient having intact neural pathways whereby the transmission 
of information to the visual centres of the brain can be enhanced (10). Compared to gene therapy, 
systems such as the Argus® II are less costly, with demonstrated favourable outcomes, albeit though 
artificial vision (265). Future improvements of retinal prostheses such as this will include better 
programming and increased electrode count within the device, however, there are technological, 
material and biological limitations to this (266). 
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Further investigation of these potential therapies is required in order to address the various stages of 
IRD. Information regarding efficacy, applicability, acceptability, cost and long-term effects of these 
treatments, however, will be required before implementation into routine clinical practice (20). 
 
 
6.3 Management of RP-CMO 
 
Given the potentially reversible nature of RP-CMO, there is a real need to better understand disease 
mechanisms and undertake prospective clinical trials of therapeutic agents to provide the evidence base 
to improve treatment of RP-CMO (1). Setting up clinical trials for RP-CMO, however, is a challenge due 
to its low prevalence, highly variable course of disease progression, significant genetic and allelic 
heterogeneity, and very slow progression to visual loss (1).  
 
Whilst anti-VEGF has been demonstrated to reduce RP-CMO in select cases of RP (for reasons that are 
yet unknown), the potential complications associated with the use of anti-VEGF therapy must be 
considered. Whilst Salom et al. (2008) observed lower aqueous levels of VEGF in eyes of patients with RP 
versus controls, it would be interesting to note levels of VEGF in the vitreous and whether there are 
significant differences between patients with RP versus controls, as well as patients with RP versus those 
with RP-CMO. This being an invasive procedure, however, would likely prove challenging to gain ethical 
approval for and is why we did not consider undertaking in the AMOUR study.  
 
Suggestions to consider when designing a future study, include: to perform FFA at baseline to see 
whether there is active leakage present and whether FFA is predictive of which patients will/will not 
respond to aflibercept, to take baseline samples of vitreous in order to assess levels of VEGF in this 
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cohort of patients, to increase the number of patients in the study to potentially offer results with 
statistical significance, to include patients who already have a molecular diagnosis (or where this is not 
possible, obtain DNA samples from patients at baseline to attempt to obtain a molecular diagnosis), to 
include a control group (possibly using placebo), to randomise patients if there is an option of a 
control/placebo group, to blind patients +/- clinicians if there is an option of a control/placebo group 
and to include OCT-A as an additional outcome measure. 
 
The free radical scavenger Edaravone, shown to be effective against retinal degeneration both in vivo 
and in vitro, may also have a role in inhibiting vascular leakage thus reducing Muller cell oedema (267). 
Studies to date include only mice / rat models. Hopefully, with continued research, we will see the 
results of this drug in human subjects. 
 
A better understanding of the underlying mechanisms and response to treatments of RP-CMO is 
required to facilitate better targeted and more efficacious therapies (1). 
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Abstract:  
Purpose: A study to report the safety and efficacy at 12-months of intravitreal aflibercept (Eylea) (ivA) 
for cystoid macular edema (CME) associated with retinitis pigmentosa (RP).  
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Design: Prospective, exploratory, phase II, non-randomized, single-center, open-label, 12-month, 1-arm 
clinical trial. 
 
Participants: A total of 30 eyes of 30 patients with center-involving RP-CME. 
 
Methods: Participants received intravitreal aflibercept (ivA) every four weeks for the first three months 
(loading phase), followed by a treat and extend protocol up to 12-months. Extension from monthly to 6, 
8, 10 and 12-week follow-up occurred when there was no further reduction in macula edema compared 
with the previous visit.  
 
Main outcome measures:  
(i) To report the safety of aflibercept in RP-CME throughout the study (17 months in total); via the 
documentation of adverse events (AEs) deemed related to the trial drug; (ii) To report the efficacy of 
aflibercept in RP-CME via mean central macular thickness (CMT) on Spectral domain OCT (SDOCT) at 12-
months after baseline.  
 
Results: Twenty-nine out of 30 (96.7%) patients completed 12-months of follow-up. A total of 4 to 11 
injections per patient were given over the 12-month study. No statistically significant reduction of CMT 
or VA improvement was demonstrated in the group overall. Eleven out of 29 (37.9%) participants were 
considered as ‘responders’ demonstrating at least an 11% reduction of CMT at 12-months on SDOCT 
compared with baseline. A reduction of CMT by mean (SD) 28.1% (12.9 %) was observed in responders 
at 12 months, however, no statistically significant corresponding improvement in BCVA was seen. 
Baseline characteristics, including duration of CME were similar between the responder and non-
responder groups. No clinically significant adverse events were deemed secondary to ivA. 
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Conclusions: This first prospective exploratory study demonstrates both the safety and acceptability of 
serial ivA in patients with RP-CME, effective at reducing CMT in 37.9% of patients. All patients 
demonstrating anatomical response did so after their first injection. Longer duration of CME did not 
negatively affect response to anti-VEGF. Further study in a larger cohort of patients with shorter CME 
duration would be valuable to better establish the utility of VEGF blockade in RP-CME.  
 
Inherited retinal disease is the second commonest cause of visual loss in childhood and the commonest 
cause of visual loss in the working age population 1. Retinitis pigmentosa-associated cystoid macular 
edema (RP-CME) is a known complication of retinitis pigmentosa (RP), reported to occur in between 10 - 
50% of patients with RP at some stage in their lifetime 2-5. One of the most commonly reported ocular 
symptoms of RP is concentric peripheral visual field loss that is relentless and progressive for which 
there is currently no cure. Complications of RP such as cataracts and RP-CME interfere with central 
vision and are thereby particularly debilitating, making effective treatments for RP-CME highly valuable.  
 
Several mechanisms have been proposed to explain why CME develops in RP, however, no single 
aetiology has been definitively established, and it is plausible that RP-CME may result from a 
combination of these6: (i) breakdown of the blood-retinal barrier7,8, (ii) failure (or dysfunction) of the 
retinal pigment epithelium (RPE) pump mechanism9, (iii) Müller cell edema and dysfunction10, (iv) anti-
retinal antibodies11, and (v) vitreous traction12,13. With this in mind, many treatment approaches for RP-
CME have been employed including: laser therapy, topical carbonic anhydrase inhibitors (CAIs), oral 
CAIs, peri-ocular and intravitreal steroids, and intravitreal anti-vascular endothelial growth factor (anti-
VEGF) agents6. However, the vast majority of the published literature is retrospective and thereby 
inherently limited, often involving small numbers of participants and short duration of follow-up. The 
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presence of CME in RP has been associated with younger age but not with gender 14. RP-CME is most 
prevalent in patients with autosomal dominant (AD) inheritance (71.4% with CME in at least one eye), 
followed by autosomal recessive (AR)/sporadic inheritance (58.9%) and XL inheritance (12.5%) 14. 
Patients with epiretinal membrane (ERM) and cataract/pseudophakia are less likely to develop CME 14. 
 
Whilst the current mainstay of treatment for RP-CME is topical/oral CAIs, there is no level 1 evidence 
supporting their use and studies have demonstrated highly variable efficacy. Liew et al. recently carried 
out a 12-month retrospective review of 81 patients with RP-CME seen at Moorfields Eye Hospital (UK) 
on treatment with either topical dorzolamide (64 patients, 125 eyes) or oral acetazolamide (17 patients, 
32 eyes)14. Forty percent of eyes (53.1% of patients) following treatment with topical dorzolamide and 
28.1% of eyes (41.2% of patients) following treatment with oral acetazolamide demonstrated response 
(defined as a reduction of central macular thickness (CMT) on OCT of at least 11% between visits) 15. A 
cross-sectional study performed on this same cohort of patients (n = 81) identified older age, earlier age 
of onset of symptoms, and thicker CMT to be associated with lower VA 16. Gender and inheritance 
pattern were not found to be associated with VA 16. 
 
Several publications have observed a variable effect of anti-VEGFs in RP-CME, including: pegaptanib 
sodium (Macugen, (OSI) Eyetech Pharmaceuticals and Pfizer Inc.) 17, bevacizumab (Avastin, 
Genentech/Roche, South San Francisco, California, USA) 18,19, ranibizumab (LUCENTIS; Genentech, South 
San Francisco, Calif., USA) 20,21 and aflibercept (EYLEA; Regeneron Pharmaceuticals, Inc., Tarrytown, New 
York, N.Y., USA, and Bayer Healthcare Pharmaceuticals, Berlin, Germany) 21,22. The largest study to date 
by Artunay et al. enrolled 30 eyes of 30 patients with RP-CME refractory to treatment with oral 
acetazolamide for at least 6 months. Fifteen eyes of 15 patients were treated with a single intravitreal 
injection of ranibizumab (ivR). Fifteen eyes of 15 patients that declined ivR were used as a control group. 
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Thirteen out of 15 eyes (87%) in the treatment group demonstrated significant reduction of CME at 6 
months post-injection although the definition of ‘significant reduction’ is not stated in the paper. No 
statistically significant difference in VA was demonstrated in this cohort as a whole, or in sub-group 
analysis of responders. Moustafa and Moschos published a case report demonstrating improvement of 
CMT and VA following a single unilateral intravitreal injection of aflibercept (ivA) in a 52-year-old with 
RP-CME. At baseline, the vision in the RE was 3/10. One month post-injection, vision improved to 4/10 
and the CME resolved. Documented visual improvement was maintained at both the 2- and 6-month 
reviews 22. Our group subsequently published a case report regarding a 38-year-old patient, who 
presented with a 3-year history of bilateral RP-CME. Previous treatment had been with topical 2% 
dorzolamide, oral acetazolamide, and ivR, which had demonstrated only minimal reduction of CME. He 
had a good structural response to bilateral doses of ivA. He subsequently received serial ivR with further 
reduction of CMT observed. VA remained stable throughout 21. 
 
Given the aforementioned lack of high quality evidence for the use of any of the therapeutic options for 
RP-CME, we have undertaken a phase II exploratory prospective study to assess the safety and efficacy 
of ivA in a well characterized cohort of patients with RP-CME in order to help provide evidence towards 
this unmet medical need.  
 
Patients and Methods 
The protocol of the study adhered to the provisions of the Declaration of Helsinki and was approved by 
the local ethics committee. Informed consent was obtained from all patients. The study was undertaken 
at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom. The study was assigned the 
number 2015-003723-65 by EudraCT and was registered with ClinicalTrials.gov and assigned the 
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following unique identifier: NCT02661711. A consort flow diagram illustrates the flow of patients 
through the study (see supplementary figure 1).   
 
Patient eligibility 
The following criteria were used to guide patient enrollment: 
 
(A) Inclusion criteria: (1) patients of either gender aged ≥16 years; (2) CME in association with RP; (3) 
Unilateral or Bilateral CME (the worse eye only treated – defined as the eye with a greater central 
macular thickness (CMT) on OCT); (4) No previous oral treatment for CME for last 3 months; (5) No 
previous peribulbar or intravitreal treatment for CME in the study eye for last 3 months; (6) No previous 
topical treatment for CME in the study eye for last 1 month; (7) Central visual impairment that in the 
view of the Principal Investigator (PI) was due to CME; (8) BCVA better than 20/400.  
 
(B) Exclusion criteria (ocular criteria were applied to the study eye only): (1) Insufficient patient 
cooperation or media clarity to allow adequate fundus imaging; (2) Evidence of visually significant 
vitreo-retinal traction or epiretinal membrane (ERM) on OCT that in the PI’s opinion was likely to 
significantly limit the efficacy of intravitreal therapy; (3) History of cataract surgery within prior 3 
months or cataract surgery anticipated within 6 months of starting the study; (4) Any anti-VEGF 
treatment to study eye within 3 months; (5) History of YAG capsulotomy performed within 3 months; (6) 
Uncontrolled IOP > = 24 mmHg for ocular hypertension (on topical IOP lowering medications); (7) 
Advanced glaucoma (in the opinion of a glaucoma specialist); (8) Patients with active or suspected ocular 
or periocular infections; (9) Patients with active severe intraocular inflammation; (10) Patients with a 
new, untreated retinal tear or detachment; (11) Patients with a stage 3 or 4 macular hole; (12) 
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Thromboembolic event (MI/CVA/Unstable Angina) within 6 months; (13) Pregnancy or family planned 
within 15 months; (14) Breast feeding; (15) Known allergy or hypersensitivity to anti-VEGF products. 
 
 
Identification of suitable patients for the trial 
An electronic search was performed to identify all patients seen at Moorfields Eye Hospital NHS 
Foundation Trust, London, UK, between 1st December 2012 and 30th November 2015 with the phrases 
‘retinitis pigmentosa’ and ‘cystoid macular edema’ appearing in their electronic patient records. This 
initial search identified 295 patients; however, after review of each electronic patient record and latest 
SDOCT imaging, 165 patients were excluded from the study for the following reasons: no/minimal CME 
(111), visually significant ERM (17), VA too poor (24), VA too good (4), macular hole (2), visually 
significant cataract (2), under 16 years of age (4) and pregnant (1).  
 
A total of 130 patients were therefore found to be potentially suitable participants. Patients were then 
contacted by the dedicated trial fellow (SAS) either in person at their routine medical retina clinic, by 
telephone or letter. The aims, methods, anticipated benefits and potential hazards of the study were 
explained to each patient and a patient information sheet provided. Patients were given a minimum of 
24 hours to consider whether they wished to attend a baseline evaluation/screening visit. Out of these 
patients: 18 could not be contacted/did not reply, 1 was found to be deceased, 32 wished to be 
considered for the study, and 79 declined to participate for reasons including: did not wish to have 
injections into their eye (n = 42), happy with their current treatment and/or vision (n = 22), or unable to 
commit to the study visits (due to distance from the hospital or concerns about the impact it would have 
on their job) (n = 15). 
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Out of 32 patients who wished to be considered for the study, 15 patients were being treated with a 
topical CAI (dorzolamide or brinzolamide) and 5 patients were being treated with an oral CAI 
(acetazolamide) at time of contact. Patients were requested to stop using CAIs for at least 1 month in 
the study eye if being used topically, or at least 3 months if orally, before their screening appointment 
was made. Ten of these 32 patients were not using any treatment at time of contact and were able to 
attend a screening visit at their earliest convenience, but 2 patients no longer had CME at screening so 
had been excluded from the trial. 
 
If patients were deemed suitable to participate in the trial at the end of their screening visit, written 
informed consent was obtained.  
 
Recruitment period 
All 30 patients were recruited over a 6 month period. 
 
Baseline evaluation/screening visit 
The baseline evaluation/screening visit took place within 28 days of the patient being contacted unless 
they were on CAIs. Patients on oral/topical CAI treatment were allowed sufficient time off treatment in 
order to fulfil the inclusion criteria for the trial, before being contacted again for re-confirmation that 
they still wished to attend a baseline evaluation/screening visit. At the screening appointment, each 
patient had the opportunity to ask any further questions before informed consent was taken. 
 
Baseline tests of visual function included the following:  
Subjective refraction and best-corrected visual acuity (BCVA) 
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All patients were subjectively refracted at baseline to obtain their spectacle correction. BCVA was 
tested monocularly at 4 metres (m) using 2 ETDRS charts (one chart for each eye) that were retro-
illuminated using a light box containing 2 Cool Daylight 20 watt fluorescent tubes. If a patient was 
unable to read 20 letters or more at this distance, the test would be repeated at 1m. In this case, only 
the first 6 rows would be attempted. If the patient was wearing a trial frame, +0.75 dioptres sphere (DS) 
was added to the prescription to correct for the closer test distance. The VA score was the number of 
letters read correctly at 4m, plus the number of letters read correctly at 1m. If the patient did not 
require testing at 1m, i.e. they read 20 or more letters at 4m, then the score was the number of letters 
read correctly at 4m, plus 30. 
 
Spectral Domain Optical Coherence Tomography (SDOCT) 
The Heidelberg Spectralis SDOCT (Heidelberg Engineering, Heidelberg, Germany) was used to obtain 
macular volume scans in order to measure CMT. The macular volume scan protocol had the following 
settings: 20°x20°, 49 Sections, High Speed, 29 frames automatic real time (ART).  
 
Ishihara colour vision testing  
The Ishihara version used contained 17 plates held at 75 cm from the patient. A light box was used to 
achieve standardised lighting and patients were adequately corrected for reading vision using plus 
lenses if required performing the test monocularly.  
 
Contrast sensitivity 
Contrast sensitivity was performed monocularly using the Pelli-Robson chart (Clement Clarke Inc., 
Columbus, OH). The patient was seated at a distance of 1m. As a standard, +0.75DS was added to each 
patient’s refraction when performing the test. The luminance of the chart was between 80 - 120 candela 
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per square metre (cd/m2). The patient was asked to name each letter on the chart, starting with the 
high-contrast letters on the upper left-hand corner and reading horizontally across the entire line. The 
test was completed when the patient failed to correctly identify two or more letters in a triplet. 
 
Retinal sensitivity 
Mesopic microperimetry using the MP-1 microperimeter (Nidek Instruments, Inc, Padua, Italy) was 
carried out twice on each eye at baseline. Spherical error was accounted for in all patients who were 
then dark-adapted for 10 minutes before performing the test.   The microperimetry protocol included: 
Cross 2  degrees, Goldmann  Ill  Stimulus  200ms, 4-2 strategy and 30 seconds of tracked fixation. The 
results were generated using a local defect map including -9:1 setting in order to provide mean sensitivity 
and mean defect together with bivariate contour ellipse area (BCEA) value (numeric and fixation). 
  
Fundus autofluorescence (FAF) 
FAF images were acquired using the Heidelberg Spectralis. For each eye, a near-infrared reflectance 
image and short-wavelength autofluorescence image of standard field 2 (centred on the fovea) were 
acquired. Both 30 and 55 degree field of view were acquired using high resolution at 50 frames (ART).  
 
If a patient was deemed eligible to enter the trial, intra-ocular pressure (IOP) was measured using 
Goldmann tonometry and their 1st ivA given on the same day (‘Visit 1’). The IOP was re-checked 30 
minutes after ivA, and if the pressure was increased (≥ 30 mmHg) appropriate treatment was 
commenced. 
 
Randomisation 
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The study consisted of only 1-arm and all trial patients received the active drug, aflibercept via 
intravitreal injection. 
 
Follow-up visits 
At each follow-up visit, patients had their vital signs checked and a medication review performed. Tests 
of visual function carried out at every visit included: BCVA, colour vision, contrast sensitivity and SDOCT. 
In addition, microperimetry and FAF were also undertaken at the 6- and 12- month (exit) visits. 
IvA was administered every four weeks for the first three months (loading phase), followed by a treat 
and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow-up 
occurred when there was no reduction in macular edema compared with the previous visit.  
Please refer to supplementary table 1 for a schedule of assessments. 
 
Intravitreal Procedure 
Aflibercept (Eylea; Regeneron, Tarrytown, New York, USA and Bayer Healthcare, Leverkusen, Germany) 
was supplied by Bayer LTD in vials containing 100 microlitres of 40mg/ml solution for injection, 
equivalent to 4mg aflibercept and stored by Moorfields Pharmaceuticals (London, UK). Each vial enabled 
a usable amount to deliver a single dose of 50 microlitres containing 2 mg aflibercept. In a designated 
intravitreal treatment room, under sterile conditions, using topical anesthesia and povidone-iodine 5% 
into the conjunctival sac and onto the lid margins, and following application of a drape and insertion of a 
lid speculum, injections were undertaken with a 30-gauge needle through the infratemporal quadrant, 
with a drop of preservative-free (PF) chloramphenicol placed in the fornix at the end of the procedure. 
Patency of the central retinal artery was determined by visual acuity (VA) of hand movements or better. 
After the injection, topical chloramphenicol was self-instilled 4 times per day for 5 days by the patients. 
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Primary outcome measures 
There were two primary outcome measures : (i) To report the safety of aflibercept in RP-CME 
throughout the study (17 months in total); via the documentation of adverse events (AEs) deemed 
related to the trial drug; (ii) To report the efficacy of aflibercept in RP-CME via mean central macular 
thickness (CMT) on Spectral domain OCT (SDOCT) at 12 months after baseline.  
 
Secondary outcome measures 
The secondary outcome measures relating to efficacy were: (i) The mean CMT on SDOCT at 6 months 
after baseline; (ii) The mean change in CMT on SDOCT from baseline to 6 months after baseline and 
baseline to 12 months after baseline; (iii) The mean Best Corrected Visual Acuity (BCVA) using the ETDRS 
visual acuity chart at a starting distance of 4m at 6 and 12 months after baseline; (iv) The mean change 
in ETDRS BCVA from baseline to 6 months and baseline to 12 months; (v) The mean macular volume on 
SDOCT at 6 and 12 months; (vi) The mean change in macular volume on SDOCT from baseline to 6 
months and baseline to 12 months; (vii) Report all AEs and serious adverse events (SAEs) throughout the 
study (17 months in total); (viii) The mean retinal sensitivity using microperimetry at 6 and 12 months; 
(ix) The mean change in retinal sensitivity using microperimetry from baseline to 6 months and baseline 
to 12 months; (x) The mean number of intravitreal injections administered throughout the study. 
 
Sample size 
No previous studies have been published for which the sample size could be powered. A sample size of 
30 patients was therefore justified on the basis that 30 subjects will provide an estimate of the mean 
change in CMT from baseline to 12 months with reasonable precision as advocated by Browne (1995)23 
and Hertzog (2008)24.  
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Masking 
This was an open-label study and therefore no masking took place. 
 
Data management 
The completed paper case report forms (CRFs) were checked for completion by the research nurse / 
research manager and data officer before data entry.  All trial data were double entered by two 
independent data officers using the database created by the R&D IT team. The first and second data 
entries were compared for completion and consistency. Discrepancies were checked against the original 
CRF for entry errors, which were subsequently corrected. Sense checks, logic checks and range checks 
were also performed. Data queries were corrected and data were cleaned. The database was then 
locked and data transferred for data to be analysed by trial statisticians using STATA statistical software. 
The data management process followed Moorfields Eye Hospital standard operating procedures (SOPs) 
for data management. 
 
Statistical analysis  
The primary analysis was an available case analysis but baseline characteristics of those who were lost to 
follow up were compared with those who were not. If the findings from this study were favourable, 
these data would be used to plan a definitive future randomised controlled trial. 
Descriptive statistics have been used to report the findings of this study due to its modest sample size 
and single arm design. 
‘Responders’ would be considered as participants demonstrating a reduction of CMT by 11% or more 
between baseline and 12 months, thus allowing comparison with previous studies that have used the 
same definition 15,25-29. 
All statistical analyses were conducted using Stata Statistical Software version 15.0.   
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Results 
Results are summarized in tables 1 to 3 and supplementary tables 2 to 9. 
Table 1: Primary outcome measures 
 Aflibercept 
 (n=29) 
95% CI 
Central Macular thickness on SDOCT (µm), 
Mean (SD) at Baseline 
458.7 (84.6)  
Central Macular thickness on SDOCT (µm), 
Mean (SD) at 12 months 
 
413.4 (98.2) 
 
376.0 to 450.7 
SDOCT = Spectral domain optical coherence tomography; µm = microns; SD = standard deviation  
 
 
Table 2: Secondary outcome measures 
 Aflibercept 
 (n =29) 
95% CI 
Central Macular thickness on SDOCT (µm), Mean (SD) at 6 
months  
 
414.8 (96.4) 
 
378.1 – 451.4 
Change in Central Macular thickness on SDOCT (µm) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-47.6 (86.6) 
-46.2 (108.7) 
 
-80.5 to -14.6 
-87.6 to -4.9 
ETDRS BCVA (letters), Mean (SD) at 6 months  66.9 (10.6) 62.8 to 70.9 
ETDRS BCVA (letters), Mean (SD) at 12 months  68.0 (11.1) 63.8 to 72.3 
Change in ETDRS BCVA (letters) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
4.3 (6.9) 
3.1 (6.6) 
 
1.7 to 6.9 
0.6 to 5.6 
Macular Volume on SDOCT (mm3), Mean (SD) at 6 months  7.9 (0.6) 7.7 to 8.2 
Macular Volume on SDOCT (mm3), Mean (SD) at 12 months  8.0 (0.7) 7.7 to 8.2 
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Change in Macular Volume on SDOCT (mm3) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-0.3 (0.7) 
-0.3 (0.8) 
 
-0.6 to -0.1 
-0.7 to 0.0 
Retinal Sensitivity (dB), Mean (SD) at 6 months  
Missing, n(%) 
4.92 (3.49) 
1 (3) 
3.56 to 6.27 
Retinal Sensitivity (dB), Mean (SD) at 12 months  
Missing, n(%) 
4.93 (3.48) 
2 (6) 
3.55 to 6.31 
Change in Retinal Sensitivity (dB) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-1.09 (2.10) 
-1.23 (2.24) 
 
-1.90 to -0.27 
-2.10 to -0.37 
Total number of injections received over the study period (12 
months), Median (IQR) 
 
7 (6 to 9) 
 
- 
CME = cystoid macular edema; µm = microns; ETDRS = early treatment diabetic retinopathy study; BCVA 
= best corrected visual acuity; SD = standard deviation; IQR = Interquartile range; cd/m2 = candela per 
square meter; IOP = intraocular pressure; mmHg = millimetre of mercury; SDOCT = Spectral domain optical 
coherence tomography; mm3 = millimetres cubed; dB = decibels 
 
 
Table 3: Descriptive statistics for responders 
     Aflibercept      (n=11) 
Central Macular thickness on SDOCT (µm), Mean (SD) at 12 months 350.3 (93.3) 
Central Macular thickness on SDOCT (µm), Mean (SD) at 6 months  360.7 (85.2) 
Change in Central Macular thickness on SDOCT (µm) from  
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-139.5 (65.8) 
-129.1 (125.1) 
ETDRS BCVA (letters), Mean (SD) at 6 months  67.5 (10.1) 
ETDRS BCVA (letters), Mean (SD) at 12 months  68.4 (11.8) 
Change in ETDRS BCVA (letters) from 
- Baseline to 12 months, Mean (SD) 
 
4.7 (9.5) 
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- Baseline to 6 months, Mean (SD) 3.8 (6.8) 
Macular Volume on SDOCT (mm3), Mean (SD) at 6 months  
 
8.5 (0.6) 
Macular Volume on SDOCT (mm3), Mean (SD) at 12 months  
 
8.5 (0.8) 
Change in Macular Volume on SDOCT (mm3) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-0.6 (0.6) 
-0.6 (0.6) 
Retinal Sensitivity (dB), Mean (SD) at 6 months  
 
4.93 (4.06) 
Retinal Sensitivity (dB), Mean (SD) at 12 months  
 
4.48 (3.83) 
Change in Retinal Sensitivity (dB) from 
- Baseline to 12 months, Mean (SD) 
- Baseline to 6 months, Mean (SD) 
 
-0.97 (1.92) 
-0.92 (2.03) 
Total number of injections received over the study period (12 
months), Median (IQR) 
 
7 (6 to 10) 
CME = cystoid macular edema; µm = microns; ETDRS = early treatment diabetic retinopathy study; BCVA 
= best corrected visual acuity; SD = standard deviation; IQR = Interquartile range; cd/m2 = candela per 
square meter; IOP = intraocular pressure; mmHg = millimetre of mercury; SDOCT = Spectral domain optical 
coherence tomography; mm3 = millimetres cubed; dB = decibels 
 
 
Baseline characteristics and injection frequency 
The baseline characteristics for all participants are summarized in supplementary tables 2 to 4. Thirty 
eyes of 30 patients were enrolled, with the first patient recruited in March 2016 and the final patient 
had their 52-week visit in August 2017. Two patients were screened who did not satisfy the criteria for 
enrolment (study ID 29 and 31); the reason being that they no longer had CME. The mean age of the 
patients was 43.3 years (SD 11.5 years, range 20 to 61 years), consisting of 17 male (56.7%) and 13 
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female (43.3%) patients. The study eye was the left eye in 16 (53.3%) patients and the right eye in 14 
(47.7%). The median duration of CME in the study eye was 252 weeks and the interquartile range (IQR) 
was 156 to 296 weeks. 
 
All patients enrolled in the study received the active drug, aflibercept. The median number of injections 
given across all patients in the study was 7 (IQR 6 to 9); with the minimum number of injections given 
being 4, and the maximum number of injections given being 11.  
 
Likely disease-causing sequence variants were identified in 16 of 30 (53.3%) study participants (see 
supplementary table 2), which included: (i) AD inheritance: neural retina leucine zipper (NRL) gene (1 
patient), rhodopsin (RHO) gene (2 patients), pre-mRNA processing factor 31 (PRPF31) gene (3 patients), 
pre-mRNA processing factor-8 (PRPF8) gene (1 patient), small nuclear ribonucleoprotein U5 subunit 200 
(SNRNP200) gene (1 patient); (ii) AR inheritance: usherin 2A (USH2A) gene (3 patients), tubby like 
protein 1 (TULP1) gene (1 patient), retinitis pigmentosa-1 (RP1) gene (1 patient), retinol dehydrogenase-
12 (RDH12) gene (1 patient), intraflagellar transport-140 (IFT140) gene (1 patient); and (iii) X-linked 
inheritance: retinitis pigmentosa GTPase regulator (RPGR) gene (1 patient). 
 
The other 14 patients have undergone genetic screening (including whole genome sequencing) and 
remain unsolved to date.  
 
Mean baseline ETDRS BCVA was 64 letters (SD 11.5 letters) with a mean CMT of 458.7 microns (SD 84.6 
microns) in the study eye for the cohort overall. Twenty-four (80%) patients were phakic, compared with 
6 (20%) patients who were pseudophakic in their study eye.  
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Nine of 29 (31.0%) patients were graded as having either questionable or definite presence of ERM 
within 3mm of the fovea. No patients were found to have vitreo-macular traction (VMT) on their 
baseline OCT scan. One of 29 (3.4%) patients was found to have vitreo-macular adhesion on their 
baseline OCT scan. Nine of 29 (31.0%) patients were graded as having either questionable or definite 
disruption of the ellipsoid zone within 1mm of the fovea on their baseline OCT scan. 
 
One participant did not complete 12 months of follow-up due to illness and withdrew from the study.  
Since a single patient only withdrew, analysis was conducted using available case data. The baseline 
characteristics for this participant who withdrew from the study were not different to patients who 
continued in the study. Twenty-nine out of 30 (96.7%) patients therefore completed 12 months of 
follow-up for the study. 
 
A post-hoc exploratory analysis of responders-only was also undertaken. Baseline characteristics for 
responders are summarized in supplementary tables 5 and 6. Sub-group analysis of responders 
demonstrated similar baseline characteristics to the group taken as a whole, with mean baseline ETDRS 
BCVA of 63.6 letters (SD 11.3 letters), mean CMT of 489.8 microns (SD 105.9 microns), and median 
duration of CME was 264 weeks (IQR 228 to 416) . The median number of injections for this group was 7 
(IQR 6 to 10); where the minimum number of injections given was 5, and the maximum number of 
injections was 11. 
 
Outcome measures 
Efficacy: analysis of all study participants  
The primary and secondary efficacy outcomes for all patients (responders and non-responders) within 
the study are summarised in tables 1 and 2. Mean CMT at 12 months was 413.4µm (SD 98.2µm, 95% CI 
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376.0 to 450.7µm), corresponding to a reduction in CMT of 47.6µm (SD 86.6µm, 95% CI -80.5 to -
14.6µm) or 9.61 % (17.56 %) between baseline and 12 months. Mean macular volume at 12 months was 
8.0mm3 (SD 0.7, 95% CI 7.7 to 8.2), corresponding to a change in macular volume of -0.3mm3 (SD 0.7, 
95% CI -0.6 to -0.1) between baseline and 12 months. Mean CMT at 6 months was similar at 414.8µm 
(SD 96.4µm, 95% CI 378.1 to 451.4µm), corresponding to a reduction in CMT of 46.2µm (SD 108.7µm, 
95% CI -87.6 to -4.9µm) or 8.13 % (23.3 %) (see supplementary figure 2) between baseline and 6 
months. Mean macular volume at 6 months was 7.9mm3 (SD 0.6, 95% CI 7.7 to 8.2), corresponding to a 
change in macular volume of -0.3mm3 (SD 0.8, 95% CI -0.7 to 0.0) between baseline and 6 months. 
 
Mean ETDRS BCVA was 66.9 letters (SD 10.6, 95% CI 62.8 to 70.9) at 6 months and 68.0 letters (SD 11.1, 
95% CI 63.8 to 72.3) at 12 months. This equated to a gain of 3.1 letters (SD 6.6, 95% CI 0.6 to 5.6) and 4.3 
letters (SD 6.9, 95% CI 1.7 to 6.9) respectively at 6 and 12 months (see supplementary figure 3). No 
patients lost ≥30 letters.  
 
Mean retinal sensitivity at 6 months was 4.92 dB (SD 3.49, 95% CI 3.56 to 6.27), corresponding to a 
change in retinal sensitivity of -1.23dB (SD 2.24, 95% CI -2.1 to -0.37).  Data were missing for 1 (3%) 
patient. Mean retinal sensitivity at 12 months was 4.93 dB (SD 3.48, 95% CI 3.55 to 6.31), corresponding 
to a change in retinal sensitivity of -1.09dB (SD 2.10, 95% CI -1.9 to -0.27). Data were missing for 2 (6%) 
patients. 
 
Efficacy: sub-group analysis of responders only 
The primary and secondary efficacy outcomes using descriptive statistics for sub-group analysis of 
responders within the study are provided in table 3.  
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Eleven out of 29 (37.9%) patients were classified as responders having demonstrated a reduction in CMT 
of 11% or more at 12 months compared to baseline. These same patients were also classed as 
responders at 6 months when applying the same criteria. Genetic mutations were identified and 
confirmed in 5 of 11 (45.5%) responders, which included: RPGR (1 patient), PRPF31 (1 patient), USH2A 
(c.11700C>A, p.Tyr3900Ter; c.4618G>A, p.Asp1540Asn) (1 patient), RHO (1 patient) and RDH12 (1 
patient). The other 6 patients are genetically unsolved to date. 
 
Following sub-analysis of these 11 patients, mean CMT at 12 months was 350.3µm (SD 93.3µm), 
corresponding to a change in CMT of -139.5µm (SD 65.8µm) or 28.1% (12.9 %) between baseline and 12 
months. Mean macular volume at 12 months was 8.5mm3 (SD 0.8), corresponding to a change in 
macular volume of -0.6mm3 (SD 0.6) between baseline and 12 months. Mean CMT at 6 months was 
similar at 360.7µm (SD 85.2µm), corresponding to a change in CMT of -129.1µm (SD 125.1µm) or 22.9% 
(29.7 %) (See figure 1) between baseline and 6 months. Mean macular volume at 6 months was 8.5mm3 
(SD 0.6) corresponding to a change in macular volume of -0.6mm3 (SD 0.6) between baseline and 6 
months. Figure 2 demonstrates SDOCT images of 2 responders taken at baseline and at 1 month post-
baseline (after having received only a single ivA). 
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Figure 1: A graph demonstrating mean change in CMT from baseline to 6 months after baseline, and 
baseline to 12 months after baseline in responders-only (n=11).  
 
 
 
Figure 2: Two representative examples of responders: 1a and 2a show SDOCT baseline images of two 
study participants (study IDs: 04 and 14); 1b and 2b are SDOCT images taken at 1 month post 1st 
aflibercept injection in the same two participants, respectively 
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Mean ETDRS BCVA at 6 months was 67.5 letters (SD 10.1) corresponding to a gain of 3.8 letters (SD 6.8). 
Mean ETDRS BCVA at 12 months was 68.4 letters (SD 11.8) corresponding to a gain of 4.7 letters (SD 9.5) 
(Figure 3). It should be noted that 3 of 11 (27.3%) responders were graded as having disruption of the 
ellipsoid zone within 1mm of the fovea on their baseline OCT scan. No improvement of vision was found 
in all 3 of these patients. Four of 11 (36.4%) responders were graded as having questionable presence of 
ERM within 3mm of the fovea. 
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Figure 3: A graph demonstrating mean change in CMT from baseline to 6 months after baseline, and 
baseline to 12 months after baseline in responders-only (n=11).  
 
 
Mean retinal sensitivity at 6 months was 4.93dB (SD 4.06), corresponding to a change in retinal 
sensitivity of -0.92dB (SD 2.03) between baseline and 6 months. Mean retinal sensitivity at 12 months 
was 4.48dB (SD 3.83), corresponding to a change in retinal sensitivity of -0.97dB (SD 1.92) between 
baseline and 12 months.  
 
The median number of injections given in responders was 7 (IQR 6 to 10). 
Additional data of non-responders 
Eighteen out of 29 (62.1%) patients were classified as non-responders. Genetic mutations were 
identified and confirmed in 10 of 18 (55.6%) non-responders, which included: NRL (1 patient), RHO (1 
patient), PRPF31 (1 patient), PRPF8 (1 patient), SNRNP200 (1 patient), USH2A (2 patients), TULP1 (1 
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patient), RP1 (1 patient) and IFT140 (1 patient). Six of 18 (33.3%) non-responders were graded as having 
disruption of the ellipsoid zone within 1mm of the fovea on their baseline OCT scan. 
 
Safety  
Ocular and non-ocular AEs and SAEs are summarized in supplementary tables 7 to 9.  
 
Ocular AEs:  
Ocular AEs were the expected standard range of AEs seen with intravitreal injections (see 
supplementary tables 7 to 9). There were no cases of endophthalmitis or retinal detachment.  
 
Ocular SAE: 
One participant reported sub-acute reduction of vision at week 32 despite being a ‘responder’, with 
testing demonstrating a reduction in vision of 14 ETDRS letters. Injections were immediately 
discontinued. Further assessments were undertaken including SDOCT, FAF, microperimetry and OCT-
angiography (OCT-A). There was no demonstrable change in outer retinal lamination compared to 
baseline, with also no change in microperimetry or FAF compared to baseline, and no abnormality 
detected on OCT-A. The non-study eye had a baseline vision of 30 ETDRS letters due to advanced 
photoreceptor loss and it was therefore concluded that the reduction in vision was most likely 
secondary to progression of underlying RP rather than as a consequence of ivA. The patient remained in 
the study and attended the 6 and 12 month follow-up appointments. 
 
Non-ocular/systemic AEs: 
All non-ocular/systemic AEs were reported during the study whether or not they were considered to be 
secondary to aflibercept. Non-ocular/systemic AEs included: back pain, headache, lethargy, tinnitus, 
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viral cold, conversion of prostate biopsy from benign to low-grade neoplasia, feeling low/low mood, 
labyrinthitis, urine tract infection, relapse of mental illness, heartburn, perforated ear drum, ear 
infection, viral gastric illness, anxiety and mosquito bite. 
 
Whilst the participant who developed labyrinthitis during the study was reassured that it was unlikely to 
be secondary to aflibercept, they decided that they would prefer to discontinue receiving injections. This 
patient remained in the study and attended the 6 and 12 month follow-up appointments. 
 
Discussion 
This is the first prospective study to obtain safety and efficacy data on the use of serial intravitreal 
injections with aflibercept for the treatment of RP-CME, employing a monthly loading phase of 3 
injections followed by a treat-and-extend protocol for a total of 12 months of follow-up. There were no 
significant safety concerns and serial injections were well tolerated. Eleven out of 29 (37.9%) patients 
were classified as responders at both 6 and 12 months, having demonstrated a reduction of at least 11% 
CMT on SDOCT compared to baseline. These patients experienced a mean (SD) percentage change in 
CMT relative to baseline of -22.9% (29.7 %) and -28.1% (12.9 %) at 6 and 12 months respectively. 
Responders gained 3.8 (SD 6.8) and 4.7 (SD 9.5) ETDRS letters respectively at 6 and 12 months. 
Responders demonstrated a greater change of macular volume over the study (-0.6mm3 at 6 and 12 
months) compared to non-responders (-0.3mm3 at 6 and 12 months). When the cohort was analysed as 
a whole, the mean (SD) percentage change in CMT relative to baseline was -8.1% (23.3%) and -9.6% 
(17.6%) at 6 and 12 months respectively. An intriguing observation, unlike other disorders where anti-
VEGF agents have been employed, is that all responders (n=11) achieved a notable reduction in CME 
after their first injection ('early-responder'). There were no 'late-responders'. This is clinically very 
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valuable as for the majority of patients it may be possible to decide at a very early stage whether 
injections should be pursued. 
 
Responders in this study were identified across all categories of inheritance pattern (AD, AR and XL). 
There was no association between response to anti-VEGF treatment and mode of inheritance. Whilst 
just over half of the patients in this study had a confirmed molecular diagnosis, no genotype was 
associated with response to treatment; including 1 USH2A patient responded, whilst 2 other USH2A 
patients did not, and 1 PRPF31 patient responded - whilst 2 others did not. This study included only 1 
patient with XL inheritance who was deemed a responder and we therefore cannot draw any 
comparison with other patients with XL-RP. More advanced disease, defined as disruption of the 
ellipsoid zone within 1mm of the fovea (seen in 27.3% of responders and 33.3% of non-responders) did 
not appear to affect likelihood of response to anti-VEGF. 
 
The release of toxic products (including VEGF) from degenerating retina/RPE in patients with RP 
contributes to weakening of the BRB and RP-CME formation 7. Anti-VEGF is thought to act by reversing 
proliferation and cell migration stimulated by VEGF and the delocalization of tight junction proteins 
induced by VEGF 165 30. Intriguingly, Salom et al. observed lower aqueous levels of VEGF in eyes of 
patients with RP versus controls 31. It would therefore be interesting to measure levels of VEGF in the 
vitreous and review whether there are significant differences between patients with RP versus controls, 
as well as patients with RP versus those with RP-CME. This being an invasive procedure, however, would 
likely prove challenging to gain ethical approval and is why we did not consider undertaking in this 
study.  
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Strengths of our study included excellent patient attendance throughout its duration, with a 96.7% 
participant retention rate at 12-months. The study drug was well tolerated and no cases of 
endophthalmitis occurred. The study design including an initial loading phase followed by a treat-and-
extend regime, which allowed for the observation of both early and (potentially) late responders. We 
also had established likely disease-causing sequence variants in 16 of 30 (53.3%) study participants. 
 
One of the limitations to our study was being unable to include treatment-naive patients with shorter 
duration of CME. Many patients were deemed eligible for the study yet declined intravitreal injections 
without first trialling topical and/or oral treatment. All patients in the study had therefore used topical 
CAI medication previously; 15 of whom were using topical CAI treatment up until 1 month prior to their 
screening appointment. Five of these patients were deemed responders. Five patients in the study were 
using oral CAI treatment up until 3 months prior to their screening appointment; 1 patient withdrew 
from the study, 2 patients were deemed responders, and 2 patients did not respond. No obvious trend 
was demonstrated to suggest whether recent use of topical or oral CAIs influences response to anti-
VEGF therapy.  
 
Long-standing CME duration was observed in many patients within our cohort, with the median 
duration being 252 weeks (IQR, 156 to 296 weeks). An interesting observation identified from this study 
was that duration of CME did not appear to affect anatomical response to anti-VEGF; median CME 
duration in responders was 264 weeks (IQR 228, 416), compared to the group overall (252 weeks (IQR 
156, 296). Indeed, the patient with the longest standing CME duration of the cohort (20 years) had 
complete resolution of CME after a single ivA.  
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As long as patients achieved a BCVA better than 20/400 at baseline, they were considered eligible for 
the study. Our study therefore included patients with fairly advanced underlying disease as 
demonstrated by photoreceptor loss and outer retinal thinning - features that have been shown to 
hinder VA improvement despite reduction of CMT 32. It was therefore unsurprising to find that all 3 of 11 
(27.3%) responders graded as having disruption of the ellipsoid zone within 1mm of the fovea on their 
baseline OCT scan demonstrated no improvement of vision. Greater improvement of VA may be 
demonstrated in patients with a relatively more intact photoreceptor layer at baseline.  
 
It would be valuable to repeat this study in a larger cohort of patients, ideally naive to other treatment 
modalities, with shorter history of CME duration and relatively intact photoreceptor layers at baseline. 
Only including patients with a molecularly confirmed genetic diagnosis would help to determine if 
genotype has a role in predicting response to anti-VEGF treatment. Additional suggestions to consider 
when designing a future study would include: to perform fundus fluorescein angiogram (FFA) at baseline 
to see whether active leakage is present and whether FFA is predictive of which patients will/will not 
respond to aflibercept, to take baseline samples of vitreous in order to assess levels of VEGF in this 
cohort of patients, to include a control group (possibly using placebo), to randomise patients if there is 
an option of a control/placebo group, to blind patients and/or clinicians if there is an option of a 
control/placebo group, and to include OCT-A as an additional imaging modality. 
 
This phase II exploratory study demonstrates that ivA can be effective at reducing CMT in patients with 
RP-CME, suggesting that aflibercept should be considered part of the armamentarium when selecting 
treatments for RP-CME. The factors predicting who is likely to respond, however, remain to be clarified. 
Our data supports more studies to further investigate the role of VEGF blockade in RP-CME.  
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Full title:  
A retrospective cohort study exploring whether an association exists between spatial distribution of 
cystoid spaces in cystoid macular oedema secondary to Retinitis Pigmentosa and response to treatment 
with carbonic anhydrase inhibitors. 
 
Abstract 
 
Background: Carbonic anhydrase inhibitors (CAIs) are frequently used as an initial step to treat Retinitis 
Pigmentosa-associated cystoid macular oedema (RP-CMO). Interestingly, it has been postulated that 
CAIs might reduce outer nuclear layer (ONL) fluid more effectively than inner nuclear layer (INL) fluid 
due to better access to retinal pigment epithelium basolateral membrane than neurosensory retina. This 
retrospective cohort study explores if an association between spatial distribution of cystoid spaces in 
RP-CMO and CAI response exists. 
 
Methods: Two independent graders reviewed pre- and post-treatment OCT images of 25 patients (43 
eyes) initiated on topical and/or oral CAI’s between January 2013 and December 2014. Documentation 
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included the presence/absence of: fluid (and layer(s) involved), external limiting membrane, epiretinal 
membrane (ERM), vitreomacular adhesion/traction, lamellar/full-thickness macular hole and central 
macular thickness (CMT)/volume. 
 
Results: INL fluid was found in all study eyes. All 13 ‘responders’ (at least 11% reduction of CMT after 
treatment) demonstrated pre-treatment ONL fluid. In 7 patients (4 responders and 3 non-responders) 
complete clearance of ONL fluid was achieved despite persistence of INL fluid. ERM presence was similar 
in responders and non-responders.  
 
Conclusion: In this study, INL fluid was found to be the most common spatial distribution of RP-CMO. 
However, patients who were classed as a ‘responder’ to CAI treatment, all demonstrated co-existing 
ONL fluid on their pre-treatment OCT scan. This may be explained by CAIs having better access to retinal 
pigment epithelium basolateral membrane than neurosensory retina. Our study also suggests a minimal 
impact on response to CAIs by epiretinal membrane.  
 
 
Introduction 
Inherited retinal disease (IRD) is the leading cause of blindness certification in the working age 
population (age 16-64 years) in England and Wales 1. Retinitis Pigmentosa (RP) is the most common 
group of IRD, causing progressive centripetal reduction of vision and associated with variants in over 80 
genes to date, accounting for approximately 50-60% of cases, with an autosomal recessive, autosomal 
dominant or X-linked mode of inheritance 2.  Secondary complications associated with RP include 
cataracts and RP-associated cystoid macular oedema (RP-CMO), which further contribute to reduction 
of visual acuity 3. RP-CMO has been reported to occur in 10 - 50% of patients 4-7. 
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Proposed mechanisms for RP-CMO include: 1) breakdown of the blood-retinal barrier (BRB), 2) failure 
(or dysfunction) of the pumping mechanism in the retinal pigment epithelium (RPE), 3) Müller cell 
oedema and dysfunction, 4) anti-retinal antibodies and 5) vitreous traction 8.  
 
Makiyama et al 9 used spectral domain optical coherence tomography (SD-OCT) to investigate the 
prevalence and spatial distribution of cystoid spaces (CS) in RP. Seventy-four of 275 patients (27%) 
demonstrated RP-CMO in at least one eye. Inner nuclear layer (INL) CS were observed in 99% of eyes 
with CMO. It is of note that Müller cell bodies reside in the INL, providing support for the 
aforementioned Müller cell oedema /dysfunction hypothesis. The outer nuclear layer (ONL)/outer 
plexiform layer was involved in 28% and ganglion cell layer involved in 7%. Interestingly, 79% of CS were 
located in areas of relatively well-preserved outer retina in keeping with the observation that CMO is 
seen more commonly in less advanced RP compared to late stage RP 9.    
 
Several case-reports and small-scale studies have been published regarding the safety and efficacy of 
carbonic anhydrase inhibitors (CAIs) in the treatment of RP-CMO, however, to-date there is currently no 
level 1 evidence to support this 8. In the largest retrospective study to date of CAIs involving 81 patients 
(157 eyes) with RP-CMO, objective improvement on OCT was observed in 53% of patients (40% of eyes) 
using topical dorzolamide versus 41% of patients (28% of eyes) using oral acetazolamide 10. CAIs are 
associated with a variety of potential side effects, including: fatigue, loss of appetite, limb paraesthesia, 
kidney stones, aplastic anaemia, hypokalaemia and cardiac arrhythmia 11. Their mechanism of action is 
through inhibition of the enzyme carbonic anhydrase IV (CA IV), resulting in acidification of the sub-
retinal space, increased chloride ion transport, and subsequent movement of water across the RPE into 
the choroid 12.  
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Acetazolamide cannot readily enter the neurosensory retina, yet has good access to the RPE basolateral 
membrane 13. It has been previously suggested that CMO with RPE pathology may respond better to 
CAIs than CMO with retinal capillary pathology13-15    
We have therefore undertaken a retrospective cohort study designed to determine if there is an 
association between the spatial distribution of CS in RP-CMO and response to CAIs.  
 
Materials and methods 
This retrospective cohort study identified all patients seen at Moorfields Eye Hospital NHS Foundation 
Trust, London, United Kingdom between January 2013 and December 2014 with ‘Retinitis Pigmentosa’ 
and ‘Cystoid Macular Oedema’ appearing in their electronic patient record. This time period was chosen 
as it was deemed a manageable period of time and number of scans to analyse. This initial search 
identified 103 patients, however, after review of each patient record, 78 patients were excluded from 
the study due to having ‘no’ cystoid macular oedema.  This study was IRB approved. 
 
Patients were subsequently included in the study if they met the following inclusion criteria (irrespective 
of age): (i) Confirmed diagnosis of RP-CMO; (ii) Unilateral or bilateral (if bilateral, each eye was 
evaluated individually) RP-CMO; (iii) Commenced on treatment with either a topical and/or oral CAI 
between January 2013 and December 2014; (iv) Pre-treatment SD-OCT scan acquired within 2 weeks of 
initiating treatment AND post-treatment SD-OCT scan acquired between 3 – 9 months after initiation of 
treatment. This time period was chosen because whilst patients in our clinics are typically reviewed at 3 
– 4 months after treatment initiation, their appointments may be postponed due to various factors.  
 
Patients were excluded if any of the following applied: (i) A diagnosis of CMO not considered to be 
related to RP; (ii) Other treatment for RP-CMO received within 3 months of initiation of CAI e.g. 
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intravitreal injection of triamcinolone/anti-VEGF agent; (iii) Pre-treatment SD-OCT scan not acquired 
within 2 weeks of initiating treatment and/or post-treatment OCT scan acquired greater than 9 months 
from initiation of treatment. 
 
After accounting for the inclusion and exclusion criteria, the total number of patients included in the 
study totalled 25. Of these, 18 had bilateral RP-CMO and 7 had unilateral RP-CMO; 43 eyes graded in 
total. 
 
SD-OCT (Spectralis, Heidelberg Engineering Ltd, Heidelberg, Germany) was undertaken in all recruited 
subjects. All patients across the cohort underwent scan acquisition according to the standard of care 
procedure used for out-patient clinics at Moorfields Eye Hospital, London. 
 
Image Grading 
Two independent graders experienced in SD-OCT interpretation graded pre-and post-treatment scans 
(SS, NH). Both graders were blinded to the treatment that each patient received and whether they were 
classed as a ‘responder’ or not.  
 
Each grader began by performing re-centration of the images if deemed necessary. The following 
variables were graded for their presence within 3600 microns of the foveal centre: sub-retinal fluid 
(SRF), inner nuclear layer (INL) fluid, outer nuclear layer (ONL) fluid, ganglion cell layer fluid, epi-retinal 
membrane (ERM), vitreo-macular adhesion (VMA), vitreo-macular traction (VMT), lamellar macular hole 
and full-thickness macular hole (FTMH). Each of these variables was graded as either: present (>90% 
certainty), questionably present (50-90% certainty), absent (<50% certainty) or ungradable. The 
presence of external limiting membrane (ELM) within 1200 microns of the foveal centre was also graded 
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and a comment made whether it was felt to be intact throughout or disrupted. A further ‘yes’ or ‘no’ 
response was required for the grading of whether there was felt to be intact ELM and/or fluid present 
(in any lamination) directly under the foveal centre. Pre- and post- treatment CMT and macular volume 
were also documented.  
 
If both graders agreed on a variable, the grading was complete. If the second grader (NH) disagreed with 
the first grader (SS), adjudication was performed by a consultant retinal specialist (MM). CMT values 
were considered to be in agreement if graded within 50 microns of each other. Macular volume values 
were considered to be in agreement if graded within 1.5mm3 of each other. The mean of the grader 
scores for CMT was used for analysis. Patients were considered to have responded to treatment if they 
achieved a CMT reduction of 11.0% or greater in keeping with previous studies 16,17. Although these 
studies were published over 8 years ago, no studies have since been published providing an alternative 
percentage reduction of CMT. We therefore chose this figure to allow comparison with other studies. 
 
Pre- and post-treatment visual acuity was also documented. 
 
Statistical Analysis 
Descriptive statistics have been used to describe the results of the CARAMEL study. For categorical 
variables, Kappa statistic was computed with respective 95% confidence interval (CI) for assessing inter-
rater agreement as Kappa is thought to be a more robust measure than simple percent agreement 
(Kappa takes into account the possibility of agreement occurring by chance). For continuous variables 
Bland-Altman agreement methods were used to quantify limits of agreement (LoA). Analysis was 
performed in STATA version 13 (STATA Corp., Texas, USA) and 95% CIs for Kappa were computed using 
the kapci package using 1000 bootstrap replicates. 
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Results 
Forty three eyes (22 right; 21 left); were included in the study consisting of 18 patients with bilateral RP-
CMO and 7 patients with unilateral RP-CMO. Seventeen of these patients were male and 8 were female. 
Median age was 48 and ranged between 17 and 79 years. Four out of 43 (9.3%) eyes were treated with 
oral acetazolamide 250mg twice a day versus 39 out of 43 (90.7%) of eyes treated with topical 
dorzolamide or brinzolamide three times a day. All 43 eyes in the study were graded as having INL fluid 
present on their pre-treatment OCT scan. Thirty three out of 43 eyes (76.7%) in the study demonstrated 
co-existing ONL fluid present on their pre-treatment OCT scan. Eleven out of 43 eyes (25.6%) in the 
study demonstrated co-existing RGC layer fluid present on their pre-treatment OCT scan. No patients 
demonstrated the presence of sub-retinal fluid. 
 
Estimates of agreement for all variables assessed by the two graders are presented in Table 1, Figure 1 
and Figure 2. No single variable was found to have poor agreement. No evidence of bias was found in 
terms of inter-rater agreement for pre-treatment CMT, mean difference -0.74. 95% CI (-3.12, 1.63). 
Inter-rater LoA were -16.18 to 14.69 for pre-treatment CMT and -18.36 to 21.76 for post-treatment 
CMT, which was considered by the chief investigator to be acceptable. Inter-rater agreement was -0.91 
to 1.14 for pre-macular volume and -1.22 to 1.24 for post-macular volume, which was considered by the 
chief investigator to be acceptable with no evidence of bias.   
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Figure 1 Bland-Altman graph for pre-CMT inter-rater agreement. CMT, central macular thickness. 
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Figure 2 Box plot illustrative of pre-CMT and post-CMT measurements made by the two graders. CMT, 
central macular thickness. 
 
 
Out of 43 eyes that were graded, 13 (30.2%) were classed as ‘responders’ having achieved a CMT 
reduction following treatment of at least 11%. All 13 responders demonstrated ONL fluid on their pre-
treatment OCT and the presence of fluid (in any layer) directly under the fovea. ERM was ‘definitely 
present’ in 8 out of 13 (61.5%) responders and ‘questionably present’ in 2 out of 13 (15.4%) responders. 
No responder demonstrated VMA, VMT or a FTMH on their pre-treatment OCT scan. ELM was 
considered to be present (intact or disrupted) within 1200 microns of the fovea and present directly 
under the fovea in all but 1 responder (92.3%). Best corrected visual acuity (BCVA) improved by at least 
10 ETDRS letters in 2 out of 13 (15.4%) responders. No responders demonstrated a loss of 10 or more 
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ETDRS letters. The remaining 11 out of 13 (84.6%) responders demonstrated no change in their BCVA 
following treatment. Interestingly, 4 out of 13 (30.8%) responders demonstrated total clearance of ONL 
fluid on their post-treatment OCT scan whilst INL cysts remained 
 
Out of 30 non-responders, 20 (66.7%) eyes had ONL fluid on their pre-treatment OCT compared to 10 
(33.3%) eyes without ONL fluid on their pre-treatment OCT. Sixteen out of 30 (53.3%) non-responder 
eyes had fluid (in any layer) directly under the fovea. Interestingly, there were three non-responders 
that demonstrated total clearance of ONL fluid on their post-treatment OCT scan whilst INL cysts 
remained (see Figure 3). VMA was definitely present in 7 out of 30 (23.3%) non-responders and 
questionably present in 2 out of 30 (6.7%) non-responders. ELM was considered to be present (intact or 
disrupted) within 1200 microns of the fovea in 26 out of 30 (86.7%) non-responder eyes, however, was 
only present directly under the fovea in 20 out of 30 (67.0%)  eyes.  BCVA improved by at least 10 ETDRS 
letters in 2 out of 30 (6.7%) non-responders. No non-responders demonstrated a loss of 10 or more 
ETDRS letters. The remaining 28 out of 30 (93.3%) non-responders demonstrated no change in their 
BCVA following treatment.  
 
Of note, all 4 patients (2 responders and 2 non-responders) who gained at least 10 ETDRS letters of 
BCVA, demonstrated ONL fluid on their pre-treatment OCT scans. 
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Figure 3 Two examples where ONL cysts have disappeared following treatment with CAIs, yet INL cysts 
remain. 1a and 2a: pretreatment SD-OCT scans of two separate patients who were classed as a ‘non-
responder’ (the white arrows demonstrate the presence of ONL fluid cysts). 1b and 2b: post-treatment 
SD-OCT scans with absence of ONL fluid cysts, yet INL cysts remain. CAIs, carbonic anhydrase inhibitors; 
INL, inner nuclear layer; ONL, outer nuclear layer; SD-OCT, spectral domain optical coherence 
tomography. 
 
 
Discussion 
In keeping with Makiyama et al 9, this study observed an overall higher frequency of INL compared to 
ONL fluid in patients with RP-CMO 9. It was interesting to note that 100% of responders demonstrated 
ONL fluid on their pre-treatment OCT; however, not every patient with pre-treatment ONL fluid 
responded. The presence of ERM graded as either ‘questionably present’ or ‘definitely present’ was 
similar in both groups (10 out of 13 (77.0%) responder eyes versus 24 out of 30 (80.0%) non-responder 
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eyes) and therefore does not appear to significantly affect response to treatment in our cohort. In 
contrast, the presence of VMA graded as either ‘questionably present’ or ‘definitely present’ was 
greater in the non-responder group (0 out of 13 (0.0%) responder eyes versus 9 out of 30 (30.0%) non-
responder eyes) and may therefore play a role in limiting response to treatment as being indicative of a 
tractional component that would not be expected to respond to CAIs.  
 
Overall, there were seven patients (including ‘responders’ and ‘non-responders’) that demonstrated 
total clearance of ONL fluid on their post-treatment OCT scan despite persistence of INL cysts. Our 
working hypothesis to explain this response includes the closer anatomical proximity of ONL fluid to the 
RPE where the action of CAI’s take place. A greater percentage of eyes in the responder group 
demonstrated at least 10 ETDRS letter improvement of BCVA compared to the non-responder group 
(15.4% of responders versus 6.7% of non-responders). It is not uncommon for anatomical improvement 
to occur without significant functional improvement18. Factors such as underlying photoreceptor loss 
and/or chronicity of RP-CMO may have an effect on visual outcome8,18. Whilst it was noted that patients 
with visual gain demonstrated ONL fluid on their pre-treatment OCT scans, a larger study with 
appropriate statistical analysis is required to be able to qualify whether this observation is significant.  
In 2015, Liew et al 10 conducted the largest retrospective study to date involving 81 patients (157 eyes) 
with RP-CMO. A positive response to treatment was only observed in 53% of patients (40% of eyes) 
using topical dorzolamide and 41% of patients (28% of eyes) using oral acetazolamide 10. CAIs are also 
associated with side-effects such as: tingling/numbness of the limbs, fatigue, renal stones, aplastic 
anaemia, hypokalaemia and cardiac arrhythmia 11. To this end, it would be valuable to identify factors 
that might help predict response of RP-CMO to CAI treatment in order to tailor patient care 
appropriately. Whilst this study might suggest the presence of ONL fluid on pre-treatment OCT scan to 
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be a positive prognostic factor in the treatment of RP-CMO, we are limited by design and numbers to be 
able to provide accurate statistical analysis and it must therefore be interpreted as observation only 
 
There is currently no level 1 evidence for the treatment of RP-CMO. The following recommendations are 
therefore based on expert opinion:  
 
3) Initial treatment using a topical CAI and review after 4-6 months.  
4) a) After 4-6 months, if there has been minimal (but not significant) reduction of CMT or 
improvement of BCVA, options may include switching to a different topical CAI agent or oral CAI.  
b) After 4-6 months, if there has been no reduction of CMT or improvement of BCVA or if the 
spatial distribution of cysts are located only in the INL, consideration should be given to trialling 
alternative therapeutic options, such as: topical non-steroidal anti-inflammatory agents or 
considering intravitreal anti-VEGF (although these latter agents are currently unlicensed for RP-
CMO).  
 
Although there was only a limited vision-improving effect observed in this study, we still believe in 
treating RP-CMO to achieve anatomical improvement to prevent irreversible structural damage as well 
as to potentially decelerate underlying photoreceptor loss8. 
 
Studies currently being undertaken for the treatment of RP-CMO include: The AMOUR study to assess 
the safety and efficacy of aflibercept for RP-CMO (clinicaltrials.gov identifier NCT02661711).  
 
Our study has several limitations including the small cohort size, with further studies with larger patient 
numbers required in order to support our findings of OCT phenotypes that may help predict treatment 
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response in patients with RP and thereby better inform patient counselling and management in this 
highly genetically heterogenous retinal dystrophy. 
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Abstract 
Hereditary retinal diseases are now the leading cause of blindness certification in the working age 
population (age 16-64 years) in England and Wales, of which Retinitis Pigmentosa (RP) is the most 
common disorder.  
 
RP may be complicated by cystoid macular oedema (CMO), causing a reduction of central vision. The 
underlying pathogenesis of RP-associated CMO (RP-CMO) remains uncertain, however, several 
mechanisms have been proposed, including:  1) Breakdown of the blood-retinal barrier, 2) Muller cell 
oedema and dysfunction, 3) Anti-retinal antibodies, and 4) Vitreous traction. There is limited data on 
efficacy of treatments for RP-CMO. Treatments attempted to date include, oral and topical carbonic 
anhydrase inhibitors, oral, topical, intravitreal and periocular steroids, topical non-steroidal anti-
inflammatory medications, photocoagulation, vitrectomy with internal limiting membrane peel, oral 
lutein, and intravitreal anti-vascular endothelial growth factor injections. This review summarises the 
evidence supporting these treatment modalities.  
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Successful management of RP-CMO should aim to improve both quality and quantity of vision in the 
short term and may also slow central vision loss over time.  
 
 
Introduction 
 
Cystoid macular oedema (CMO) may complicate Retinitis Pigmentosa (RP) and has been reported to 
occur in 10 - 50% of patients (1-4).  
 
Hereditary retinal diseases are now the leading cause of blindness certification in the working age 
population (16-64 years) in England and Wales, of which RP is the most common disorder (5). RP causes 
nyctalopia and progressive peripheral visual field loss, with particular disability experienced when 
disease progression results in central visual compromise. One important treatable cause of central vision 
loss is RP-associated CMO (RP-CMO) (6). A better understanding of the underlying mechanisms and 
response to treatments of RP-CMO is required to facilitate better targeted and more efficacious 
therapies. In this review we will discuss the pathogenesis of RP-CMO and the multiple avenues of 
intervention that have been investigated or being considered. 
 
 
Pathogenesis  
 
No single aetiology has been attributed to the overall cause of RP-CMO. Whilst we describe several 
individually proposed mechanisms, it is plausible that RP-CMO may result from a combination of these.  
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 Breakdown of the blood-retinal barrier 
The blood-retinal barrier (BRB) exists to maintain homeostasis via the highly selective diffusion and 
active transport of molecules into and out of the retina thus preventing extravascular accumulation of 
fluid within the retina (7).  This is achieved in two ways: (i) an outer barrier of apical tight junctions 
between retinal pigment epithelial (RPE) cells (8, 9), and (ii) an inner barrier of tight junctions between 
vascular endothelial cells (10). CMO can occur from BRB breakdown secondary to RPE and/or 
endothelial damage/dysfunction.   
 
Studies have investigated whether one barrier is more affected than the other in order to better focus 
potential therapies. Vinores et al used immunolocalisation of endogenous albumin to highlight areas of 
extravasation in normal eyes compared to those with RP (11). In eyes with RP alone, albumin leakage 
was greatest from the inner barrier (11). In RP-associated with other ocular complications (e.g. aphakia, 
glaucoma), leakage varied between the inner and outer barriers. No correlation was found between 
severity of photoreceptor degeneration and albumin leakage (11) suggesting that therapies for RP-CMO 
could be used regardless of underlying disease status. 
  
The release of ‘toxic products’ from degenerating retina/RPE may cause RP-CMO by disrupting the BRB 
(12). In keeping with CMO observed in other disorders, RP-CMO has been associated with release of 
vascular endothelial growth factor (VEGF), adenosine (7), prostaglandins (13), histamine (14), Insulin-like 
growth factor 1 (15), tumour necrosis factor alpha and interleukin 1 alpha and beta (16).  
 
 Failure (or dysfunction) of the pumping mechanism in the RPE 
An important function of the RPE is to pump fluid out from the sub-retinal space in order to maintain 
the negative hydrostatic pressure required for adhesion between RPE and photoreceptors (17). Under 
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normal conditions, Cl- enters the RPE cell via Na+/K+ ATP-ase located on the apical membrane and exits 
via Cl- channels on the basolateral membrane. It is this active transport that drives water through 
aquaporin channels from the sub-retinal space into the choriocapillaris . It may be that failure (or 
dysfunction) of this pumping mechanism occurs in RP, thus resulting in RP-CMO. The presence of CMO 
has been suggested to result in loss of polarised distribution of membrane-bound carbonic anhydrase 
(CA) IV in the RPE, which further contributes to RP-CMO (10).  
 
 
 Muller cell oedema and dysfunction  
The Muller cell is essential for visual transduction and retinal homeostasis, including fluid dynamics. 
Water enters the retina by two routes: directly from the blood, coupled to glucose up-take and/or as a 
by-product of aerobic metabolism; with the bidirectional movement of water osmotically coupled to the 
transport of osmolytes such as potassium (18).  
 
Potassium ions are released by activated retinal neurons. To prevent a build-up and potential excito-
toxicity, potassium is passively taken up into Muller cells via inwardly-rectifying channels (Kir2.1) with 
release of potassium occurring via Kir4.1 channels (18).  Kir channels consist of two transmembrane 
regions with cytosolic NH2 and COOH termini connected by a pore-forming loop. Molecules such as Mg2+ 
and polyamines are able to physically block this channel pore from allowing outward movement of K+, 
while still able to accept inwards movement of K+ (19). Under pathological conditions such as 
inflammation and oxidative stress, Kir4.1 channels redistribute, becoming more evenly spread 
throughout the Muller cell. Kir2.1 channels do not redistribute, however, resulting in intracellular 
potassium overload, increased osmotic pressure within the Muller cell, reduction in water efflux and 
ultimate Muller cell swelling (18). 
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Makiyama et al used optical coherence tomography (OCT) to investigate the prevalence and spatial 
distribution of cystoid spaces (CS) in patients with RP. Seventy-four of 275 patients (27%) demonstrated 
RP-CMO in at least one eye. Inner nuclear layer (INL) CS were observed in 99% of eyes with CMO. The 
outer nuclear layer (ONL)/outer plexiform layer was involved in 28% and ganglion cell layer involved in 
7% (20). Muller cell bodies reside in the INL, which supports the hypothesis of Muller cell swelling and 
dysfunction. Interestingly, 79% of CS were located in areas of relatively well-preserved outer retina (20); 
in keeping with the observation that CMO is seen more commonly in less advanced RP compared to late 
stage RP.   
 
 Anti-retinal antibodies 
Serum levels of immunoglobulins G, A and M have been investigated in 52 patients with RP compared to 
40 controls. Higher levels of IgM were found in patients with RP compared to controls (21). Spiro et al, 
however, found no difference in IgM levels between 75 patients with RP and 51 controls (22). Spalton et 
al performed immunological studies on 17 RP patients with central and/or peripheral vascular leakage 
observed on fluorescein angiogram (FA). Five out of 17 patients had raised IgM unrelated to degree of 
vascular leakage. All patients demonstrated positive immunofluorescence to rat photoreceptors at 1:5 
dilution of serum, however, this could be attributed to cross reactivity of smooth muscle antibodies with 
photoreceptor contractile organelles (12).  
 
Anti-retinal antibodies have been prospectively studied in 30 RP patients with CMO compared to 30 RP 
patients without. Anti-retinal antibodies were found in 27 of 30 RP-CMO patients compared to 4 of 30 
RP patients without CMO (23). Nevertheless, the role of anti-retinal antibodies in RP progression or RP-
CMO remains unclear, with many unanswered questions including whether they are a secondary 
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consequence of the degenerative process, the wide range of auto-antibodies identified, and the high 
prevalence in normal controls (23, 24).  
 
 Vitreous traction 
It has been suggested that vitreous traction and epiretinal membrane contributes to RP-CMO by causing 
mechanical damage to Muller cells, an inflammatory reaction with subsequent capillary dilatation and 
leakage (25, 26). Schepens et al and Takezawa et al have reported cases of RP-CMO in the presence of 
vitreous traction (26, 27).  
 
Diagnosis and monitoring of RP-CMO 
 
Prior to the advent of OCT, monitoring RP-CMO included slit-lamp biomicroscopy together with FA. OCT 
has since been shown to be more sensitive in detecting macular oedema compared to biomicroscopy in 
patients with diabetic retinopathy and RP-CMO (28, 29). OCT can detect CS in RP-CMO even when little, 
or no leakage is demonstrated on FA (29, 30) and being non-invasive is ideal for monitoring RP-CMO. No 
studies have been performed using OCT-A to investigate RP-CMO. 
 
RP-CMO is not always associated with a reduction in visual acuity (VA) (31). Oishi et al found no 
correlation between total macular thickness and VA (32). The integrity of the inner segment ellipsoid 
layer, however, has been shown to correlate well with VA and inform the likely prognosis (31-33).  
Central vision loss in RP-CMO may be due to retinal thinning (from atrophy), thickening (from CMO), or a 
combination of both (34). Anatomical but not functional improvement following treatment could be due 
to underlying retinal dysfunction/loss.  
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Automated static perimetry may also be useful for monitoring RP-CMO given the documented 
correlation between changes in retinal thickness due to CMO and retinal sensitivity (35-37).  
 
Inheritance patterns and specific associations 
 
Whilst pedigree structures may be informative, definitive conclusions on mode of inheritance can only 
be made with a molecular diagnosis.  
 
In a retrospective cohort study, CMO was present in 133/581 (23%) Italian patients with RP. This 
appeared to be significantly associated with autosomal dominant (AD) inheritance (2). In contrast, Liew 
et al constructed pedigrees for RP-CMO patients in a retrospective cohort and found 55/81 (68%) 
patients with autosomal recessive (AR) inheritance (4 of whom were molecularly proven) (38).   
 
A family with AD-RP associated with the p.P347L variant in rhodopsin (RHO) has been reported, where 
all four children had bilateral CMO, suggesting this RHO mutation may be associated with early-onset 
CMO (39).  
 
RP-CMO has been associated with female gender (2) and does not appear to be age-related (1).  
 
Avenues of Intervention 
 
Despite RP being the most common inherited retinal degeneration in the working age population, it   
remains a rare condition with only a portion of these patients developing CMO (5). It can therefore be a 
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challenge to set up clinical trials targeting RP-CMO and most evidence to date therefore comprises of 
case reports/series and small prospective/retrospective studies. 
 
We conducted a Pubmed search to include all reports/studies reviewing interventional treatment for 
RP-CMO published between 1975 and 2016. The search strategy involved the terms ‘retinitis 
pigmentosa’, ‘rod cone dystrophy’, ‘retinal dystrophy’, ‘inherited retinal dystrophy’ and ‘macular 
oedema'. We identified 203 publications the abstracts of which were retrieved and reviewed. Inclusion 
criteria included prospective and retrospective reports/studies using a drug and/or procedure to treat 
RP-CMO. We also included patients with syndromic RP such as Usher syndrome and those with Coats-
like exudation. We excluded patients with MFRP (membrane-type frizzled-related protein)-related 
nanophthalmos-retinitis pigmentosa-foveoschisis-optic disc drusen syndrome due to its complexity. We 
identified 45 reports/studies that met our inclusion criteria and retrieved these articles. Whilst 
preparing this manuscript, a case report published by the authors’ became available on-line, which was 
also included in the studies reviewed, bringing the total up to 46. 
 
Most of the evidence published is in the form of small cohort and case control studies. These may be 
influenced by publication bias as negative reports are unlikely to be published. There are no RCTs to 
date which may help alleviate this concern. We did not construct funnel plots or perform other 
statistical tests for publication bias due to the small number of studies and the highly heterogeneous 
populations and study designs. 
 
Significant studies that describe interventions in detail or highlight important / interesting points are 
mentioned in the text. Supplementary table 1 provides an overview of all studies that met our inclusion 
criteria. 
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Pharmacological 
 
 Carbonic Anhydrase Inhibitors: Oral and Topical 
. Inhibition of CA IV results in acidification of the sub-retinal space, increased chloride ion transport, with 
subsequent movement of water across the RPE into the choroid (10).  
 
Several studies have shown RP-CMO improvement following treatment with CA inhibitors (CAIs) (38, 40-
53). In the largest retrospective study to date involving 81 patients (157 eyes) with RP-CMO, objective 
improvement on OCT was observed in 53% of patients (40% of eyes) using topical dorzolamide and in 
41% of patients (28% of eyes) using oral acetazolamide (see figure 1) (38). VA improved from 6/15 to 
6/12 in most patients. AR-RP and greater initial central macular thickness (CMT) predicted better 
response to treatment.  
 
 
 
 
 
 
Figure 1 Spectral domain optical coherence tomography of a man aged 30 years with autosomal 
recessive retinitis pigmentosa and cystoid macular oedema. (A) Before treatment was initiated (visual 
acuity (VA) 6/18). (B) Following 6 months usage of topical carbonic anhydrase inhibitors (VA 6/12). 
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In another retrospective study, 33 eyes (51%) of 20 patients with RP-CMO using topical dorzolamide 
demonstrated CMT reduction of at least 11% (46). While there are other reports in keeping with these 
findings (42), some studies have documented improvement of anatomy or leakage on FA only, with little 
or no corresponding improvement in VA (47-49).  
 
In a prospective, crossover study, 9 out of 17 patients using oral methazolamide demonstrated 
angiographic improvement of CMO, however, VA improved in at least one eye, by at least 2 lines in only 
3 patients (43). Another prospective, masked, crossover study using oral acetazolamide versus placebo 
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observed VA improvement of at least one line, in at least one eye in 10 out of 12 patients. Three of 
these patients initiated on placebo only demonstrated improvement once switched to acetazolamide 
(44). 
 
Location of CS in RP-CMO may influence response to treatment with CAIs. Acetazolamide cannot readily 
enter the neurosensory retina making it potentially less effective at reducing INL CS (54). However, with 
good access to the RPE basolateral membrane (41), acetazolamide may be more effective at reducing 
ONL CS (55).  
 
Rebound CMO has been observed after stopping CAIs (42, 47). Importantly, a restored response has 
been demonstrated after the re-introduction of CAI treatment following a period of discontinued usage 
(between 1-6 months) in 3 patients with rebound RP-CMO (53). 
  
Oral CAI’s have more side-effects than topical CAIs ranging from fatigue, loss of appetite and limb 
paraesthesia, to the development of kidney stones, aplastic anaemia and electrolyte disturbance 
including hypokalaemia with potential associated cardiac arrhythmia (56). 
 
 Steroids: Oral, Periocular and Intravitreal   
Steroids reduce the synthesis and release of pro-inflammatory cytokines, including: prostaglandins, 
leukotrienes, VEGF and intercellular adhesion molecule 1 (57-60). This, together with suppression of 
inflammatory cell proliferation and migration contributes to improved BRB function and reduction of 
CMO. Indeed, steroids have been trialled and observed to improve VA and / or CMT in RP-CMO (4, 6, 61-
75).. 
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A one year pilot study using oral deflazacort in 10 patients with RP-CMO reported significant 
improvements in near VA, retinal sensitivity, and angiographic findings (65). No ocular or systemic side-
effects were recorded. 
 
Five patients with RP-CMO underwent unilateral intravitreal injection of 4mg (0.1ml) of triamcinolone 
acetonide (IVTA). CMT improved from 418mµm (range 376–626µm) at baseline, to 224µm (range 214–
326µm) at 1-month, 275µm (range 215–584µm) at 3-months and 312µm (range 239–521µm) at 6-
months. VA improved in 2 patients by 1-month but was not maintained. CMO recurrence occurred in 2 
patients between 3-6 months (4).   
 
In comparison, a prospective, non-randomised trial compared 20 eyes of 20 RP-CMO patients treated 
with IVTA with 20 eyes of 20 RP-CMO patients who declined treatment. All treated patients showed 
anatomical improvement, greatest at 3-months post-injection. No statistical improvement in VA was 
observed. At day-1 post-IVTA, 10 eyes (50%) had a raised IOP (>21mmHg) including 2 patients (10%) 
measuring between 30-35mmHg.  All IOPs returned to baseline within 6 months (6).  
 
A case report of bilateral RP-CMO refractory to IVTA, reported CMO reduction and VA improvement 
following bilateral sub-tenon injections of triamcinolone (63). CMO recurred in one eye at 3-months.  
Intravitreal dexamethasone (DEX implant; Ozurdex, Allergan, Inc., Irvine, CA) has also been used in 3 
patients with RP-CMO refractory to oral CAI’s and/or sub-tenon triamcinolone and/or topical non-
steroidal anti-inflammatory. Two patients required re-treatment at 3-months due to recurrence (73). 
Another case report demonstrated similar outcomes with initial improvement of CMO and VA, but 
recurrence at 2-3 months (69).  
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The use of regular steroids in RP-CMO is significantly limited by their side-effect profile. Ozurdex appears 
to have a lower incidence of cataract and raised intra-ocular pressure (IOP) compared to IVTA in 
treatment of retinal vein occlusion-CMO (76, 77), however, the incidence in RP-CMO is unknown. 
 
 Combination of topical Non-Steroidal Anti-Inflammatory (NSAID) together with topical Steroid or 
topical CAI 
A case report using topical steroid (prednisolone acetate 1%) together with topical NSAID (ketorolac 
trometamol 0.5%) in an 85-year-old lady with unilateral RP-CMO demonstrated CMO resolution and VA 
improvement at 3-months. CMO recurrence on cessation required re-treatment to good effect (78). 
 
A recent prospective study of 18 patients, randomised 15 eyes to topical ketorolac and 13 eyes to 
topical dorzolamide for 12-months. No significant change in CMT was observed in either group. VA 
improved in both groups at 6-months, however, this improvement was lost in the dorzolamide group at 
12-months (79). 
 
 Intravitreal Anti-Vascular Endothelial Growth Factor (anti-VEGF) 
The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (80). In addition 
to promoting angiogenesis, VEGF-A reduces endothelial barrier function and increases permeability of 
choroidal vessels, both of which cause CMO (80).  
 
Salom et al (2008) identified markedly lower levels of VEGF-A in the aqueous humour of 16 eyes of 16 
patients with RP (94.9 +/- 99.8 (mean +/- SD) pg/mL) compared to the same number of controls (336.5 
+/- 116.8 pg/mL). Relative hyperoxia of the inner retina due to photoreceptor cell death may reduce 
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VEGF production from retinal cells such as pericytes, endothelial cells, glial cells, Muller cells, and 
ganglion cells (81).  
 
While no studies have assessed vitreous levels of VEGF in patients with RP or RP-CMO, anatomical 
and/or functional improvement of RP-CMO has been observed following intravitreal anti-VEGF 
medication (82-87). Anti-VEGF agents are routinely used to treat CMO and neovascularisation (NV) in 
multiple retinal diseases. NV is rare in RP; Triolo et al reported  choroidal NV in 3 of 176 eyes (2%) with 
RP (88). Indeed, intravitreal bevacizumab (Avastin, Genentech/Roche, South San Francisco, California) 
has been observed to improve RP-choroidal NV (89, 90). While VEGF may contribute to RP-CMO 
formation, anti-VEGF medication remains under review as a treatment modality.  
 
- Pegaptanib 
A case report using a single intravitreal injection of 0.3mg pegaptanib (Macugen, Eyetech 
Pharmaceuticals, Inc. and Pfizer Inc, New York, NY) together with oral acetazolamide in a 33-year-old 
male with RP-CMO demonstrated improvement of CMT and VA, which was maintained at 4-months 
(82). 
 
- Bevacizumab 
Bevacizumab has been used off-label to treat RP-CMO with varying results. Melo et al observed neither 
anatomical nor functional improvement in 2 eyes of 2 patients following treatment with a single 
injection of intravitreal 1.25mg bevacizumab: Case 1 maintained VA of 20/200 both pre and post-
bevacizumab injection with no further improvement following IVTA. Case 2 had a baseline VA of 20/100, 
which worsened at 1-month post-bevacizumab to 20/200. Due to worsening cataract, the patient 
subsequently underwent phacoemulsification plus IVTA and VA at 3 months post-op improved to 20/25 
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(91). In contrast, Yuzbasioglu et al performed an average of 3.3 (range, 1-8) injections of 1.25mg 
bevacizumab over 10.3 (range, 6-14) months in 13 eyes of 7 patients and observed a reduction of CMT 
from 370.15 m (range, 245-603 m) at baseline to 142.53 m (range, 124-168 m). Pre- and post-
treatment visual acuity ranges were 5/400 - 20/100 and 20/200 - 20/63, respectively (83). 
 
- Ranibizumab  
Artunay et al enrolled 30 eyes of 30 patients with RP-CMO into a prospective, controlled interventional 
study of 0.5mg intravitreal ranibizumab (LUCENTIS; Genetech, South San Francisco, California, USA). 
Thirteen eyes (87%) in the treatment group demonstrated a significant reduction of CMO at 6-months. 
No statistically significant difference in VA was seen between the groups (84).  
 
- Aflibercept  
Improvement of CMT and VA following a single unilateral intravitreal injection of aflibercept (EYLEA; 
Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA and Bayer Healthcare Pharmaceuticals, 
Berlin, Germany) in a 52-year-old patient with RP-CMO was observed and maintained at 6-months (85). 
We have observed similar responses (86)and have commenced a prospective study to determine safety 
and efficacy of intravitreal aflibercept in RP-CMO (ClinicalTrials.gov identifier NCT02661711). Aflibercept 
may be superior to other anti-VEGF medications due to its intermediate size (115 kDa) and higher 
binding affinity. 
 
Nutritional 
 
 Oral Lutein 
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Lutein and zeaxanthin are carotenoid pigments that contribute to the formation of macular pigment 
which is thought to be protective against oxidative damage (92). A 48-week study tested the effect of 
oral lutein on CMT in 39 patients with RP. Lutein was found to have no statistically significant effect on 
CMT in RP patients with, or without CMO (3).  
 
 Oral omega-3 fatty acid 
 
Oral omega-3 has been used in RP to investigate whether loss of cone or rod ERG function can be 
slowed. A systematic review carried out by Hodge et al (2006) summarised trends in improvement have 
been seen in some retinitis pigmentosa outcomes (93). A placebo controlled RCT found no effect of 
omega 3 fatty acid supplementation on the primary endpoint of ERG changes in RP. However, beneficial 
changes in secondary endpoints were observed, namely slowed progression of visual field loss and dark 
adapted thresholds (94, 95). 
 
 Oral intake of iodine 
While oral iodine has not been trialled specifically for RP-CMO, higher urinary iodine 
concentration has been observed to be significantly associated with reduced macular swelling in 
non-smoking adults with RP-CMO, suggesting a potential role for limiting iodine intake (96).  
 
Surgical 
 
 Laser 
In 1987, grid laser photocoagulation was undertaken in one eye of 16 patients with bilateral RP-CMO. 
Six treated eyes gained one or more lines of vision, while none of the untreated eyes did. Seven 
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untreated eyes lost one or more lines of vision, while none of the treated eyes did. Thirteen of 16 eyes 
showed decreased fluorescein leakage after treatment (97). Laser may remove hypoxic degenerating 
retina thus reducing VEGF production (98).  
 
 
 Vitrectomy 
In 2003, vitrectomy combined with inner limiting membrane peel was carried out on 12 eyes of 8 
patients with RP-CMO refractory to treatment with acetazolamide. The presence or absence of pre-
operative vitreo-macular traction was not confirmed. Mean CMT improved from 478µm (range, 380 - 
570µm) pre-operatively to 260µm (range, 177 - 424µm) at 6-months. Mean VA improved from 20/115 
(range, 20/60 – 20/400) pre-operatively to 20/45 (range, 20/30 – 20/100) at 6-months (25).  
 
 
Conclusions and Future Directions 
 
RP-CMO commonly complicates RP, however, its exact underlying pathogenesis remains uncertain. 
Proposed mechanisms which are most likely to be involved include breakdown of the BRB and/or RPE 
pump mechanism failure and /or Muller cell oedema and dysfunction. When CS are present they are 
most commonly located in the INL, suggesting that inner BRB dysfunction may have a greater role than 
the outer BRB, in development of RP-CMO.  A better understanding of these mechanisms will facilitate 
better targeted and likely more efficacious and durable therapies. 
 
Setting up clinical trials for RP-CMO, however, remains a challenge due to its low prevalence, the highly 
variable course of disease progression, lack of clearly accepted endpoints, multiple underlying 
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mutations, and very slow progression to visual loss. With the majority of studies producing levels of 
evidence between 3 and 4 and no large RCTs, we remain in a position where there are still no studies 
providing high level evidence for treatments for RP-CMO. In the absence of RCTs, the effect of known 
and unknown confounders affecting the findings cannot be excluded. The majority of studies did not 
have a control group (level 4 evidence) which limits the validity of findings as these may be a result of 
natural history rather than the intervention. Many studies were retrospective which may be affected by 
recall bias. This review has highlighted the lack of high quality evidence for treatments of RP-CMO.  
Whilst concrete conclusions cannot be drawn, the evidence available to us suggests that topical CAIs 
may be used as first-line approach in the treatment of RP-CMO. Consideration should be given to the 
possibility of side-effects and potential for rebound CMO. Oral CAIs may be a second line agent but 
there is the risk of more side effects.  
As there are currently no treatments for the underlying retinal degeneration in RP and given the 
potentially reversible nature of RP-CMO, there is a real need to better understand disease mechanisms 
and undertake prospective clinical trials of therapeutic agents to provide the evidence base to improve 
treatment of RP-CMO. Successful management of CMO should aim to both improve quality and quantity 
of vision in the short term and slow the rate of vision loss over time. 
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Supplementary table 1: A summary to date of the pharmacological, nutritional and surgical 
interventional studies for RP-CMO 
 
Authors Year 
publi
shed 
Study 
design 
N 
(pts) 
Intervention Results Comments  Level of 
evidence* 
Carbonic Anhydrase Inhibitors  
Liew et 
al  
2015 Retrospec
tive 
cohort  
81  
 
125 eyes of 64 
patients received 
topical 
dorzolamide, 32 
eyes of 17 
patients received 
oral 
acetazolamide 
250mg BD or 
500mg OD 
CMT reduction 
greater in 
dorzolamide 
group than 
acetazolamide 
group 
VA 
improvement 
both groups 
 3B 
286 
 
Ginead 
et al  
2010 Retrospec
tive case 
series  
32  Topical 
dorzolamide 2% 
TDS or BD for 6 - 
58 months 
CMT 
improvement 
more than VA 
improvement 
 4 
Fishman 
et al  
1994 Prospecti
ve, 
placebo-
controlled
, double-
masked, 
crossover 
design  
17  Methazolamide 
or placebo taken 
for 3 weeks 
Sub-group 
received 
additional 3/12 
methazolamide 
treatment 
Angiographic 
improvement 
more than VA 
improvement  
No change in VA 
with extended 
methazolamide 
treatment 
 3B 
Grover 
et al  
2006 Prospecti
ve, non-
randomis
ed 
15  Topical 
dorzolamide TDS 
for at least 4 
weeks BE  
CMT 
improvement 
more than VA 
improvement 
Recurrence in 
4 patients 
4 
Fishman 
et al  
1989 Prospecti
ve, 
masked, 
cross-
over  
12  Oral 
acetazolamide or 
placebo for 2 
week periods 
 
BCVA improved, 
CMT reduced. 
Improvement 
angiographically 
in almost 50% 
500 mg/day 
acetazolamide 
more effective 
than 250 
mg/day 
3B 
Ikeda et 
al 
2013 Prospecti
ve 
10  Topical 
dorzolamide 1% 
CMT reduction 
with majority 
effect lasting 18 
Recurrence in 
5 eyes 
4 
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TDS BE for 18 
months 
 
months. 
Macular 
sensitivity 
improvement  
No significant 
change in BCVA 
between 12-
18 months 
Ikeda et 
al  
2012 Prospecti
ve 
9  Topical 
dorzolamide 1% 
TDS BE for 6 
months 
 
CMT reduction 
greater than 
macular 
sensitivity 
improvement  
No difference in 
BCVA 
 4 
Fishman 
et al  
2007 Prospecti
ve cohort 
8  Topical 
dorzolamide 2% 
TDS BE for 7 - 15 
months 
 
CMT 
improvement 
more than VA 
improvement 
 
Patients 
previously 
included in 
study by 
Grover et al 
2006 
Two patients 
experienced 
rebound CMO 
4 
Orzalesi 
et al  
1993 Prospecti
ve pilot  
7  Oral 
acetazolamide for 
VA 
improvement 
Effect 
independent 
4 
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2 weeks then 
reduced / 
maintained / 
increased 
according to 
response 
Follow-up 
between 3 weeks 
– 16 months 
of reduction 
of CMO on 
FFA 
Apushki
n et al  
2007 Prospecti
ve cohort 
6  500 mg oral 
acetazolamide 
CMO improved 
at 3-5 weeks  
Recurrence at 
8-12 weeks 
4 
Grover 
et al  
1997 Prospecti
ve, 
double-
masked, 
crossover  
5  Topical 
dorzolamide or 
placebo given for 
4 weeks followed 
by crossover 
treatment for 4 
weeks 
Oral 
acetazolamide 
then given for 2 
weeks 
VA no change 
using 
dorzolamide 
VA 
improvement 
using 
acetazolamide 
CMO and FFA 
improvement 
more marked 
using 
acetazolamide 
4 week flush-
out period in 
between each 
phase 
3B 
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than 
dorzolamide  
Pacella 
et al  
2014 Case 
reports 
3  Topical 
dorzolamide BE  
 
CMT 
improvement 
within 7 - 20 
days 
No significant 
change in VA 
observed 
 4 
Thobani 
& 
Fishman 
2011 Retrospec
tive case 
series 
3 Only 2 patients 
with RP and CMO. 
Recurrence whilst 
taking 500mg oral 
acetazolamide. 
Re-introduced to 
treatment after 
period of 
discontinuation  
Improvement of 
macular 
oedema. VA not 
mentioned in RP 
patients. 
 4 
Fishman 
et al  
1993 Prospecti
ve  
3  Oral 
methazolamide 
50mg BD 
Slight 
improvement 
BCVA 
Recurrence at 
6-12 weeks 
 
 
4 
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Chen et 
al 
1990 Case 
study 
1 Oral 
acetazolamide  
BCVA 
improvement 
RE only 
Improvement of 
CMO BE 
 4 
Steroids  
Wang et 
al 
2003 Retrospec
tive chart 
review 
50 Only 2 of these 
patients were 
diagnosed with 
RP-CMO. Single 
bilateral  
intravitreal 
injection of 
triamcinolone 
given. 
Improvement in 
CMT and VA. 
 4 
Scorolli 
et al  
2007 Prospecti
ve, 
nonrando
mised, 
comparati
ve trial 
40  20 eyes received 
a unilateral single 
intravitreal 
injection of 
triamcinolone 
acetonide, 20 
eyes who 
declined were 
used as controls 
No significant 
change in BCVA 
CMT reduction 
IOP increased 
after the first 
day, at 1 
month, and at 
3 months in 
both groups 
but no 
significant 
3B 
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1 year follow-up increase 
afterwards 
Giusti et 
al  
2002 Pilot  10  Treated for 1 year 
with oral 
deflazacort 
Near VA, FFA 
and perimetry 
improved 
significantly  
Distance VA 
varied only 
slightly 
 4 
Ozdemir 
et al  
2005 Prospecti
ve small 
series 
5  IVTA given  
Follow up 6-8 
months  
 
CMT 
improvement 
No 
improvement 
VA seen 
Refractory to 
oral 
acetazolamide 
Recurrence in 
3 patients 
between 3 – 6 
months 
4 
Srour et 
al 
2013 Prospecti
ve  
3  Intravitreal 
dexamethasone 
implant (Ozurdex) 
Follow-up for 6 
months 
 
 
CMT and VA 
improvement 
 
 
Refractory to 
oral 
acetazolamide
, sub-tenon 
triamcinolone, 
topical NSAID 
Recurrence at 
3 months in 2 
4 
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patients 
requiring re-
treatment 
Schaal 
et al 
2016 Case 
study 
1 Right eye 
received a sub-
tenon injection of 
triamcinolone 
A 2nd sub-tenon 
injection was 
performed in the 
right eye 8 
months following 
the 1st injection 
VA and CMT 
improvement 2-
weeks post 1st 
injection 
Mild rebound 
CMO at 8 
months 
following 1st 
injection 
 
Refractory to 
oral 
acetazolamide 
500mg OD for 
2 years and 
topical 2% 
dorzolamide 
TDS together 
with topical 
0.09% 
bromofenac 
OD for 1 year 
IOP increase 
at 4 months 
controlled 
with 0.5% 
timolol BD 
4 
Ahn et 
al  
2014 Case 
study 
1 0.7mg intravitreal 
Ozurdex 
BCVA improved 
OCT central 
thickness 
improved 
Refractory to 
oral  
acetazolamide 
and 
4 
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intravitreal 
bevacizumab 
Patil L & 
Lotery 
A.J  
2014 Case 
study 
1 Treated with 
0.7mg of 
intravitreal 
injection of 
dexamethasone 
implant (Ozurdex) 
 
VA and CMT 
improvement, 
maintained 
after 10 months 
Exudation at the 
disc and the 
inferior retina 
resolved.  
 
Patient from 
De Salvo 2011 
study. RE RP-
CMO and 
Coats'-like 
exudative RD. 
Refractory to 
oral 
acetazolamide
, topical 
dorzolamide, 
orbital floor 
injection of 
depo-
medrone and 
CMO 
recurrence 
following 
initial success 
with 
cryotherapy. 
4 
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Alhassa
n, M & 
Quintyn, 
J.C 
2013 Case 
study 
1 
 
Single unilateral 
intravitreal 
dexamethasone 
implant  
(Ozurdex) 
Bilateral BCVA 
improvement 
and CMT 
reduction at 1 
month  
Refractory to 
oral 
acetazolamide 
500mg OD 
and topical 
brinzolamide 
BD 
4 
Barge et 
al  
2013 Case 
study 
 
1 Bilateral 
intravitreal 
injections of 
triamcinolone 
(IVTA) before sub-
tenon depot of 
triamcinolone  
BCVA improved 
CMT reduced 
IOP raised BE  
Refractory to 
oral 
acetazolamide 
and topical 
ketoralac 
Recurrence at 
2-5 months 
post-IVTA 
4 
Buchaim 
et al  
2013 Case 
study 
1 Bilateral 
intravitreal 
dexamethasone 
implant (Ozurdex) 
 
BCVA improved 
No CMO at 4 
months 
 
Previously 
received 19 
IVTAs RE and 
13 IVTAs LE 
but with 
decreasing 
therapeutic 
effect 
4 
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Saati et 
al  
2013 Case 
study 
1 Bilateral 
intravitreal 
dexamethasone 
implant (Ozurdex) 
 
CMO resolution 
at 1/52 
VA 
improvement 
Refractory to 
topical 
dorzolamide 
Recurrence BE 
between 2-3 
months   
4 
Urban 
et al  
2009 Case 
study 
1 4 x unilateral 
intravitreal 
triamcinolone 
repeated every 4 
months 
 
FT reduction 
within 3 months 
BCVA 
improvement 
Endophthalmitis 
following 4th 
IVT diagnosed 
day of RTA  
Traumatic 
inferior RD, 
migration of 
triamcinolone 
into sub-retinal 
space. Scleral 
buckling and 
vitrectomy 
performed  
Intolerant to 
oral 
acetazolamide 
Previous 
autologous 
plasmin 
enzyme–
assisted 
vitrectomy 
without ILM 
peel 
4 
296 
 
Resolution of 
CMO observed, 
however, BCVA 
remained at 
20/100.  
Kim et 
al  
2006 Case 
study 
1 2 x Intravitreal 
triamcinolone 
(4mg/0.1ml)  
RE cataract 
surgery at 3 
months post-1st 
IVTA 
1st IVTAs 
resolution of 
CMO by 1/12. 
No significant 
change in VA 
2nd IVTAs 
resolution of 
CMO by 2 
weeks 
Refractory to 
oral 
acetazolamide 
500mg for 1 
year and sub-
tenon 
triamcinolone 
40mg 
Recurrence in 
BE at 11 
months post 
1st IVTA.  
4 
Minella 
et al 
2006 Case 
study 
1 IVTA 
Follow-up for 6 
months 
 
CMT reduced 
No significant 
change FERG 
amplitude/phas
e  
VA showed a 
significant 
 4 
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tendency to 
improve 
Sallum 
et al  
2003 Case 
study 
1 Bilateral IVTAs 
 
CMO resolution 
between 30 - 40 
days 
VA 
improvement LE 
only 
Refractory to 
oral 
acetazolamide 
Recurrence at 
6 months 
4 
Saraiva 
et al  
 
2003 Case 
study 
1 Bilateral IVTAs  CMO reduction 
 
VA 
improvement LE 
only  
Refractory to 
oral 
acetazolamide 
Recurrence at 
6 months  
4 
Non-steroidal anti-inflammatory together with steroid or CAI  
Lemos-
Reis et 
al  
2015 Prospecti
ve, 
randomis
ed and 
interventi
onal  
 
18  15 eyes received 
topical ketorolac 
and 13 eyes 
received topical 
dorzolamide for 
12 months 
No significant 
change in CMT 
in either group 
Improvement 
BCVA both 
groups at 6/12 
but reduced in 
dorzolamide 
group at 1 year 
 3B 
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Park et 
al  
2013 Case 
study 
1 Topical 
prednisolone and 
ketorolac 3 
months 
VA 
improvement 
and resolution 
of CMO at 3 
months 
 
Treatment re-
introduced at 
6 months due 
to recurrence 
of CMO 
4 
Intravitreal anti-vascular endothelial growth factor  
Artunay 
et al  
 
2009 Prospecti
ve cohort 
30 
 
15 eyes received 
intravitreal 
ranibizumab, 15 
eyes remained off 
treatment 
CMT improved 
but no change 
in BCVA at 6 
months  
 
Refractory to 
oral 
acetazolamide 
3B 
Yuzbasi
oglu et 
al  
2009 Prospecti
ve  
7  Intravitreal 
bevacizumab  
CMT and VA 
improvement 
 4 
Melo et 
al  
2007 Case 
reports 
2  
 
Single unilateral 
intravitreal 
bevacizumab  
1st patient 
received IVTA at 
3/12 post IVT 
2nd patient 
underwent 
cataract 
Unchanged 
CMT, VA same 
or worse 
following IVT 
1st patient CMT 
improved 
following IVTA 
2nd patient: VA 
reduced due to 
Previously 
received 2 or 
3 IVTAs with 
transient VA 
improvement 
4 
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surgery/IVTA at 1 
month post IVT  
lens opacity. VA 
and CMT 
improvement 
documented at 
3 months post-
cataract surgery 
Strong 
et al 
2016 Case 
report 
1 Bilateral 
intravitreal 
injections of Eylea  
CMT 
improvement  
Refractory to 
topical 
dorzolamide. 
Minimal 
response 
previously to 
intravitreal 
ranibizumab. 
4 
Moustaf
a et al  
2015 Case 
study 
1 Single unilateral 
intravitreal 
injection of 
aflibercept  
VA and CMT 
improvement 
No significant 
multifocal ERG 
changes 
Improvements 
maintained at 
6 months 
4 
Shah et 
al  
2010 Case 
study 
1 3 x Intravitreal 
unilateral 
injections of 
ranibizumab  
CMT reduction 
BCVA 
improvement 
after 3rd IVT  
 
Unable to 
tolerate PO 
acetazolamide 
4 
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Refractory to 
topical 
dorzolamide 
Recurrence at 
3 months 
after 3rd IVT 
Querqu
es et al  
2009 Case 
study 
1 Single unilateral 
intravitreal 
injection of 
pegaptanib 
sodium 0.3mg 
given whilst PO 
acetazolamide 
continued 
 
VA and CMT 
improvement 
No recurrence 
of CMO seen at 
4 months post-
IVT 
Refractory to 
oral 
acetazolamide  
4 
Oral lutein  
Adackap
ara et al  
2008 Prospecti
ve  
39  Patients already 
enrolled in phase 
I/II clinical trial 
with double-
masked, placebo-
lutein, crossover 
design 
No significant 
effect on CMT in 
patients with, or 
without CMO 
19 / 39 
patients had 
RP-CMO, 20 
/39 patients 
had RP 
without CMO 
3B 
Laser  
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Newso
me et al  
1987 Prospecti
ve pilot  
16  Unilateral grid 
photocoagulation 
performed 
Follow-up 
between 4 - 21 
months 
Decreased dye 
accumulation 
on FFA 
VA better in 
treated 
compared to 
untreated eyes 
 4 
Vitrectomy  
Garcia-
Arumi et 
al 
2003 Prospecti
ve non-
comparati
ve case 
series 
8  Pars plana 
vitrectomy with 
ILM peel  
 
VA and CMT 
improvement  
Refractory to 
oral 
acetazolamide 
250mg BD for 
1 month 
4 
Other  
Siqueira 
et al  
2013 Case 
report 
within 
phase 2 
study 
1 Unilateral 
intravitreal 
autologous BM-
derived 
hematopoietic 
stem cell 
transplantation 
CMO resolution 
and VA/macular 
sensitivity 
improvement 
 
 
Refractory to 
oral 
acetazolamide 
and topical 
dorzolamide  
4 
De Salvo 
et al  
2011 Case 
study 
1 Cryotherapy 
applied to infero-
Slight increase 
BCVA with mild 
Coats'-like 
exudative RD. 
4 
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temporal 
quadrant of RE 
retina 
 
residual CMO at 
6 months 
 
Refractory to 
oral 
acetazolamide
, topical 
dorzolamide 
and orbital 
floor injection 
depomedrone  
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Full title: 
Treatment of Retinitis Pigmentosa-associated cystoid macular oedema using intravitreal aflibercept 
(Eylea) despite minimal response to ranibizumab (Lucentis) : A case report 
 
Abstract: 
Background:  We present an interesting case of bilateral Retinitis Pigmentosa (RP)-associated cystoid 
macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, 
despite previously demonstrating only minimal response to intravitreal ranibizumab. This unique case 
would support a trial of intravitreal aflibercept for the treatment of RP-associated cystoid macular 
oedema. 
 
Case presentation: A 38-year-old gentleman from Dubai presented to the UK with a 3-year history of 
bilateral RP-associated cystoid macular oedema. Previous treatment with topical dorzolamide, oral 
acetazolamide and intravitreal ranibizumab had demonstrated only minimal reduction of cystoid 
macular oedema. Following re-confirmation of the diagnosis by clinical examination and optical 
coherence tomography imaging, bilateral loading doses of intravitreal aflibercept were given. Central 
macular thickness reduced and the patient returned to Dubai. After 6-months, the patient was treated 
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with intravitreal ranibizumab due to re-accumulation of fluid and the unavailability of aflibercept in 
Dubai. Only minimal reduction of central macular thickness was observed. Once available in Dubai, 
intravitreal aflibercept was administered bilaterally with further reduction of central macular thickness 
observed. Visual acuity remained stable throughout.  
 
Conclusions:  This is the first case report to demonstrate a reduction of RP-associated CMO following 
intravitreal aflibercept despite inadequate response to ranibizumab on two separate occasions. 
Aflibercept may provide superior action to other anti-VEGF medications due to its intermediate size (115 
kDa) and higher binding affinity. This is worthy of further investigation in a large prospective cohort over 
an extended time to determine the safety and efficacy of intravitreal aflibercept for use in this 
condition.  
 
Keywords: 
Aflibercept, Cystoid Macular Oedema, Eylea, Retinitis Pigmentosa, Case report 
 
Background: 
Retinitis Pigmentosa (RP) is the most prevalent inherited retinal disease (IRD), with IRD now 
representing the commonest cause of visual impairment registration in the working age population and 
the second commonest in childhood in the UK [1].  Typical symptoms of RP include nyctalopia, photopsia 
and progressive visual field loss, however, vision can also be affected by cataracts and/or cystoid 
macular oedema (CMO).  
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Around 20% of RP patients develop CMO, the pathogenesis of which is not clearly understood.  
Suggested mechanisms include: anti-retinal antibodies [2], retinal pigment epithelium (RPE) dysfunction 
[3], Muller cell oedema [4] and vitreous traction [5].  
 
Many treatments have been attempted for RP-associated CMO, including: grid laser, vitrectomy, oral 
lutein, intravitreal dexamethasone, intravitreal triamcinolone, topical carbonic anhydrase inhibitors, oral 
carbonic anhydrase inhibitors, oral corticosteroids, topical non-steroidal anti-inflammatory medication 
and topical steroid [6-10]. However, all of the aforementioned treatments have limited and highly 
variable efficacy. This, together with several side-effects of these medications that markedly restrict 
their use, has led to the search to find alternative therapies that are both well tolerated and are more 
consistently effective.  
 
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) medication is now licenced for use within 
the UK for CMO secondary to macular degeneration, diabetic retinopathy and retinal vein occlusion. 
While the pathogenesis of RP-associated CMO is still unclear, it is believed that VEGF may play a role in 
the development of CMO. It has therefore been suggested as an alternative treatment for RP-associated 
CMO. 
 
Limited data has been published regarding the use of intravitreal anti-VEGF medication for RP-
associated CMO. Querques et al (2009) observed improvement of visual acuity and macular thickness in 
a patient with refractory RP-associated CMO taking oral acetazolamide, one month following a single 
injection of intravitreal pegaptanib (MACUGEN; EyeTech Pharmaceutical, Inc., New York, USA). No 
recurrence of CMO was seen at 4 months post-injection [11]. Melo et al (2007) observed no 
improvement in 2 patients with RP-associated CMO treated with a single injection of intravitreal 
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bevacizumab (AVASTIN; Genentech, South San Francisco, California, USA) [12], however, Yuzbasioglu et 
al (2009) documented improvement of macular thickness and visual acuity in all 13 eyes of 7 patients 
[13].  
 
Artunay et al (2009) treated 15 eyes with RP associated CMO with intravitreal ranibizumab and 
compared them with 15 eyes of similar patients who refused treatment. A significant improvement in 
macular thickness was observed in those patients treated with intravitreal ranibizumab [14].  
 
In a recent case report, a single unilateral intravitreal injection of aflibercept was given to a patient with 
RP associated CMO.  Improvement in both visual acuity and macular thickness was seen at one month 
post-injection as well as maintenance of this improvement documented at 6 months [15]. Aflibercept is 
a recombinant fusion protein consisting of portions of the extracellular domains of human VEGF 
receptors 1 and 2 fused to the Fc portion of human IgG1. This unique design is what sets aflibercept 
apart from other intravitreal anti-VEGF medications by enabling its action as a decoy receptor. 
 
 
Case presentation: 
In August 2013, a 38-year-old gentleman from Dubai, United Arab Emirates was seen by a medical retina 
specialist in the UK. He was previously diagnosed with Autosomal Recessive Retinitis Pigmentosa (RP) in 
Dubai and bilateral CMO had been documented over the last 3 years. The patient had undergone 
uncomplicated bilateral cataract surgery with the insertion of posterior chamber intraocular lenses in 
2004. There was no other relevant past medical history. Family history revealed parental consanguinity, 
with his parents being first cousins.  
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He had previously received topical dorzolamide and a 3 week trial of oral acetazolamide (Diamox) 
250mg three times per day, with no significant improvement in the degree or extent of CMO. Bilateral 
injections of ranibizumab (LUCENTIS; Genentech, South San Francisco, California, USA) had been 
performed once a month for three months in Dubai in 2013 with only minimal response observed. At 
the time of the consultation in the UK, the patient was no longer receiving topical or oral treatment for 
CMO. 
 
On examination, BCVA was 6/18 in the right eye and 6/36 in the left eye. Visual field testing to 
confrontation revealed constricted fields of 10 to 20 degrees in both eyes. Fundoscopy revealed bilateral 
dense bone-spicules, bilateral CMO, attenuated retinal vessels and pale optic discs. Spectral domain 
optical coherence tomography (SDOCT) revealed marked bilateral CMO with central macular thickness 
(CMT) of 394 and 414 microns in the right and left eye respectively (Figure 1, A and E).  
  
The anti-VEGF medication selected for use in this gentleman was aflibercept (EYLEA; Regeneron 
Pharmaceuticals, Inc., Tarrytown, New York, USA and Bayer Healthcare Pharmaceuticals, 
Berlin, Germany). This was due to there being only a minimal response observed following treatment 
with ranibizumab as well as consideration that its effects may be longer lasting than other anti-VEGF 
medication. The risks and benefits of treatment with aflibercept together with its off-label use were 
discussed with the patient. It was also highlighted that there was a limited evidence base for its usage in 
RP-associated CMO.  
 
Informed consent was taken and bilateral intravitreal injections of 0.05ml aflibercept (40mg/ml) given 
via standard aseptic technique. There were no peri-operative complications. Post-operative 
chloramphenicol drops were prescribed. 
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One month after treatment, BCVA improved to 6/12 in the right eye but remained 6/36 in the left eye. 
The patient did not notice any subjective improvement.  SDOCT revealed markedly less CMO in both 
eyes, with CMT of 263 and 243 microns in the right and left eye respectively (Figure 1, B and F). A 
second uncomplicated intravitreal injection of aflibercept was undertaken bilaterally. 
 
One month after his 2nd injection with aflibercept, BCVA remained at 6/12 in the right eye and 6/36 in 
the left eye. At this visit the patient reported a subjective improvement of vision.  SDOCT revealed a 
similar level of CMO bilaterally compared to the previous visit. CMT was 268 and 239 microns in the 
right and left eye respectively (Figure 1, C and G).  
 
The patient then returned to the United Arab Emirates where he was seen by the medical retina team at 
Moorfields Eye Hospital, Dubai in December 2013.  BCVA was 6/18 in the right eye and 6/24 in the left 
eye. SDOCT revealed a similar level of CMO bilaterally (Figure 1, D and H) despite his last aflibercept 
injection being 8 weeks prior. CMT was recorded as 253 and 224 microns in the right and left eye 
respectively.  As the patient was stable, the decision was taken not to treat with an alternative anti-
VEGF since aflibercept was due to be made available for use in Dubai from January 2014. 
 
Fig. 1. Optical coherence tomography of both eyes before and after intravitreal injections of 
aflibercept given in the UK.  
Optical coherence tomography in the right eye before injection with aflibercept (Figure 1A), one month 
after 1st injection of aflibercept (Figure 1B), one month after 2nd injection of aflibercept (Figure 1C), 8 
weeks after 3rd injection with aflibercept (Figure 1D). Optical coherence tomography in the left eye 
before injection with aflibercept (figure 1E), one month after 1st injection of aflibercept (Figure 1F), one 
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month after 2nd injection of aflibercept (figure 1G), 8 weeks after 3rd injection with aflibercept (Figure 
1H). 
 
 
 
Unfortunately there was an unexpected delay in aflibercept being made available for use in Dubai. In 
March 2014 (5 months after the patient’s last injection with aflibercept) BCVA was 6/18 right eye and 
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6/36 in the left eye. SDOCT revealed a significant increase of CMO bilaterally, with CMT of 385 and 434 
microns in the right and left eye respectively (Figure 2, A and C). In order not to delay treatment any 
further, the decision was taken to perform 3 monthly loading doses of ranibizumab bilaterally.  
 
The response to ranibizumab was markedly less pronounced compared to aflibercept. In May 2014, 
BCVA remained at 6/18 in the right eye and had decreased to 6/48 in the left eye. SDOCT revealed 
bilateral CMO, with CMT of 304 and 342 microns in the right and left eye respectively (Figure 2, B and 
D). The decision was taken not to undertake further injections with ranibizumab. 
 
Fig. 2. Optical coherence tomography of both eyes before and after intravitreal injections of 
ranibizumab given in Dubai. Optical coherence tomography in the right eye immediately before 
injection with ranibizumab (Figure 3A) and on the day he received his 3rd injection with ranibizumab 
(Figure 3C). Optical coherence tomography in the left eye immediately before injection with 
ranibizumab (Figure 3B) and on the day he received his 3rd injection with ranibizumab  (Figure 3D). 
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In August 2014, the patient had an increased amount of CMO. SDOCT measured 452 and 513 microns in 
the right and left eye respectively (Figure 3, A and E). Fortunately, aflibercept became available for use 
in Dubai and the patient received treatment with 3 monthly loading doses of aflibercept bilaterally. 
 
A good response was noted once again. In October 2014, BCVA had improved to 6/18 in the right eye 
and 6/36 in the left eye. SDOCT showed a marked reduction in CMO (Figure 3, B and F) measuring 248 
and 226 microns in the right and left eye respectively. 
 
The patient continued to receive aflibercept injections in January 2015, March 2015, June 2015 and 
September 2015 and CMT remained stable (Figure 3, C and G). In September 2015, BCVA was 6/15 in 
the right eye, 6/36 in the left eye, with stable CMT of 250 and 194 microns in the right and left eye 
respectively (Figure 3, D and H). Figure 4 summarises the effect of anti-VEGF medications on CMT over 
time. 
 
Fig. 3. Optical coherence tomography of both eyes before and after intravitreal injections of 
aflibercept given in Dubai.  
 
Optical coherence tomography in the right eye immediately before injection with aflibercept (Figure 4A), 
immediately before the 3rd injection with aflibercept (Figure 4B), two months following the 4th injection 
with aflibercept (Figure 4C) and 3 months following the 6th injection with aflibercept (Figure 4D). Optical 
coherence tomography in the left eye immediately before injection with aflibercept (Figure 4E), 
immediately before the 3rd injection with aflibercept (Figure 4F), two months following the 4th injection 
with aflibercept (Figure 4G) and 3 months following the 6th injection with aflibercept (Figure 4H). 
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Fig. 4. The effect of anti-VEGF medications on CMT over time is presented. 
 
 
 
Conclusions 
There are currently no proven treatments for RP-associated CMO. The use of medication such as 
carbonic anhydrase inhibitors has demonstrated inconsistent efficacy and unwanted side effects. FDA 
approval of anti-VEGF medication has now extended to include CMO secondary to age-related macular 
degeneration, diabetic retinopathy and retinal vein occlusion. While the pathogenesis of RP-associated 
CMO is not entirely understood, VEGF may play a role in the formation of RP-associated CMO thereby 
representing a potential target for treatment. RP is not an ischaemic condition and if anything, the 
natural bone spicule formation secondary to photoreceptor cell death results in an overall reduction of 
oxygen consumption by the retina. We hypothesise that a localised source of VEGF produced, for 
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example, by Muller cells under pathological conditions contributes to CMO formation whilst also 
explaining why it is rare to find reports of peripheral neovascularisation in RP.  
This is the first case report to demonstrate a reduction of RP-associated CMO following intravitreal 
aflibercept despite inadequate response to ranibizumab. Alibercept may provide superior action to 
other anti-VEGF medications due to its intermediate size (115 kDa) and higher binding affinity. This is 
worthy of further investigation in a large prospective cohort over an extended time to determine the 
safety and efficacy of aflibercept for use in this condition.  
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